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The identification of targets of early immune responses associated with control of HIV-1 
infection will inform immunogen design for vaccine interventions.  The early evolution of 
transmitted/founder subtype C virus sequences was investigated to determine the location 
and frequency of immune selection, and the impact of early immune escape mutations on 
viral replicative capacity. 
Single-genome amplified env sequences from 26 acutely-infected women were evaluated for 
conformance to a model of random evolution to elucidate multiplicity of infection.  Near full-
length genome sequences from the first six months of infection were generated for five 
women and sites evolving under immune selection were mapped.  CD8+ cytotoxic T-
lymphocyte escape mutations in HLA-B-restricted epitopes were introduced into infectious 
molecular clones of cognate transmitted/founder viruses by site-directed mutagenesis and 
their impact on viral replicative fitness was evaluated using parallel replication assays. 
In 77% of women (n=20) a single transmitted/founder variant established infection and two 
to five variants in the remaining 23% (n=6).  Near full-length genome sequencing in five 
women confirmed single variant/low-diversity transmission and identified fifty-five genome 
regions evolving under immune selection, 40% of which was attributed to CD8+ cytotoxic T-
lymphocyte pressure, 35% to antibody-mediated pressure, 16% to reversion and 9% could 
not be classified.  The rate of sequence diversification and number of sites evolving under 
immune selection was highest in nef.  The majority of evolving CD8+ cytotoxic T-lymphocyte 
epitopes (82%) contained shuffling/toggling mutations.  A novel B*15:10-associated 
mutation, A164T, combined with a V85A Pol mutation reduced viral replication capacity in 
one individual.  In a second individual, the attenuating HLA-B*58:01-associated mutation, 
T242N, enhanced viral replication capacity due to pre-existing compensatory polymorphisms 
in the transmitted/founder virus.  A third individual, who had extremely rapid disease 
progression, was infected with the virus with the highest replication capacity.  
This thesis describes the complex nature of early immune selection and escape in 
transmitted/founder viruses.  Although attenuating escape mutations were identified in 
viruses from two individuals, this was not associated with clinical benefit.  The extensive 
variability of epitopes evolving under early selection may implicate many early immune 
targets as poor candidates for vaccine immunogens; however some early targets may be 
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Chapter 1: Literature Review 
1.1 Current perspective of the global HIV-1 pandemic and the progress of vaccine 
development 
Human Immunodeficiency Virus (HIV) continues to be a global health threat.  Although the 
WHO reported stabilization in the global HIV incidence in 2010, the disease burden 
continues to increase in sub-Saharan Africa (World Health Organization, 2011).  In 2012, 
there were 35 million infected individuals worldwide of which 25 million were in sub-Saharan 
Africa (http://www.who.int/gho/hiv/en/) constituting greater than two-thirds of the pandemic.  
South Africa carries the highest burden of any country globally (Figure 1, 
http://www.unaids.org/en/dataanalysis/datatools/aidsinfo/), and in 2013 it was estimated that 











Figure 1.  Global HIV disease burden in 2012. Disease burden is illustrated at country level, and the 
coverage of antiretroviral therapy (ART) is illustrated graphically for South Africa (inset) (modified from 
http://www.unaids.org/en/dataanalysis/datatools/aidsinfo/).  The number of individuals living with HIV 
is indicated by colour coding: dark brown = >1 million people, pale brown = 100 000 to 1 million 
people, dark red = 10 000 to 100 000 people, pale red = < 10 000 people, and grey = no data 
available.  South Africa remains the country with the highest number of HIV cases despite the roll-out 




Furthermore, in South Africa HIV-related mortality is exacerbated by the burden of 
tuberculosis (TB) and HIV-TB co-infection (Karim et al., 2009).  While antiretroviral (ARV) 
therapy has provided relief with respect prolonging life, and the lowering of HIV incidence, 
(Tanser et al., 2013; Bor et al., 2013), treatment is still not accessible to all those who need 
it.  In the absence of a cure, a vaccine remains urgently needed. 
To date, only one HIV vaccine, tested in the Thai RV144 trial, has provided protection, 
preventing infection in 31% of recipients (Rerks-Ngarm et al., 2009).  The trial tested a 
combination of a canarypox viral vector carrying HIV genes (gag, pol and env) for stimulating 
cytotoxic T-lymphocyte (CTL) responses, with a viral envelope (Env) protein immunogen for 
stimulating antibody (Ab) responses.  Prior to the RV144 trial, only five phase IIb/III vaccine 
efficacy trials were conducted, none of which protected from infection, nor lowered viral 
loads in recipients (Figure 2).  Two of these trials used only viral protein immunogens 
(VaxGen trials VAX003 and VAX004), two used adenovirus viral vectors expressing HIV 
genes with no protein immunogens (HVTN502/Merck rAd5 Step and HVTN503/Phambili 
trial), and the last used a DNA prime followed by an adenovirus viral vector boost (HVTN 
505) (Esparza, 2013).   
A multi-pronged approach may thus be needed to prevent HIV infection, wherein vaccines 
will need to elicit a combination of Ab and CTL responses.  The success of the RV144 trial in 
providing, albeit modest, protection against HIV infection demonstrates that an effective 
vaccine is an attainable goal.  A similar vaccine trial approach to RV144, but using subytpe 
C immunogens which are more relevant to the pandemic in southern Africa, is planned for 
South Africa (Figure 2).   
With the slow implementation of new vaccine trials, it is imperative that additional research is 
undertaken to elucidate the correlates of protection against the establishment of infection, 
and correlates of disease attenuation.  Investigation of HIV-infected individuals to gain an 
understanding of the interplay between the virus and the host immune system following viral 
transmission can provide important clues regarding early responses associated with viral 
control.  This would involve characterising transmitted viruses and determining whether they 
possess common properties that can be exploited by a vaccine or if mutational pathways 





Figure 2.  HIV-1 vaccine efficacy trials conducted to date or in progress (obtained from Esparza, 2013).  The HVTN503 Phambili trial, which tested the 
same vaccines as the HVTN502 Step trial, is not illustrated here as it was stopped early due to lack of protection seen in HVTN502 vaccine recipients, and 
also for safety reasons (Gray et al., 2014). 
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The purpose of this literature review is to summarize the current understanding of HIV 
transmission and subsequent interaction with the host immune system, for informing the design 
of effective vaccines. The following areas are discussed: (i) HIV diversity, (ii) the transmitted 
virus, (iii) early immune pressure on the virus, and (iv) challenges to vaccine design. 
 
1.2 Viral diversity 
HIV-1 exists as a diversity of subtypes (reviewed in Ndung’u and Weiss, β01β), and 
development of a vaccine requires a detailed characterization of this diversity as viral subtype 
may impact vaccine efficacy.  HIV-1 is classified into nine subtypes (A, B, C, D, F, G, H, J and 
K).  A number of viral chimeras having genetic material from two different subtypes also exist 
and are referred to as circulating (if associated with spread)  and unique recombinant forms 
(CRFs and URFs).   Most vaccine trials to date have tested vaccine constructs containing 
subtype B immunogens (reviewed in Esparza 2013). However, global statistics reveal that 
subtype C is by far the most dominant strain (Hemelaar et al., 2011).   
In an analysis of global HIV-1 subtype distribution between the years 2000 and 2007, subtype C 
was found to account for almost half (48%) of global infections, and is the focus of this thesis.  
Recombinant viruses are the second most common strain (21%), followed by subtype A (12%) 
and B (11%) (Hemelaar et al., 2011) (Figure 3A).  Subtype C predominates in Southern Africa, 
Ethiopia and India, and appears to be on the increase in the southern regions of Brazil (Raboni 
et al., 2010, Almeida et al., 2012).  Most research has been performed on subtype B as this is 
the dominant strain in the Americas, Europe and Australia (Hemelaar et al., 2011) (Figure 3B).   
Subtypes may impact the efficacy of vaccines designed to elicit both B- and T-cell responses.  
Recently, in a study investigating a large panel of env pseudoviruses from a range of different 
subtypes, viruses were shown to be more sensitive to neutralization by plasma from individuals 
infected with a matched subtype compared to that from mismatched subtypes (Hraber et al., 
2014).  Similarly, CTL responses are more likely to recognise viruses from matched subtypes 


















Figure 3.  Global burden and distribution of HIV-1 subtypes.  The contribution of the different 
subtypes, circulating and unique recombinant forms (CRFs and URFs) to (A) the global, and (B) the 
regional HIV-1 disease burden.  In addition, the global distribution of subtypes and recombinant forms is 
illustrated in B, where the sizes of the circles reflect the extent of the pandemic in each region. The 
dominance of subtype C in Southern Africa and the contribution of this subtype to global infections are 
evident. Modified from Hemelaar et al., 2011. 
Concepts for overcoming subtype diversity for CTL-based vaccines have been developed and 
include, among others, universal vaccines presenting subtype consensus sequences of the 
most conserved regions of the HIV genome (Letourneau et al., 2007, Rolland et al., 2007, 
Borthwick et al., 2014) or vaccines presenting COT (centre of tree) immunogens which are 
designed using phylogenetic methods and are more representative of diversity of viral gene 
regions (Nickle et al., 2007).  Another concept is that of mosaic vaccines, which are 
recombinant vaccines designed and synthesized to represent a diversity of HIV strains. These 
immunogens, when tested in rhesus monkeys, were shown to stimulate broader cellular 





consensus antigens (Barouch et al., 2010, Santra et al., 2010). There has been no vaccine 
construct to date that has elicited broadly neutralizing antibodies. 
 
1.3 The transmitted virus 
It has long been known that a bottleneck exists at the point of HIV-1 transmission wherein the 
genetic diversity of viruses in a newly infected individual is usually homogeneous despite the 
high diversity of viral quasispecies in the infecting donor (Wolinsky et al., 1992, Derdyn et al., 
2004). 
Keele et al. (2008) were the first group to quantify this bottleneck where, in a subtype B cohort, 
they estimated that approximately 80% of infections were the result of a single 
transmitted/founder (t/f) viral variant establishing clinical infection.   This was subsequently 
confirmed in a number of studies including a subtype C study in South Africa and Malawi 
(Abrahams et al., 2009), a subtype A and C study in Zambia and Rwanda (Halaand et al., 
2009), and in a study of Tanzanian samples which included a variety of different subtypes as 
well as recombinant forms (Nofemela et al., 2011).  This thesis expands the characterization of 
the reported t/f viruses from South African women (Abrahams et al., 2009).  
The transmission bottleneck is less pronounced in cohorts of men who have sex with men 
(MSM) (Li et al., 2010), and conflicting reports exist on the multiplicity of infection in intravenous 
drug users (IDUs) (Masharsky et al., 2010; Li et al., 2010).  While approximately 70% of IDUs 
from a cohort from St Petersburg, Russia were reported to be infected with a single variant 
(Masharsky et al., 2010), single variant infection was reported in only 40% of IDUs in a Montreal 
cohort (Bar et al., 2010).  The restriction in the number of viruses that establish clinical infection 
in heterosexual transmission is likely a reflection of the effectiveness of the mucosal barrier that 
the virus has to cross.   Supporting this, in macaque studies the number of transmitted variants 
establishing infection was seen to increase with increasing inoculum dose and intravenous 
inoculation resulted in both a higher efficiency of transmission as well as a higher number of 
transmitted variants compared to intrarectal inoculation (Keele et al., 2009, Liu et al., 2010). 
The different scenarios which could result in this transmission bottleneck are depicted in Figure 
4.  It is possible that during transmission multiple viral variants traverse the mucosal barrier but 
that only one or a few successfully infect target cells (Cohen et al., 2011), in which case these 
viruses may be referred to as ‘transmitted’ viruses.  Alternatively, during transmission, multiple 
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viral variants may successfully infect target cells but infection may be aborted by all but one or a 
few which go on to expand (Cohen et al., 2011).  In this scenario the virus which persists and 
expands would be referred to as the ‘founder’ virus. 
 
Figure 4.  The HIV transmission bottleneck. The scenarios depicted are for productive infection (A), 
infection with a virus of lower fitness which propagates but less efficiently (B), and abortive infection (C) of 
viruses crossing the mucosal barrier during infection.  Ro indicates the reproductive ratio of the transmitted 

















This thesis examines a subset of women from the study which enumerated the multiplicity of 
infection in heterosexual subtype C-infected individuals from South Africa and Malawi, which 
found that the frequency of infection with two and greater than two variants was too high to be 
accounted for by random, chance events, suggesting that additional factors were involved 
(Abrahams et al., 2009).  An association between the presence of other sexually transmitted 
infections (STIs) at transmission and infection with multiple viral variants was identified as one 
potential mechanism for overcoming the bottleneck (Halaand et al., 2009).  Existing STIs may 
create physical breakages in the mucosal barrier thus allowing easier passage of virus particles, 
or may stimulate production of inflammatory cytokines which recruit activated HIV target cells to 
the site of infection.  Also, infection with a cell containing multiple virus particles or possibly even 
host factors such as the semen-derived enhancer of virus infection (SEVI) could be speculated 
to facilitate establishment of infection with multiple variants (Abrahams et al., 2009, Munch et 
al., 2007).   
Previous studies have proposed that viruses identified in recipients with early infection 
corresponded to minor variant populations in the blood (Zhu et al., 1993) and genital tract 
(Boeras et al., 2011) of the donor, and were more closely related to the common ancestor of the 
donor and recipient sequences combined in each transmitting pair (Sagar et al., 2009).  
Recently, in a study of Ugandan transmission pairs using Sanger sequencing, cloning and deep 
sequencing methods, it was shown that viral populations in the recipient more closely 
resembled those from earlier in infection, and not the virus present close to the time of 
transmission in the donor (Redd et al., 2012).  These studies potentially indicate that properties 
of transmitted or ancestral viruses exist which make them more transmissible.  Most recently, 
Carlson and associates described, in heterosexual transmission pairs, a biasing of transmission 
towards viral variants with amino acids which confer enhanced fitness (Carlson et al., 2014). 
Thus, despite the overwhelming diversity of HIV strains, there may be properties specific to 
transmitted viruses which need to be taken into consideration for vaccine design.   
Distinct phenotypic properties of transmitted viruses reported in multiple studies include shorter 
Env V1-V2 loop lengths that are less glycosylated, which may facilitate more efficient binding of 
and entry into target cells but may also confer greater sensitivity to antibody neutralization 
(Derdyn et al., 2004, Chohan et al., 2005, Liu et al., 2008, Sagar et al., 2009, Wilen et al., 2011).  
Transmitted viruses have consistently been shown to have CCR5 co-receptor tropism (Keele et 
al., 2008, Ping et al., 2013); however they infect macrophages poorly due to low levels of CD4 
receptor expression on these cells (Salazar-Gonzalez et al., 2009, Ochsenbauer et al., 2012; 
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Ping et al., 2013).  It has also recently been shown that transmitted/founder viruses are more 
sensitive to inhibition of CCR5 binding using CCR5 antagonists (Parker et al., 2013, Ping et al., 
2013).  While certain studies have shown transmitted or early viruses to be more sensitive to 
neutralization than donor viruses (Derdyn et al., 2004), or chronic viruses (Wilen et al., 2011), 
others have not shown this to be true (Parrish et al., 2012, Ping et al., 2013).  Similarly, 
compared to chronic viruses, transmitted viruses were previously reported to have higher 
reactivity to the α4 7 integrin on the surface of CD4+ T-cells (Nawaz et al., 2011), however 
subsequent studies failed to show this difference in binding affinity (Parrish et al., 2012, Perez et 
al., 2014). 
Genetic signatures associated with transmission have been identified near the CCR5 and CD4 
receptor binding sites, at amino acid position 12 of the signal peptide and within a single 
potential N-linked glycosylation site (PNGS) (positions 413-415) of Env in subtype B transmitted 
viruses (Gnanakaran et al., 2011).  The transmission signature within the signal peptide was 
demonstrated to enhance protein expression, trafficking and incorporation into virus particles, 
and also proposed to enhance infectivity (Asmal et al., 2011).   In keeping with these findings, 
Parrish et al. (2013) demonstrated, using participant-specific full-length genome infectious 
molecular clones, that transmitted/founder viruses were 1.7-fold more infectious in TZMbl cells 
(a HeLa cell-line expressing high levels of CD4 and CCR5) than viruses derived from chronic 
infection, that they packaged more Env and were more readily taken up by dendritic cells.   
Whether or not the genotype of the transmitted virus is a determinant of the rate of disease 
progression is still uncertain, but convincing evidence exists to suggest that it is including that 
the replication capacity of transmitted viruses correlated with viral load and that viral load set-
point was shown to be a heritable trait (reviewed in Fraser et al., 2014).  Alizon et al showed, 
using phylogenetic methods, that disease progression is a heritable trait strongly associated 
with viral genotype (Alizon et al., 2010).  This is supported by a number of studies on 
transmission pairs, where viral load set-point in the recipient was associated with viral load in 
the source partner (Yue et al., 2013; Lingappa et al., 2013; Tang et al., 2004, Hecht et al., 2010, 
Hollingsworth et al., 2010).  Furthermore, the replication capacity of Gag chimera viruses 
derived from a Zambian transmission pair cohort correlated with viral load in both the recipient 
and the donor close to the time of transmission (Prince et al., 2012).   
Deletions within the viral genome may facilitate viral control, for example, an elite suppressor 
who was infected with a virus containing a deletion in nef became viremic only when the viral 
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sequence evolved to incorporate a mutation which restored nef function (Salgado et al., 2014).  
Thus genetic properties of transmitted/founder viruses or the very early diversifying virus/es may 
very likely play a part in determining the severity of disease. 
 
1.4 High viral mutability  
 
HIV sequence diversification following transmission is driven by high viral mutability.  HIV-1 is a 
retrovirus from the genus Lentivirus, which reproduces its RNA genome via a DNA intermediate 
generated by the reverse transcriptase (RT) enzyme.  During each cycle of viral replication, the 
RT enzyme first generates single-stranded cDNA from the RNA template and thereafter double-
stranded DNA while misincorporating nucleic acid residues resulting in mutation at an estimated 
frequency of 3.4 x 10-5 mutations per base pair per cycle (Mansky et al., 1995) prior to 















Figure 5. The error-prone reverse transcriptase of 
HIV-1.  . Misincroporation of nucleotide base pairs 
occurs with each cycle of HIV-1 replication as single-
stranded RNA is reverse transcribed to cDNA. This 
introduces variability within participant viral 
populations and facilitates immune evasion of 
neutralizing antibody and cytotoxic T-lymphocyte 





The integrated DNA is then transcribed and translated by host cellular enzymes and viral 
packaging and assembly ensues.  In an infected individual, over time, a diverse swarm of 
closely related but distinct viral populations develops, referred to as a quasispecies (Nowak et 
al., 1992).  The virus is thus able to rapidly alter its genotypic and phenotypic properties through 
mutation and evade immune responses due to loss of antigen recognition and binding.   
 
This high mutability remains one of the biggest challenges to vaccine design.  The rapid genetic 
divergence and population diversification of the env gene over the course of infection was 
elucidated in a study by Shankarappa et al. (1999).  These authors described an initial period of 
restricted genetic evolution, followed by a linear increase in both divergence from founder and 
population diversity and finally a plateau of both as the person progressed to  AIDS 
(Shankarappa et al., 1999).  A later study examining near full-length genome sequences from 
acute infection reported a contraction of viral diversity in the first month of infection before an 
increase in diversity (Herbeck et al., 2011). 
 
Studies approximate an overall 0.55-1% increase in sequence diversity per year within an 
infected individual (Herbeck et al., 2006, Li et al., 2007, Herbeck et al., 2011).  Individual genes 
within the viral genome, however, diversify at different rates.  Of the nine genes encoded by the 
HIV-1 genome (Figure 6A), structural and enzymatic genes gag and pol are more conserved 
and diversify slower, compared to env and nef which diversify much faster (Yusim et al., 2002, 
Li et al., 2007, Herbeck et al, 2011) (Bansal et al., 2005) (Figure 6B).    Functional constraints in 
proteins such as the Gag p24 capsid, a major structural protein, play a role in this conservation 








Figure 6. Conserved and variable regions in the HIV-1 genome.  All nine genes of the viral genome in 
their respective reading frames are illustrated above (modified from 
http://www.hiv.lanl.gov/content/sequence/HIV/MAP/landmark.html). Where certain genes encode multiple 
proteins, these are indicated. A graph of Shannon entropy scores for each gene/gene region was 
obtained from Bansal et al., 2005. Conserved genes (those having Shannon Entropy values below 0.15 
(Bansal et al., 2005)) are indicated in red. PR/prot = protease, RT/p51 RT = reverse transcriptase, 
RN/p15 RNase = RNase and IN/p31 int = integrase.  
 
 
1.5 Immune responses to HIV-1 infection 
 
Vaccines need to stimulate responses which neutralize the transmitted virus, or control early 
replication, and clues as to which responses are needed can be gleaned from studies of natural 
infection. The innate immune responses modulated by dendritic cells and natural killer (NK) 
cells are the first responses detected following HIV infection, with CD8+ CTLs and non-
neutralizing Ab responses evolving as viral load increases, and later autologous neutralizing 
antibody (nAb) responses develop (Figure 7) (reviewed in McMichael et al., 2010).  Recently, a 
subtype B study reported a role for HIV-specific CD4+ T-cell responses in acute infection in 




Figure 7.  Immune responses to HIV-1 infection.  Acute phase reactants refer to host antiviral proteins 
and cytokines.  The eclipse phase refers to a period during which no markers of HIV infection are 
detectable (McMichael et al., 2010).  Illustration taken from McMichael et al. (2010). 
 
In natural infection, the earliest Ab responses are constituted by binding Abs such as IgG and 
IgM which may arise as early as eight days post-infection but do little to reduce virus burden 
(Tomaras et al., 2008).  Abs able to neutralize the virus were initially reported to arise only some 
weeks or months following infection (Wei et al., 2003; Gray et al., 2007; Yeh et al., 2010), and 
the virus is able to rapidly escape their responses.  However, the presence of low-titre nAbs as 
early as two weeks following seroconversion has been evidenced by identification of nAb-
escape mutations in acute infection (Bar et al., 2012).  Antibodies that can neutralize a diversity 
of viruses, broadly cross-neutralizing (BCN) Abs, are the target responses for vaccines to elicit 
(see section 1.8.1).  These types of responses develop in only a portion of individuals and are 
evidently too late to afford any benefit to the course of disease (reviewed in Mascola and 
Haynes 2013). 
 
Immune responses that are proven to reduce viral load in natural infection are those mediated 
by CD8+ CTLs.   CTLs have been shown to reduce peak viral load in acute infection thereby 
lowering the virus burden to a relatively steady state or set-point (Borrow et al., 1994, Koup et 
al., 1994, Ogg et al., 1998, Goonetilleke et al., 2009).  Viral set-point is predictive of time to 
onset of AIDS (Lyles et al., 2000).  
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CTL responses are induced once a target cell becomes infected and the virus's proteins are 
processed by the cellular proteasome to produce short peptide fragments which are then 
trafficked via the endoplasmic reticulum (ER) to be presented on the surface of that cell via a 
human leukocyte antigen (HLA) (York and Rock, 1996).  HLA molecules have the ability to 
recognize short viral peptides, typically nine to eleven amino acids in length and bind these 
targeted epitopes through specific interactions with amino acid anchor residues (reviewed in 
Goulder and Walker, 2012).  HLA genotype determines which regions of the virus will be 
recognized and subsequently targeted, for example HLA-B*57/5801 recognizes the epitope 
TW10 (TSTLQEQIGW).  CD8+ T-cell receptors on the surface of CTLs, which also recognize 
specific residues within the peptides displayed by the HLA, initiate killing of infected cells 











Figure 8.  The cytotoxic CD8+ T-
lymphocyte response.  The presentation 
of HIV peptide fragments (in this instance 
the Gag TW10 epitope) to a CD8+ T-cell 
receptor via HLA binding on the surface of 
an infected antigen presenting cell (APC) 
is illustrated.  
 
 
HIV escapes these immune responses largely due to the virus’s mutability. The role of CTL 
immune selection of nucleotide mutations in viral escape will be discussed in the following 





1.6 Immune selection and CTL escape 
 
Host immune pressure drives the selection of nucleotide mutations (Moore et al., 2002, 
Richman et al., 2003, Wei et al., 2003, Rybarczik et al., 2004, Allen et al., 2005, Frost et al., 
2005, Carlson et al., 2008, Treurnicht et la., 2010), which are introduced by the viruses error-
prone RT enzyme (see section 1.2.4).  Nucleotide substitutions, insertions or deletions 
introduced into or proximal to viral epitopes can result in loss of immune recognition.  Mutations 
which alter amino acid translation are referred to as non-synonymous or non-silent, whereas 
those which do not are referred to as synonymous or silent.  Not all mutations are maintained by 
the virus, but those which do become fixed within the genome and persist through subsequent 
replication cycles are referred to as evolving under positive selection. 
 
Non-synonymous mutations identified early in infection have been reported to be more 
frequently associated with pressure from CTLs (Bernardin et al., 2005, Brumme et al., 2008a, 
Salazar-Gonzalez et al., 2009, Goonetilleke et al., 2009, Herbeck et al 2011).  These mutations 
facilitate CTL escape as early as the first few weeks of infection (Borrow et al., 1997, Jones et 
al., 2004, Liu et al., 2006, Gray et al., 2009, Goonetilleke et al., 2009, Wood et al., 2009, 
Mlotshwa et al., 2010) and are generally characterized by transitions from more common 
(consensus) to less common (non-consensus) amino acids within or flanking the targeted 
epitope (Allen et al., 2004).   
 
Mechanisms of evasion from CTL responses include alterations in either peptide binding at HLA 
anchor residues, peptide recognition by CD8+ T-cell receptors or antigen peptide processing 
within infected cells (Borrow et al., 1997, Goulder et al., 1997, Feeney et al., 2004, Draenert et 
al., 2004, Tenzer et al., 2009, Carlson et al., 2012a, Bronke et al., 2013).  Continuing the 
example of the TW10 epitope targeting, these three mechanisms of CTL escape are illustrated 





Figure 9.  Mechanisms of viral escape from CTL responses.  Following infection of an antigen 
presenting cell, CTL-mediated cell killing via HLA presentation of the Gag TW10 epitope to a CD8+ T-cell 
receptor is prevented by (A) altered antigen processing within the cell, (B) loss of HLA binding due to 




Escape mutations can become fixed within a demographic population wherein a specific HLA 
type is dominant, such as occurred in Japan where amino acid escape mutations within multiple 
B*51 epitopes have now become the consensus amino acids in circulating viruses that are 
transmitted within the population (Kawashima et al., 2009).  Indeed, a more recent study by 
Chikata et al. (2014) reported extensive population HLA-restriction influence on the evolution of 
HIV in Japan, driven by the introduction of HLA polymorphisms.  HLA adaption on a population 
level has also recently been reported for North America, although this was not as extensive 
(Cotton et al., 2014). 
 
Studies by Liu et al. (2013) and Ferrari et al. (2011) demonstrated that CTL escape occurs more 
rapidly in high entropy epitopes, and that CTL responses to conserved epitopes arise later but 
are more effective in viral control.  Escape from CTL pressure may come at a cost to the virus 
since some mutations impede viral protein function and replication (Leslie et al., 2004, 
Brockman et al., 2007, Troyer et al., 2009, Wright et al., 2011, Prince et al., 2012, Boutwell et 
al., 2013).  This may comprise its ability to survive in a given environment, referred to as viral 
fitness (reviewed in Domingo et al., 1997).  Summarised in Figure 10 are the possible 
implications of CTL escape.  
 
An example of this is the escape mutation T242N in the TW10 epitope used in previous 
illustrations, which results in a significant loss of viral replicative fitness due to its impact on 
function of the viruses Cyclophilin A binding loop (Martinez-Picardo et al., 2006, Brockman et 
al., 2007, Song et al., 2012).  The virus may compensate for this loss by additional mutations 
within or adjacent to the TW10 epitope which restores the fitness loss incurred by the initial 
escape mutation to varying extents (Leslie et al., 2004; Brockman et al., 2007).  It is 
advantageous to identify epitopes containing mutations which reduce viral fitness as these may 









Figure 10. Implications of immune selection and escape in CTL epitopes. The eventual impact of 
CTL escape on control of virus is outlined in a flow diagram. Mutations which result in a cost to viral 
fitness and subsequent reduced viral replication are of interest for vaccine design. 
 
 
1.7 CTL responses and viral control 
 
A number of studies have postulated that stable responses to conserved, slow-to-escape 
epitopes would also be desirable for a vaccine to stimulate.  For example, Mlotshwa and 
colleagues evaluated CTL responses in 53 acutely subtype C-infected individuals and reported 
that responses were temporal and fluid in nature within each individual, with responses to 
certain epitopes arising early and being lost early due to escape, and others arising later and 
being more stable in nature (Mlotshwa et al., 2010).  Stable responses were less frequent in 
individuals with rapid disease progression (Mlotshwa et al., 2010).  
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It is well established that specific HLA alleles are associated with control of viremia or 
conversely with rapid progression.   HLA alleles B*57, B*58:01, B*27, B*51, and B*81:01, 
commonly referred to as protective HLA alleles, have been associated with disease control and 
are enriched in individuals able to control viral loads (Kaslow et al., 1996, Carrington et al., 
1999, Hendel et al., 1999, Migueles et al., 2000, Tang et al., 2002a, Tang et al., 2002b,  
Kiepiela et al., 2004, Pereyra et al., 2008, Leslie et al., 2010, Walker & Yu, 2013), whereas HLA 
alleles B*58:02 (Kiepiela et al., 2004, Ngumbela et al., 2008), B*35, Cw*04 and B*58:02 have 
been associated with rapid disease progression (Carrington et al., 1999; Lazaryan et al., 2006).  
 
Identifying the immune targets associated with control of viremia following infection may inform 
the selection of vaccine immunogens.  Protective HLA alleles more frequently target conserved 
regions of the virus resulting in disease control (Asquith, 2008).  In addition, in the major 
structural protein Gag, escape mutations in epitopes restricted by protective HLA alleles were 
reported to reduce viral replication capacity (Brockman et al., 2010).  Supporting the 
considerable replicative fitness cost of immune escape in Gag, a study in recently infected 
individuals showed that mutations in Gag epitopes targeted by protective HLA alleles reverted 
significantly more rapidly than mutations elsewhere in the gene (Brumme et al., 2008b).  In fact, 
in general, CTL targeting of Gag has been associated with better control of disease regardless 
of the presence of protective HLA alleles (Zuniga et al., 2006; Brumme et al., 2008b; Pererya et 
al., 2008; Brennan et al., 2012).  
 
Individuals infected with a virus carrying an immune escape mutation associated with reduced 
viral replicative capacity from a donor with a protective HLA, but who themselves do not have 
that protective HLA, was associated with reduced viral load or increased CD4+ counts in 
recipients (Chopera et al., 2008; Goepfert et al., 2008; Miura et al., 2010).  This is not 
necessarily the case with transmission between individuals with matched protective HLAs since 
the virus transmitted would already have escaped the responses associated with viral control 
(Crawford et al., 2009).  Wright et al. (2011) further demonstrated that the transmission of HLA-
B polymorphisms in Gag to individuals with protective HLA alleles was associated with higher 
viral loads compared to individuals who did not have protective HLA alleles.  
 
Thus the literature suggests that a vaccine presenting conserved epitopes (with Gag epitopes 
being the most promising candidates) known to be targeted by protective HLA alleles, to escape 
slowly and to mediate a loss of viral replication fitness in the event of escape may induce 
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protective responses in recipients.  Indeed, vaccine immunogens representing conserved 
genome regions have been designed (Letourneau et al., 2007, Rolland et al., 2007) and one 
such vaccine, HIVconsv incorporating conserved elements of Gag, Pol, Vif and Env from 
subtypes A, B, C and D, has recently been tested in phase I clinical trials and elicited broad 
CD8+ T-cell responses which inhibited HIV replication in vitro (Borthwick et al., 2014).  
However, efficacy of such vaccines in preventing infection remains to be demonstrated, 
particularly since the HVTN502 Step trial, which included Gag as an immunogen, did not elicit 
protective responses against infection (Esparza et al., 2013).  It is possible that the combination, 
number or sequence of epitopes presented was not sufficiently immunogenic.   
 
 
1.8 Challenges to HIV-1 vaccine design 
Imperative to the design of an HIV vaccine is the identification of immunogens that elicit 
protective responses.  The study of natural infection has provided insights into responses 
associated with control of disease progression, while vaccine efficacy studies have provided 
insights into vaccine-induced responses associated with protection from infection.  Combatting 
the extraordinary diversity and adaptability of the virus remains one of the greatest challenges to 
vaccine development.   
 
1.8.1 Identifying immune correlates of protection: clues from natural infection 
Host genetic determinants of disease control are most commonly associated with Class I HLA-
mediated targeting of viral epitopes which results in stimulation of specific CD8+ CTL-mediated 
immune responses. HLA-B and C alleles have been shown to be the strongest determinants of 
disease progression in human genome-wide association studies (Fellay et al., 2007, Fellay et 
al., 2009, Pereyra et al., 2010, Bartha et al., 2013), implying a substantive role for CTL 
responses in controlling the virus (see section 1.6).   
Understanding the differences between responses in individuals who are able to naturally 
control disease, such as elite controllers (these individuals have viral loads that cannot be 
detected by currently available assays) (reviewed in Walker & Yu, 2013), compared to 
individuals who do not control replication can provide insights into defining protective immune 
responses.  Studies have shown CTLs from elite controllers to have greater polyfunctionality 
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(Betts et al., 2006), enhanced proliferative properties (Migueles et al., 2002) and unique 
activation phenotype which allow them to better destroy infected CD4+ T-cells (Saez-Cirion et 
al., 2007).  Also in elite controllers, CTLs produced higher levels of granzymes and perforin that 
have cellular cytotoxic effects (Migueles et al., 2002; Migueles et al., 2008; Hersperger et al., 
2010).   
An important role for Abs in preventing HIV infection has been demonstrated. Monoclonal nAbs 
prevented infection when passively infused into macaques that were later challenged with virus 
(Mascola et al., 1999; Shibata et al., 1999, Mascola et al., 2000).  Also in animal models, use of 
monoclonal nAbs has proven effective in immunotherapy to lower viral load (Barouch et al., 
2013, Shingai et al., 2013). These antibodies recognize epitopes within the viral envelope which 
exists as a trimeric structure composed of gp120 and gp41 (transmembrane) subunit proteins 
(Figure 11A). The envelope protein is heavily glycosylated and has variable regions, referred to 
as V loops, as well as conserved domains. These serve to shield the virus from antibody binding 
and neutralization (Reitter et al., 1998, Mccaffery et al., 2004, Sagar et al., 2006).  A detailed 
structure of an antibody-bound trimer in its soluble, cleaved form was recently elucidated using 
cryo-electron microscopy (Julien et al., 2013; Lyumkis et al., 2013) (Figure 11B).  
 
Figure 11. The structure of the HIV-
1 envelope trimer. Illustrated are (A) 
an HIV-1 particle coated with env 
gp160 spike trimers with subunit 
proteins gp120 and gp41 indicated, 
and (B) a top view of the recently 
reconstructed cryo-EM of the BG505 
SOSIP gp140 trimer as determined by 
Lyumkis et al. with gp120 shown in 
blue, gp41 in orange, V1V2 in purple, 
V3 in green, and the bound broadly 
neutralizing Ab PGV04 is shown in 
gray (cryo-EM image taken from 




Approximately 20 - 30 % of individuals produce nAbs that neutralize an extensive range of 
viruses, known as broadly cross-neutralizing (BCN) Abs, and which arise after approximately 
two years of infection (reviewed in Mascola and Haynes, 2013).  Breakthroughs in the isolation 
of BCN Abs, insights into their ontogeny, as well as in identification of their targets, have been 
the cause of much excitement in the HIV research field in recent years (Walker et al., 2011, 
Huang et al., 2014, Moore et al., 2012, Liao et al., 2013, Doria-Rose et al., 2014).  BCN targets 
that have been identified to date include the membrane proximal external region (MPER), the 
CD4 binding domain, the V1V2 and V3 loops (Mascola and Haynes, 2013). 
Development of a vaccine that is able to stimulate the production of BCN Abs would make for 
an ideal barrier to infection. The challenge to BCN Ab production is that these Abs are unusual 
in their conformation and are challenging to induce since they require a high number of somatic 
mutations introduced over time (Mascola and Haynes, 2013).  Some of these BCN Abs also 
have very long CDR H3 arms needed to penetrate the viral glycan shield, such as those isolated 
from broad-neutralizer CAP256 which target an epitope in the V2 loop (Doria-Rose et al., 2014).  
Maturation of BCN Abs may be driven by env evolution as the virus escapes sequential waves 
of antibody responses (Liao et al., 2013, Doria-Rose et al., 2014).  This process would be 
extremely challenging to reproduce in the context of vaccination.   
 
1.8.2 Identifying immune correlates of protection: the RV144 trial 
Analyses of vaccine participant samples from the RV144 Thai trial provided insights into what 
types of immune responses HIV vaccines need to stimulate in order to prevent infection.  Initial 
analyses identified high levels of IgG binding Abs targeting epitopes in the Env V1V2 and V3 
loop regions as a correlate of protection (Haynes et al., 2012, Karasavvas et al., 2012, de 
Souza et al., 2012, Gottardo et al., 2013).  Conversely, high levels of IgA Abs targeting the C1 
region of Env were associated with lack of protection through inhibition of antibody-dependent 
cellular cytotoxicity (ADCC) (Haynes et al., 2012; Tomaras et al., 2013). These findings may 
implicate a role for ADCC in vaccine-mediated protection (Bonsignori et al., 2012). 
In a sequence analysis study of RV144 breakthrough viruses, two amino acid signature sites in 
V2 were associated with vaccine protection, one of which is a broadly-neutralizing Ab target 
(amino acid 169) (Rolland et al., 2012). Abs targeting position 169 were isolated from vaccinees 
and closer examination of the target site revealed it to be variable in nature (Liao et al., 2013) 
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indicating a role for cross-reactive responses in protection.  The cross-reactive nature of these 
Abs was confirmed when tested against V1V2 targets from multiple subtypes (Zolla-Pazner et 
al., 2014).  
Taken together, results from the RV144 vaccine trial implicate a role for cross-reactive binding 
Abs and antibody-dependent cellular responses in mediation of protection against HIV infection.  
Since this vaccine elicited protection in only one third of vaccinees (Rerks Ngarm et al., 2009), 
much more is still to be learned about responses that would offer broader protection against 
infection. 
 
1.9 Study rationale 
Understanding the impact of immune pressure on the virus following transmission will inform the 
development of effective vaccines.  This thesis aims to characterize transmitted/founder viruses, 
how they are moulded by early immune selection, and the effect of immune selection on viral 
replicative fitness.   Viral sequencing was used as a sensitive, indirect method of characterizing 
immune pressure through the identification of mutations associated with immune selection. 
Furthermore, it allows the inference of the sequence of transmitted/founder viruses and the 
construction of research tools such as infectious molecular clones for evaluating the impact of 
immune escape on viral fitness.  
We propose that mapping of virus sequence evolution provides a sensitive tool to detect 
immune pressure, and that immune escape will alter virus replication.     
This is a focused study of five HIV-1 subtype C-infected South African women with differing 
disease progression, with the following objectives:   
1. To derive the sequence of the near full-length transmitted/founder virus and to describe 
early viral genetic diversification  
2. To identify immune selection in sequences from acute and early infection 
3. To determine the effect of early CTL-mediated immune selection on replication fitness of 
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An HIV vaccine would need to stimulate immune responses that block transmitted viruses from 
establishing (founding) clinical infection.  Defining the sequences of transmitted/founder viruses 
and identifying sites evolving under immune pressures associated with early viral control, will 
aid in vaccine immunogen design. 
The number of viral variants that established clinical infection in 26 acutely-subtype C-infected 
South African women was determined by comparing env sequence diversity to a model of 
random evolution.  Early sequence diversification was evaluated for five women (one viremic 
controller, two rapid progressors and two intermediate progressors) by near full-length genome 
sequencing over the first six months of infection. 
Infection was established by a single transmitted/founder variant in 77% of women, and by two 
to five variants in the remaining 23% percent.  In the expanded study of five women, near full-
length genome sequencing confirmed single variant infection in three women (CAP45, CAP210 
and CAP239), while two women (CAP63 and CAP85) were found to be infected with a second 
closely related, minor variant differing at five and seven nucleotide positions respectively.  Rates 
of sequence diversification were modestly higher in the first three months of infection compared 
to between three and six months.  The transmitted/founder virus of a rapid progressor (CAP63), 
whose CD4+ T-cell counts declined to 200 cells/µl in the first year of infection, displayed the 
highest rate of diversification compared to the other women. 
In conclusion, in line with other studies, we found nearly 80% of infections were a result of a 
single viral variant.  We identified the near full-length transmitted/founder virus sequence of five 
women, and found that the woman who failed to control viral replication and rapidly progressed 
to AIDS within the first year of infection, also had the highest rate of viral diversification in early 
infection. 
This study was performed as part of the Center for HIV/AIDS Vaccine Immunology (CHAVI) 
project, and was part of a larger study to characterize HIV transmission.  A portion of this work 







An HIV vaccine would need to stimulate immune responses to block the establishment and 
dissemination of viral infection.  It is possible to derive the sequence of the virus that is the 
founder of clinical infection (transmitted/founder) as the consensus of sequences sampled close 
to the time of infection, prior to immune selection.  Tracking early viral evolution from the 
transmitted/founder (t/f) virus allows identification of viral adaption to host immune responses 
and immune selection.  This data can provide insights into responses associated with disease 
control, providing information which could be important to inform the types of responses to be 
elicited by a vaccine.  This chapter utilizes viral sequencing to elucidate the sequence of viruses 
that established clinical infection in acutely subtype C-infected women and to evaluate early 
viral diversification and evolution. 
In the last five years, HIV transmission studies have improved with respect to the identification 
of acute infections and the methodology used to characterize genetic properties of early 
diversifying viruses. These studies have used a combination of (i) early virus sampling, (ii) 
single genome amplification of viral RNA, and (iii) mathematical modelling to identify the genetic 
identity of t/f viruses and their early evolution (Salazar-Gonzalez et al., 2008; Keele et al., 2008) 
and have been validated in mucosal infection models in macaques (Keele et al., 2009; Liu et al., 
2010). Each of these three approaches is briefly elaborated on below: 
(i) Early virus sampling 
Due to the rapid diversification of HIV following infection of a new host, to identify signatures of 
transmission and early immune selection, it is necessary to sample viruses from very early in 
infection.  
Using plasma donor samples with intense follow-up, Fiebig et al. (2003) devised a system for 
staging early HIV infection by the sequential appearance of biological markers such as viral 
RNA and HIV-specific antibodies.  The earliest stages of infection were defined as periods 
during which viral RNA only (stage I) and viral RNA and Gag p24 antigen but not HIV-specific 
antibodies (stage II) were detectable (Fiebig et al., 2003).  Clinical samples from these early 
stages of infection are most desirable for transmission and early viral evolution studies, since 
there would be limited immune pressure on the virus and thus the viral sequences generated 
should be close to the transmitted genotype. 
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In order to obtain clinical samples from this early in infection, a prospective cohort of uninfected 
individuals is imperative.  This thesis utilized samples from the Centre for the AIDS Programme 
of Research in South Africa (CAPRISA) 002 Acute Infection (AI) study (see section 2.4), which 
recruited high-risk women from a prospective HIV negative cohort in Durban who were enrolled 
once identified as viral RNA or antibody positive following regular screening (van Loggerenberg 
et al., 2008).  In this study infection was detected as early as an estimated two weeks post-
transmission prior to the development of antibodies (van Loggerenberg et al., 2008). 
(ii) Single genome amplification (SGA) 
This method, originally developed by Simmonds et al. (1990) and Edmondson and Mullins 
(1992) was later modified by Palmer et al. for the screening of antiretroviral drug resistance 
mutations (Palmer et al., 2005), and was adapted by Salazar-Gonzalez et al. (2008) for 
application in HIV transmission studies.  The approach dilutes cDNA templates such that <30% 
of subsequent PCR reactions are positive, which according to Poisson distribution would 
suggest that each amplicon would be from a single viral cDNA template 80% of the time 
(Salazar-Gonzalez et al., 2008).  Amplification from a single genome template eliminates 
recombination during PCR, and direct sequencing of PCR products to generate a consensus 
sequence of the amplicon would control for PCR errors.  Further validating this approach, cDNA 
products of reverse transcription of mixed RNA templates generated in vitro showed no 
evidence of recombination between templates (Salazar-Gonzalez et al., 2008).  As a result, 
false signals of virus diversity are eliminated and sequence data are considered a true reflection 
of the sampled viral population.  The SGA method has revolutionized HIV acute infection 
studies and has since been widely used in the field (Keele et al., 2008, Abrahams et al., 2009,  
Salazar-Gonzalez et al., 2009, Halaand et al., 2009, Bar et al., 2010, Li et al., 2010, Masharsky 
et al., 2010). 
(iii)  Mathematical modelling of early viral diversification 
Utilizing sequences from early infection, the number of viruses causing clinical infection and the 
approximate period of infection for an individual can be determined.   A mathematical model 
was developed by Keele et al. (2008) to identify the number of transmitted viruses in an infected 
individual.  It incorporates the error rate of reverse transcriptase (2.16 x 10-5) (Mansky et al., 
1995) as well as the doubling time of HIV (approx 2 days) (Markowitz et al., 2003) and assumes 
no changes exist as a result of immune selection. If a single virus is transmitted, the  resulting 
viral population following infection will be homogeneous/low diversity, having a star-like 
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phylogeny and a Poisson distribution of nucleic acid mutations (each mutation is a random and 
independent event) (Slatkin and Hudson, 1991).  If this is violated, then more than one variant is 
thought to cause infection, or alternatively early immune selection may be driving sequence 
heterogeneity.  Elucidation of multiplicity of infection is supported by phylogenetic methods 
which extrapolate time from infection based on derivation of a most recent common ancestral 
sequence (Drummond et al., 2006; Drummond and Rambaut, 2007).  
This approach was initially applied to subtype B infection of men who have sex with men (MSM) 
and heterosexual populations in the USA, and subsequently to heterosexual subtype C 
populations in South Africa and Malawi (Abrahams et al., 2009), and subtype A- and C-infected 
populations in Zambia (Halaand et al., 2009).  Together these studies showed that 
approximately 80-90% of infections result from a single t/f virus (Keele et al., 2008; Abrahams et 
al., 2009; Halaand et al., 2009).   
Viral diversification is driven in part by immune selection and may thus occur at different rates 
within infected individuals.   Early reports have described relationships between rate of viral 
diversification and the rate of progression of clinical disease (Wolfs et al., 1990; Lukashov et al., 
1995; Wolinsky et al., 1996; Ganeshan et al., 1997; Liu et al., 1997; McDonald et al., 1997; 
Shioda et al., 1997; Markham et al., 1998), however there have only been a limited number of 
studies that have utilized cognate near full-length t/f virus sequences.  This approach enables a 
more accurate approach to mapping early immune selection, and is of greater relevance to 
vaccine design.   
This chapter describes the identification of single t/f viral infections in 26 women from the 
CAPRISA 002 AI cohort through env sequencing.  Some of this work has been published as 
part of the larger South Africa/Malawi multiplicity of infection study (Abrahams et al., 2009).  A 
subset of five women was selected for elucidation of near full-length genome t/f virus sequences 
and characterization of early viral evolution.  These women were classified as having differential 
clinical disease progression: two women were rapid disease progressors, one woman was a 
viremic controller and finally two women were intermediate to these categories. 
 
2.3 Research Aim and Objectives 
Aim:  To derive the sequence of the full-length t/f virus from acutely subtype C-infected women 
with differing disease progression and characterize early viral diversification. 
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Objective 1: To identify women from the CAPRISA 002 AI cohort with single variant infection 
and generate near full-length genomes from five women following infection (two 
to five weeks post-infection), at three and at six months post-infection 
Objective 2: To determine if there are differences in early viral evolution and expansion of 
viral population diversity in individuals with different disease progression profiles  
 
2.4 Rationale 
This project formed part of a larger study by the Center for HIV/AIDS Vaccine Immunology 
(CHAVI) characterizing the HIV-1 transmission bottleneck and t/f viruses through env 
sequencing.   At the time of this study, there were limited studies elucidating early diversification 
of full-length HIV-1 genomes, and no studies on HIV-1 subtype C viruses – which may differ 
from subtype B due to differences in host genetic and environment.  Furthermore, South Africa 
and women in general carry the highest burden of HIV disease, this study will further our 
knowledge of acute and early infection in South African women. 
 
2.5 Methods and Materials 
A total of 515 env SGA sequences from 26 CAPRISA 002 AI participants used in the multiplicity 
of infection analysis in this chapter, were part of the larger CHAVI study published in Abrahams 
et al., 2009 (Appendix 1).    PCR amplification of near full-length genomes was carried out by 
F. Truernicht (University of Cape Town), and sequencing was performed as part of this thesis.  
Of the 112 near-full length genome sequences generated 58 were generated as part of this 
thesis, and 54 were contributed by R. Thebus, J. Marais, F. Treurnicht and S. Goodier 
(University of Cape Town).   
Clinical and STI data was provided by CAPRISA (K. Mlisana, University of KwaZulu-Natal), and 






2.5.1 Study participants 
Samples were obtained from the CAPRISA 002 AI study cohort, a prospective negative cohort 
of high-risk women recruited in Durban, South Africa (van Loggerenberg et al., 2008).  Women 
were followed either monthly or three monthly, and were identified as HIV-infected based on two 
rapid HIV antibody tests, an HIV EIA and an HIV-1 RNA test (van Loggerenberg et al., 2008).  
Date of infection was estimated as the mid-point date between the last negative and first 
positive HIV antibody test.  Where women were HIV antibody negative but viral RNA positive, 
the date of infection was taken as 14 days prior to the first viral RNA positive date.  Four-digit 
high-resolution Human Leukocyte Antigen (HLA) typing was used to determine participant HLA-
A, B and C types as described in Chopera et al. (Chopera et al., 2008).  The study was 
approved by ethics committees from the University of Cape Town, Witwatersrand and KwaZulu-
Natal.  Informed consent was obtained from all participants.   
Viral loads and CD4+ T-cell counts were determined using COBAS Amplicor v1.5 vRNA assay 
(Roche Diagnostics, Rotkreuz, Switzerland) and the BD FACSCalibur™ Flow Cytometer (BD 
Biosciences, San Jose, USA). Staging of infection, according to Fiebig et al (2003), was carried 
out on plasma using the COBAS Amplicor v1.5 vRNA assay (Roche Diagnostics, Rotkreuz, 
Switzerland), Determine AntiHIV-1/2 3rd Generation EIA (Abbott Laboratories, Illinois, USA), 
EIA BEP 2000 (Dade Behring, Marburg, Germany) and GS HIV-1 Western blot analysis kit (Bio-
Rad, Washington, USA). The stages were as follows: (I) viral RNA positive only, (II) viral RNA 
and p24 antigen positive, (III) EIA antibody positive but Western blot negative, (IV) 
indeterminate Western blot, (V) Western blot positive without p31 (integrase) band, and (VI) 
Western blot positive with p31 band. 
  
2.5.2 RNA extraction and cDNA synthesis 
Viral RNA was extracted from a volume of 200 µl of plasma using the Qiagen Viral RNA Mini Kit 
(Qiagen, Valencia, CA, USA) according to manufacturers’ instructions.  For low viral load or 
difficult to amplify samples, a volume of 400 µl of plasma was used.  Reverse transcription of 
viral RNA to cDNA was performed using the Superscript III reverse transcriptase and 
Oligo(dT)20 (Invitrogen, GmbH, Karlsruhe, Germany) ( or HIV-specific primer OFM-19 (5’-
GCACTCAAGGCAAGCTTTATTGAGGCTTA-γ’) in the case of env) in a 100 µl final reaction 
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volume.  Reaction reagents were prepared in two separate premixes.  Per reaction volumes and 














5X Buffer 20 
dNTPs (20 mM) 2 
 
100 mM DTT 5 
Oligo-dT or specific primer (50 µM)  2 
 
H2O 14-15 
    
 
RNase OUT (40 U/µl) 2 
    
 





Premix 1 was incubated at 65°C for 5 minutes in a PCR cycler.  The temperature of the cycler 
heating block was then reduced to 45°C at which point premix 2 was briefly warmed on the 
heating block before adding the 46 µl to premix 1.  The final 100 µl reaction was incubated at 
45°C for 2 hours to allow for reverse transcription of full-length product, followed by 70°C for 15 
minutes to inactivate the RNase inhibitor enzyme RNase OUT (Invitrogen, GmbH, Karlsruhe, 
Germany).  Thereafter a volume of 1 µl of RNase H (Invitrogen, GmbH, Karlsruhe, Germany) 
enzyme was added and incubated at 37 °C for 20 minutes to degrade all RNA-DNA complexes 
so that only single-stranded cDNA remained. 
 
2.5.3 Single Genome Amplification (SGA) and sequencing of env 
SGA of env was carried out as described by Salazar-Gonzalez et al (2008) and Keele et al 
(2008) using Platinum Taq DNA Polymerase High Fidelity (Invitrogen, GmbH, Karlsruhe, 
Germany).  Amplification was performed by nested PCR using primers VIF-1 (5’- 
GGGTTTATTACAGGGACAGCAGAG-γ’) and OFM-19 (5’-
GCACTCAAGGCAAGCTTTATTGAGGCTTA-γ’) (first round), and ENV-A (5’- 
GGCTTAGGCATCTCCTATGGCAGGAAGAA-γ’) and ENV-N (5’- 
CTGCCAATCAGGGAAGTAGCCTTGTGT-γ’) (second round).  cDNA was serially diluted in 
order to determine at which dilution <30% of PCR replicate reactions were positive.  Once this 
dilution was determined, the number of replicate PCR reactions was expanded in order to 
produce the desired number of SGA amplicons.  A negative control reaction (no cDNA template) 
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was included as a contamination control. PCR reagent mixes (per reaction) and cycling 
parameters are indicated below. 
 











dH2O 15.3  94 2 min  
10 X High Fidelity Buffer 2  94 15 sec 
35 MgSO4 (50 mM) 0.8  55 30 sec 
dNTPs (10 mM) 0.4  68 4 min 
VIF-1 (20µM) 0.2  68 20 min  
OFM-19 (20µM) 0.2  4 Hold  
Platinum Taq High Fidelity 0.1     
cDNA 1     
Total 20     
 











dH2O 15.3  94 2 min  
10 X High Fidelity Buffer 2  94 15 sec 
45 MgSO4 (50 mM) 0.8  55 30 sec 
dNTPs (10 mM) 0.4  68 4 min 
ENV-A (20µM) 0.2  68 20 min  
ENV-N (20µM) 0.2  4 Hold  
Platinum Taq High Fidelity 0.1     
1st round product 1     
Total 20     
 
PCR products (3-5 µl) were electrophoresed on a 1% agarose gel alongside a 1 kb DNA ladder 
marker (Promega, Madison, USA).  Full-length env amplicons were approximately 3 000 base 
pairs in size.  PCR products were directly sequenced using the ABI 3000 genetic analyzer 
(Applied Biosystems, Foster City, CA, USA) and BigDye terminator reagents. Sequences with 
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chromatograms double peaks (indicating amplification of more than one template) were 
excluded. Likewise sequences with deletions that were > 100 base pairs when compared to the 
derived intraparticipant consensus were excluded. 
 
2.5.4 Single Genome Amplification (SGA) and sequencing of near full-length genomes 
SGA of near full-length genomes was carried out as described by Salazar-Gonzalez et al (2009) 
using the Expand Long Template Taq PCR system (Roche Diagnostics, Rotkreuz, Switzerland).  
Amplification was performed by nested PCR using primers described by Rousseau et al (2006).  
Primers 1U5C 5’-GGGTGAGTGCTCTAAGTAGTGTGTGCCCGTCTGT-γ’, 1U5Cb 5’-
GGGTGAGTGCTCTAAGTAGTGTGTGCCCATCTGT-γ’ and 1.γ.γpIC 5’-
GGGACTTAGAGCACTCAAGGCAAGCTTTATTG-γ’ (first round) and primers βU5C 5’-
GGCCGCGGATCCAGTAGTGTGTGCCCGTCTGTTGTGTGACT-γ’ and β.γ.γpIC 5’-
GGCCGCGCGGCCGCTAGAGCACTCAAGGCAAGCTTTATTGAGGCTTA-γ’ (second round) 
were used.  cDNA was serially diluted in order to ascertain at which dilution <30% of PCR 
replicate reactions were positive.  Once this dilution was determined, the number of replicate 
PCR reactions was expanded in order to produce the desired number of SGA amplicons.  PCR 
reagent mixes (per reaction) and cycling parameters are indicated below. 
 










dH2O 41.45  94 2 min  
10 X Buffer 1 (with Mg++) 5  94 10 sec 
10 dNTPs (20 mM) 0.9  68 30 sec 
Primer 1U5C (50µM) 0.3  68 8 min 
Primer 1U5Cb (50µM) 0.3  94 10 sec 
20 Primer 1.3.3pIC (50µM) 0.3  68 30 sec 
Expand High Fidelity polymerase 0.75  68 8 min* 
cDNA 1  68 20 min  
Total 50  4 Hold  














dH2O 41.75  94 2 min  
10 X Buffer 1 (with Mg++) 5  94 10 sec 
10 dNTPs (20 mM) 0.9  68 30 sec 
Primer 2U5C (50µM) 0.3  68 8 min 
Primer 2.3.3pIC (50µM) 0.3  94 10 sec 
20 Expand High Fidelity polymerase 0.75  68 30 sec 
1st round product 1  68 8 min* 
Total 50  68 20 min  
   4 Hold  
*An additional 20 sec of template elongation time was added on per cycle 
 
The PCR cycler heating block was heated to 80°C before inserting PCR tubes so as to allow for 
more specific primer binding.  PCR products (3-5 µl) were electrophoresed on a 1% agarose gel 
alongside a 1 kb DNA ladder marker (Promega, Madison, USA).  Near full-length amplicons 
were approximately 9 000 base pairs in size.  PCR products were purified using ExoSAP-IT 
(USB, Cleveland, USA) according to manufacturer instructions and directly sequenced.  All 
products were directly sequenced using the ABI 3000 genetic analyzer (Applied Biosystems, 
Foster City, CA, USA) and BigDye terminator reagents. 
Amplicons with up to six ambiguous base pair positions were accepted.  While the stipulated 
criteria for SGA sequences is zero base pair ambiguities for the env gene (Salazar-Gonzalez et 
al., 2008), near full-length genomes without any base ambiguities were rare.  Salazar-Gonzalez 
et al. (2009) accepted up to five ambiguous base pair positions per near full-length genome 
when sequencing amplicons obtained at <20% PCR positivity, attributing these to polymerase 
Taq error when considering the fidelity of the Taq enzyme rather than a consequence of 
amplification of mixed template populations.  Sequences with deletions that were >6 000 base 
pairs in length were accepted for inclusion in data analysis. 
 
2.5.5 Limiting dilution amplification (LDA) 
Due to difficulties with near full-length genome amplification which included low viral load 
plasma samples and limited volume of plasma samples (particularly for the viremic controller in 
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this study), sequence numbers were supplemented by including PCR amplicons obtained at 
>30% reaction positivity generated as per the protocol indicated in section 2.4.3 above.   Seven 
percent of these contained more than six base pair ambiguities. 
 
2.5.6 Derivation of the transmitted/founder (t/f) virus sequence 
Sequences from the earliest time-point post-infection (2-5 weeks post-infection for the five 
women in this study) were aligned using BioEdit version 7.0.8.0 (Hall, 1999).  A consensus of 
these sequences for each participant was generated by determining the majority nucleic acid 
base identity at each position along the genome.  The t/f derivation for near full-length 
sequences was further dependent on all open reading frames (ORFs) of the consensus 
generated being intact (Salazar-Gonzalez et al., 2009) and on the env ORF matching that 
derived for t/f env-only data for that participant. 
 
2.5.7 Sequence analyses 
Sequences were subtyped using the REGA HIV Subtyping Tool 
(http://dbpartners.stanford.edu/RegaSubtyping/).  Sequence diversity was evaluated using pair-
wise DNA distance matrices and Neighbour-Joining phylogenies generated in MEGA 4 (Tamura 
et al., 2007), as well as pair-wise hamming distances.  Branch lengths (the number of nucleotide 
substitutions per site) were estimated using Treerate 
(http://www.hiv.lanl.gov/content/sequence/TREERATEv2/treerate.html).  Nucleotide base 
synonymous and non-synonymous mutations were visualized using Highlighter plots 
(http://www.hiv.lanl.gov/content/sequence/HIGHLIGHT/highlighter).  Sequences were assessed 
for the presence of host restriction enzyme APOBEC-driven G to A hypermutation using the 
Hypermut tool (http://www.hiv.lanl.gov/content/sequence/HYPERMUT/hypermnut.html).  
Potential N-linked glycosylation sites were identified using N-GlycoSite 
(http://www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html).  CTL epitope prediction, 
based on participant HLA information and identification of anchor residues within env 
sequences were identified using Motif Scan 
(http://www.hiv.lanl.gov/content/immunology/motif_scan/motif_scan).  Evidence of 
recombination in env sequences was identified using GARD (www.datamonkey.org/GARD/) 
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(Kosakovsky Pond et al., 2006), RAP Beta version (www.hiv.lanl.gov) and RDP version 3.27 
(http://darwin.uvigo.es./rdp/rdp.html) (Martin et al., 2005). 
The time to most recent common ancestor (tMRCA) of env sequences was determined by N. 
Wood (University of Cape Town) using BEAST (Bayesian Evolutionary Analysis Sampling 
Trees) v1.4.7 (Drummond et al., 2006; Drummond and Rambaut, 2007) with the following 
parameters: a relaxed, uncorrelated exponential molecular clock with general time-reversible 
substitution model, gamma distribution with four categories and a proportion of invariant sites, 
substitution rates unlinked across codon sites at 2.16 x 10-5 substitutions/site/generation 
(Mansky et al., 1995).  Relative substitution rates were determined using HyPhy (Pond et al., 
2005; Keele et al., 2008).   
Distribution of env sequence hamming distances and conformance to a star-like phylogenetic 
tree structure was determined by E. Giorgi (Los Alamos National Laboratory, New Mexico).  
 
2.5.8 Statistical testing 




2.6.1 Multiplicity of infection of women in the CAPRISA 002 AI cohort 
In order to determine the number of t/f variants that established clinical infection in 26 women 
from the CAPRISA 002 AI cohort, Durban, South Africa, a total of 515 full-length env sequences 
were generated using single genome amplification and direct sequencing of amplicons.  An 
average of 20 env SGA sequences was generated per participant from the earliest time point 
post-infection.  These women were estimated to be infected for two to five weeks based on 
clinical testing (see Methods and Materials, section 2.5.1).  Estimates of recent infection were 
confirmed by staging of plasma for the presence of biological markers as described by Fiebig et 
al. (2003), which revealed that seven women were in stage I/II (viral RNA positive only), three 
were in stage III (EIA antibody positive but Western blot negative), four in stage IV 
(indeterminate Western blot), ten in stage V (Western blot positive without p31 (integrase band) 
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and finally two in stage VI (Western blot positive with p31 band).  Although peak viremia occurs 
in Fiebig I/II prior to detectable antibody responses, this is not evident in this cohort possibly 
because viral load was still increasing for some women at the time of sampling (Figure 12).   
I/I




























Figure 12. Staging of acute HIV infection and early viremia. The range of log viral load 
values for women in the six stages of acute infection defined by the appearance of early clinical 
markers (Fiebig et al., 2003).  
In order to determine the number of t/f variants that established clinical, intraparticipant env 
sequences were analyzed for conformance to the following criteria: (i) sequence diversity based 
on pair-wise DNA distance and structure of a Neighbour-Joining phylogeny, (ii) the distribution 
of hamming distances between sequences, and (iii) the time to the most recent common 
ancestral sequence (tMRCA) based on a Bayesian analysis of sequence evolution.  Sequences 
having high homogeneity, a star-like phylogeny, a Poisson distribution of hamming distances, 
and a tMRCA conferring with the clinical estimate of time of infection were classified as 
conforming to the model of random evolution from a single t/f virus (Keele et al., 2008).   
Intraparticipant sequences from thirteen of the 26 women conformed to these criteria and were 
classified as infected with a single variant (Table 1A, Figure 13A).  Sequences from a further 
seven women displayed low-level diversity (0.05-0.26% DNA distance) and violated one or 
more of the criteria for single t/f variant infection due to the presence of shared mutations or 
APOBEC hypermutation (Table 1B, Figure 13B).   For these women, the mean tMRCA in days 
exceeded the clinically estimated days post-infection by a factor of two to eight.   Five women 
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conformed to the model after removal of APOBEC mutations and for a further two women 
(CAP8 and CAP269) shared mutations could be explained by immune pressure. In the case of 
CAP8, these shared mutations were situated within a Class I HLA-B*08:01-restricted epitope 
and were classified as CTL-mediated immune pressure.  In the case of CAP269, amino acid 
insertions resulted in the lengthening of the V1 loop and the introduction of multiple potential N-
linked glycosylation sites and were therefore associated with Ab-mediated selection.  
Sequences from the remaining six women displayed high-level diversity and did not conform to 
the model criteria.  These women were classified as infected with multiple (two-five) t/f variants 
(Table 1C).  Intraparticipant DNA distances of sequences from these women ranged from 0.4 to 
1.29%, and the structure of the sequence phylogenies displayed clustering of unique variants 
(Figure 12C). Mean tMRCA in days exceeded the clinically estimated days post-infection by 33 
to 400-fold.  Recombination between variants was identified in four of the six women. 
 
2.6.2 Sexually transmitted infections and multiplicity of infection 
A relationship between sexually transmitted infections (STIs) close to the time of transmission 
and the number of variants transmitted was investigated.  STI data from the time of study 
enrolment (two to nine weeks post-infection) were available from CAPRISA.  Twenty-four of the 
26 women had a current STI (Table 2).  Only two women had genital ulcers at the time of 
examination. 
All women were Herpes Simplex Virus 2 (HSV2) antibody positive, however only one woman, 
CAP220, who was infected with a single t/f variant, was viral PCR positive indicating active 
HSV2 infection.  Bacterial vaginosis was the most common STI, detected in 73% percent of 
women.  Fisher’s categorical tests were used to investigate an association between having an 
STI and single or multivariant infection.  No statistical difference was detected between the 
frequency of individuals with either Neisseria gonorrhoea (p=0.2184), Bacterial vaginosis (p=1), 
Trichomonas vaginalis (p=0.4154) or Mycoplasma genitalium (p=1) in the two groups. The 
average number of STIs in the single and multivariant-infected groups was equal (n=1).   
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number of days 







CAP45 I/II 20-Apr-05 12 500 16 0.02 18 (4-35) 14 
CAP129 IV 13-Jun-06 1 800 000 19 0.03 22 (6-42)  17 
CAP174 V 22-Sep-05 40 000 21 0.06 33 (15-54) 14 
CAP177 I/II 07-Mar-06 359 000 20 0.03 17 (5-33) 14 
CAP188 I/II 25-Jan-07 13 800 000 22 0.04 22 (7-40) 14 
CAP200 IV 11-Oct-05 398 000 18 0.04 26 (13-45) 14 
CAP206 V 15-Jun-05 196 000 21 0.05 29 (15-49) 28 
CAP210 I/II 03-May-05 468 000 21 0.01 11 (3-25)  14 
CAP217 IV 02-Dec-05 3 260 000 20 0.02 16 (4-38)  16 
CAP220 V 15-Feb-07 2 070 15 0.08 45 (17-75) 23 
CAP221 I/II 02-Mar-06 24 300 21 0.07 42 (23-73) 14 
CAP237 III 06-Mar-07 1 020 000 22 0.04 26 (9-46) 13 



























no. days since 
MRCA      





MRCA      













reasons for not 
conforming to 
the model 
CAP8 V 11-May-05 207 000 19 0.18 147 (67-261) N/A 18 No No CTL- selection 
CAP40 VI 25-Apr-06 90 500 22 0.18 129 (68-208) 102 (42-168) 27 No No APOBEC-3G 
CAP63 III 06-Jan-05 3 210 000 19 0.06 33 (17-55) 30 (10-53) 15 Yes Yes APOBEC-3G 
CAP84 V 16-Feb-05 559 000 22 0.06 36 (17-64) 26 (8-49) 10 No Yes APOBEC-3G 
CAP85 V 22-Jun-05 621 000 21 0.15 106 (50-181) 53 (20-101) 36 Yes No APOBEC-3G 
CAP225 III 25-Oct-05 63 600 000 20 0.05 39 (20-68) 25 (12-46) 14 No Yes APOBEC-3G 
CAP269 VI 27-Sep-06 2 170 18 0.26 205 (110-325) N/A 25 No Yes Ab- selection 
 
 




















BEAST mean no. 








CAP37 IV 11-May-06 248 000 20 3 Yes 1.18 5998 (2192-12321) 15 
CAP69 I/II 31-Jan-06 15 300 20 5 Yes 1.29 2449 (1059-4622) 14 
CAP136 V 29-Jun-06 85 300 16 2 Yes 0.37 605 (221-1208) 12 
CAP222 I/II 05-Apr-06 69 700 21 3 No 0.79 1390 (512-2767) 14 
CAP224 V 15-Nov-06 1 348 000 19 2 No 0.4 687 (257-1363) 21 
CAP260 V 08-Feb-06 17 600 18 2 Yes 1.23 1702 (750-3083) 16 















Figure 13. Env t/f multiplicity of infection. The diversity of env sequences sampled from two to five weeks post-infection for three women from 
the CAPRISA 002 AI cohort is illustrated by Neighbour-Joining phylogenies (left) and Highlighter plots of nucleotide differences to the derived t/f 
consensus sequence (www.hiv.lanl.gov) (right). Green=A, Red=T, Orange=G, Light Blue=C, Black=gaps.  Represented are: (A) an homogeneous 
single t/f variant infection, (B) a single t/f variant infection with evidence of Ab-mediated immune selection in the form of amino acid insertions in 
the V1 loop (encircled), and (C) a multivariant t/f infection (five variants with recombination).  The tree scale bar = 0.0001. 
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Sexually transmitted infection* 
CAP8 3 Single C. trachomatis 
CAP37 6 Multiple B. vaginosis, N. gonorrhoea 
CAP40 3 Single T. vaginalis, M. genitalium 
CAP45 5 Single B. vaginosis 
CAP63 4 Single B. vaginosis 
CAP69 5 Multiple N. gonorrhoea 
CAP84 3 Single B. vaginosis, C. trachomatis 
CAP85 5 Single B. vaginosis 
CAP129 4 Single B. vaginosis 
CAP136 2 Multiple B. vaginosis 
CAP174 4 Single B. vaginosis 
CAP177 4 Single B. vaginosis, N. gonorrhoea 
CAP188 4 Single B. vaginosis  
CAP200 6 Single B. vaginosis 
CAP206 8 Single B. vaginosis 
CAP210 5 Single 
 
CAP217 9 Single B. vaginosis, M. genitalium 
CAP220 3 Single HSV2 PCR+ 
CAP221 5 Single B. vaginosis, N. gonorrhoea 
CAP222 6 Multiple T. vaginalis 
CAP224 5 Multiple B. vaginosis 
CAP225 3 Single B. vaginosis 
CAP237 4 Single 
 
CAP239 5 Single B. vaginosis 
CAP260 2 Multiple B. vaginosis, M. genitalium 
CAP269 4 Single B. vaginosis 
*C. trachomatis = Chlamydia trachomatis; B. vaginosis = Bacterial vaginosis; N. gonorrhoea = Neisseria 
gonorrhoea; T. vaginalis = Trichomonas vaginalis; M. genitalium = Mycoplasma genitalium; HSV2 = 








2.6.3 Selection of five women for near full-length genome characterization 
Five participants CAP45, CAP63, CAP85, CAP210, and CAP239 were selected for further 
characterization based on their recent infection with a single t/f variant and differential disease 
progression profiles.  Demographic information for each of the women is provided in Table 3.  
Participants CAP45 and CAP210 were Ab negative, viral RNA positive (stage I/II) at the first 
sampling date, while participants CAP63 and CAP85 were Ab positive but did not yet have the 
full spectrum of reactive HIV-specific Abs (stage III and V).  For participant CAP239, due to 
limited sample availability, staging of infection was carried out on the sample taken three weeks 
subsequent to the earliest sampled time-point.  However, since the stage of infection for the 
later sample was classified as stage V, we can extrapolate that this participant was likely to be 
in the very early stages of infection at the first sampled time-point.  All participants harboured 
viruses with low env sequence diversity (mean DNA distance 0.06%) and a calculated mean 
tMRCA of 34 days (see Table 1A). 
Disease progression was defined based on viral loads and CD4+ T-cell trajectory in the first 
year of infection.  Participant CAP45 was a viremic controller with viral loads consistently below 
2 000 copies/ml and CD4 counts above 350 cells/µl (Pereyra et al., 2008), while participants 
CAP63 and CAP210 were rapid progressors based on CD4 counts below 350 cells/µl and viral 
loads of >100 000 copies/ml on two consecutive visits in the first year of infection (Mlotshwa et 
al., 2010, Moore et al., 2009) (see Figure 14).   
For participant CAP63 disease progression was particularly rapid with referral to anti-retroviral 
therapy (based on prevailing guidelines of therapy initiation at counts <200 cells/µl) (National 
Department of Health South Africa, 2004) within nine months post-infection.  Participants 
CAP85 and CAP239 did not fit criteria for either rapid progression or viremic control and were 








Table 3.  Demographic and viral sequencing information for five selected women from the 






















CAP45 41 Viremic controller I/II A*23:01, 29:02 20-Apr-05 2 3 
    
B*15:10, 45:01 11-May-05 5 6 
    
Cw*06:02, 16:01 28-Jun-05 12 3 
     
27-Jul-05 16 1 
     
   
CAP63 32 Rapid III A*02:01, 23:01 06-Jan-05 2 11 
    
B*45:01 09-Mar-05 11 7 
    
Cw*04:01, 16:01 13-Jul-05 29 10 
        
CAP85 24 Intermediate V A*30:02 22-Jun-05 5 8 
    
B*08:01, 45:01 18-Aug-05 13 9 
    
Cw*07:01, 16:01 07-Dec-05 29 7 
        
CAP210 43 Rapid I/II A*68:02 03-May-05 2 9 
    
B*15:10 13-Jun-05 12 7 
    
Cw*03:04 19-Oct-05 26 11 
        
CAP239 44 Intermediate nd
3
 A*01:01, 29:02 19-Jul-05 2 2 (3) 
   
V* B*42:01, 58:01 10-Aug-05 5 8 
    
Cw*06:02, 17:01 21-Sep-05 11 2 
     
07-Dec-05 22 9 
     
   
1
According to CD4 count/viral load in the first year of infection 
2
Fiebig stages (Fiebig et al., 2003) determined for first sequenced time-point: (I/II) HIV RNA positive but antibody 




Time from mid-point date between first positive and last negative HIV EIA test to date of sampling, or time since first 
HIV RNA positive date plus 14 days in antibody negative individuals 
5
Whole genome sequence numbers include smaller genomes no less than 6 000 bp in size 




























Figure 14.  Clinical disease progression in five selected women. Viral load (black lines) and CD4+ T-
cell count (blue lines) trajectory over 120 weeks of infection for five women from the CAPRISA 002 AI 
cohort, participants CAP45 (A), CAP85 (B), CAP239 (C), CAP63 (D) and CAP210 (E).  Disease 
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2.6.4 Derivation of near full-length genome t/f sequences  
To derive the sequence of the t/f virus and characterize early viral diversity, a total of 113 near 
full-length genomes were generated from time-points corresponding to CAPRISA 002 AI study 
screening/enrolment (two to five weeks post-infection; average n=9 sequences per participant), 
three months (11-13 week post-infection; average n=6 sequences per participant) and six 
months (22-29 weeks post-infection; average n=9 sequences per participant) (see Table 3).  
Due to low viral loads for viremic controller participant CAP45, no sequences could be 
generated at six months post-infection for this individual.  
Sequences were all HIV-1 subtype C across the genome and intra-participant sequences 
grouped together on a phylogenetic tree (Figure 15).  The median intra-participant viral 
population diversity at the earliest sampled time-point was 0.03% (range 0.008 to 0.257%).  As 
expected, participants sampled earlier in infection (Fiebig stage I/II, CAP45 and CAP210), 
displayed lower intra-participant pair-wise DNA distances (0.016% and 0.008% respectively) 
compared to participants sampled later in infection (Fiebig stage III and V for CAP 63 and 85 
respectively), whose intra-participant population diversity was 0.032% and 0.257% respectively.  
Finally, for participant CAP239 who was classified as stage V at five weeks post-infection, 
population diversity was 0.047% based on the only two sequences sampled at the earliest time-
point (two weeks post-infection).  Low numbers of sequences sampled at the earliest time-point 
for participants CAP45 (n=3) and CAP239 (n=2) may have resulted in an under-estimation of 
diversity.  
Using methodology described by Salazar-Gonzalez et al.  (2009), a consensus of sequences 
sampled at the earliest time-point was extrapolated and assumed to be the t/f viruses for each 
of the five women.  A limited number of non-SGA sequences, obtained from limiting dilution 
PCR, were included in derivation of the t/f consensus since any nucleotide ambiguities in these 
sequences would represent a minority at a given position and thus their impact would be 
negated through consensus generation.  For example, in the case of viremic controller CAP45 
for whom a limited number of sequences (n=3) could be generated, shared ambiguity between 
two sequences at one nucleotide position was resolved by the third sequence which had no 



















Figure 15.  Neighbour-Joining tree of HIV-1 near full-length genome sequences from five subtype 
C-infected women from the CAPRISA 002 AI cohort.  Clinical disease progression is indicated by 
colour: viremic control (grey), intermediate progression (black) and rapid progression (red).  Sequences 
from two weeks post-infection are indicated by open circles, five weeks post-infection by solid circles, 11-
13 weeks post-infection by open squares, and 22-29 weeks post-infection by solid squares. 
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As with the env-only analyses, near full-length genome sequences from CAP45, CAP210 from 
the earliest time-point and CAP239 from five weeks post-infection (the time-point used for the 
env-only study) displayed a star-like phylogeny (Figure 16-18). No shared mutations were 
present in earliest sequences from CAP45 and CAP210; however shared mutations potentially 
associated with immune selection were identified in CAP239 (Figure 18). These participants 
were thus confirmed to be infected with a single t/f full-length genome viral variant. For 
participants CAP63 and CAP85, although env-only sequencing indicated infection with a single 
t/f variant, analysis of near full-length genome sequences revealed that each of these 
individuals was infected with a second very closely related variant (Figure 17).  In the case of 
CAP63, the two variants differed at five nucleotide positions, none of which were in env.  In the 
case of CAP85, the two variants differed at seven nucleotide positions, of which three were 







Figure 16. Near full-length genome t/f virus 
derivation for CAP45. The diversity of near full-
length genome sequences sampled from two 
weeks post-infection for participant CAP45 is 
illustrated by a Neighbour-Joining phylogeny 
(below) and a Highlighter plot of nucleotide 
differences to the derived t/f consensus 
sequence (www.hiv.lanl.gov) (top). Green=A, 
Red=T, Orange=G, Light Blue=C, Black=gaps.  
Env SGA sequences from two weeks post-
infection, used for identification of multiplicity of 



























Figure 17. Near full-length genome t/f virus derivation for CAP63 and CAP85. The diversity of near 
full-length genome sequences sampled from two weeks post-infection for participant CAP63 (A) and five 
weeks post-infection for participant CAP85 (B) is illustrated by Neighbour-Joining phylogenies (below) 
and Highlighter plots of nucleotide differences to the derived t/f consensus sequence (www.hiv.lanl.gov) 
(top). Green=A, Red=T, Orange=G, Light Blue=C, Black=gaps. The second, closely related t/f variant 
identified in each of these individuals is indicated in a grey box.  Env SGA sequences used for 
identification of multiplicity of infection are included. The tree scale bar = 0.0001. 
0.0001
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Figure 18. Near full-length genome t/f virus derivation for CAP210 and CAP239. The diversity of 
near full-length genome sequences sampled from two weeks post-infection for participant CAP210 (A) 
and CAP239 (B) is illustrated by Neighbour-Joining phylogenies (below) and Highlighter plots of 
nucleotide differences to the derived t/f consensus sequence (www.hiv.lanl.gov) (top). Green=A, Red=T, 
Orange=G, Light Blue=C, Black=gaps. Env SGA sequences used for identification of multiplicity of 
infection are included. Gag sequences used in derivation of the near full-length t/f virus sequence in 
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2.6.5 Viral diversification in acute and early infection 
Longitudinal near full-length genomes from each woman were analyzed for the rate and extent 
of nucleotide sequence diversification in early infection.  Diversity was measured as 
intraparticipant pair-wise DNA distances at screening/enrolment, three months (acute infection) 
and six months (early infection) post-infection.   
The mean DNA distance across the genome increased by an average of 0.15% between the 
earliest sampled time-point (two to five weeks post-infection) and three months for four of the 
women, and decreased by 0.017% in one woman (CAP85) (Figure 19A).  In the subsequent 
three months, mean DNA distances increased in all women analyzed by an average of 0.13% 
(no sequence data was available for CAP45 for this analysis). 
When considering the rate of sequence diversification, on average, mean intraparticipant DNA 
distances increased by 0.016% per week (range 0.013 – 0.024%) across the genome for all 
women between screening/enrolment and three months post-infection with the exception of 
CAP85 for whom diversity decreased, by 0.008% per week (range 0.003 – 0.012%) between 
three and six months.  The rate of sequence diversification for rapid progressor CAP63 was 
highest compared to other women from both screening/enrolment to three months and three to 
six months with mean DNA distance increases of 0.024 and 0.012% per week respectively.  
Rates of diversification across the genome from the earliest time-point to three months were 
modestly higher than in the subsequent three months, even when including the participant for 
whom diversity initially decreased, however values were not significantly different (Figure 19B).   
The range of pair-wise DNA distances for acute and early infection was compared between 
participants using one-way ANOVA with Bonferroni correction for multiple comparisons.  
Significant differences in diversity between participants were observed at both three and six 
months (p<0.0001) (Figure 19C and D).  Rapid progressor CAP63 and intermediate progressor 
CAP85 stood out as having greater diversity.  DNA distances for these women were significantly 






















Figure 19.  Sequence diversity of near full-length genome sequences in early infection. The rates of 
sequence diversification in the first three months and between three and six months of infection are 
illustrated in (A) and compared in (B).  Pair-wise DNA distance ranges for the five women at three (C) and 
six (D) months of infection are illustrated by box and whisker (minimum to maximum) plots.  Data for 
CAP45 was only available for the first three months. Significant differences in data sets are indicated by 
horizontal bars (* = p<0.05 but >0.01, ** = p<0.01 but >0.001, *** = p<0.001). 
Although viremic controller CAP45 had the lowest range of DNA distances at three months, this 
did not differ significantly from other participants, possibly due to low sequence numbers.  For 
both participants CAP45 and CAP239 at three months, low sequence numbers (n=3 and n=2 
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2.6.6 Viral evolution of the t/f sequence 
In order to investigate whether the rate of evolution from t/f virus sequences in early infection 
differed between individuals with different disease progression, branch lengths of near full-
length genome and gene-specific phylogenies over the first three and six months of infection 
were calculated.  Branch lengths represent the number of substitutions per nucleotide site over 
time.  
In a comparison of evolution of near full-length genomes between participants, significant 
differences in branch lengths were identified at both three (p=0.0009) (Figure 20A) and six 
months post-infection (p<0.0001) (Figure 20B) [using one-way ANOVA with Bonferroni 
correction for multiple comparisons].  Sequences from participants CAP63 and CAP85 had the 
longest branch lengths at both time-points.  Differences in branch lengths between these two 
women and participants CAP210 and CAP239 were more pronounced at six months than at 
three months.  Viremic controller CAP45 had the shortest branch lengths, however this may be 










Figure 20. Near full-length genome branch length comparisons between women. The range of 
branch lengths of phylogenetic trees from each of the five women are illustrated by minimum-to-maximum 
box and whisker plots for (A) three months and (B) six months post-infection.  Significant differences in 
branch lengths between participants are indicated by horizontal bars (* = p<0.05 but >0.01, ** = p<0.01 
but >0.001, *** = p<0.001). 
















































































The evolution of sequences was next investigated on a per-gene level and compared between 
women.  Smaller genes tat, rev and vpu were excluded since evolution in these genes on a 
nucleotide level would overlap with the env open reading frame and would conflict comparisons 
between genes.  Average per-gene branch lengths were longest in env and nef at three and six 




































































































Figure 21. Average per-gene branch lengths in early infection. An average per-gene branch length of 
phylogenetic trees from each of the five women is plotted at three and six months post-infection.  
Horizontal bars indicate mean values. 
When comparing between women, significant differences in branch lengths were identified at 
three months post-infection in four of the six genes analyzed, gag (p=0.0011), vpr (p=0.0044), 
env (p<0.0001) and nef (p=0.0001) [one-way ANOVA with Bonferroni correction for multiple 
comparisons] (Figure 22A).  Significant differences in branch lengths between women were 
identified in the same four genes at six months post-infection (gag p=0.0101; vpr p<0.0001; env 






















Figure 22. Per-gene branch length comparisons between women. The range of branch lengths of 
phylogenetic trees at three (A) and six (B) months post-infection from each of the five women for gag 
(green), pol (black), vif (blue), vpr (grey), env (red) and nef (purple) are illustrated by minimum-to-
maximum box and whisker plots.  Significant differences in branch lengths between participants are 
indicated by horizontal bars (* = p<0.05 but >0.01, ** = p<0.01 but >0.001, *** = p<0.001). 
Sequences from intermediate progressor CAP239 had significantly longer branch lengths in gag 
in the first three months post-infection compared to all other women, while viremic controller 
CAP45 and rapid progressor CAP63 had the shortest branch lengths for this gene.  CAP63 and 
intermediate progressor CAP85 had the longest branch lengths in env at three and six months 
post-infection.  In nef, at both time-points analyzed, participant CAP85 had the longest branch 




















































































































































































































































































This study investigated the number of t/f viruses establishing clinical infection in acutely subtype 
C-infected women from the CAPRISA 002 AI cohort in Durban, South Africa, using env 
sequence data. In a focused analysis of five women with differing disease progression, and 
identified as infected with a single t/f variant by env sequence analyses, near full-length t/f virus 
genome sequences were derived and early viral diversification and evolution across the 
genome in each woman was described.  To our knowledge, this was the first subtype C near 
full-length genome study which investigated early viral evolution of t/f virus sequences in the 
context of disease progression. 
In 26 CAPRISA 002 women investigated, 77% of infections were found to be due a single t/f env 
variant based on conformance to a model of random evolution (Keele et al., 2008).  This result 
is similar to that described for the larger CHAVI study, which these women formed part of, which 
reported 78% of 69 individuals with subtype C infection from Malawi and South Africa to be due 
to a single variant (Abrahams et al., 2009).  Sequences from six women (23%) did not conform 
to the model of random evolution and these women were classified as infected with between 
two and five t/f variants.  For seven women with single-variant infection, low-level sequence 
diversity was identified and attributed to host-restriction from APOBEC and adaptive immune 
responses.  This diversity resulted in deviation from model conformance, since evolution was 
not random but rather influenced by selection. 
Halaand et al. (2009) reported an association between multivariant t/f virus infection and the 
presence of STIs.  The women in the present study had a high frequency of STIs.  The 
frequency of infection with any STI (38%) for the 26 CAPRISA 002 women was slightly 
increased compared to the 31% reported for HIV-uninfected high-risk South African women 
(Mlisana et al., 2012).  The percentage of women infected with N. gonorrhoea, the STI most 
strongly associated with risk of HIV infection (Mlisana et al., 2012), was however three-fold 
higher than that reported for uninfected women (5% compared to 15%) (Mlisana et al., 2012).  
No association between the number of STIs or specific STIs and multiplicity of infection was 
identified.  Of interest, the woman with the highest multiplicity of infection (five variants) also had 
N. gonorrhoea, however two other women with single-variant infection were also infected with 
this STI.   
Transmission of single-variant, low-diversity t/f viruses in a subset of five women was confirmed 
by near full-length genome sequencing.  Two women (CAP63 and CAP85), although identified 
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as infected with a single variant by env-only sequence analyses (Abrahams et al., 2009), were 
each found to be infected with a second very closely related variant following near full-length 
genome analyses.  These variants represented minority populations and were not detected at 
subsequent time-points.  However, since half the number of genomes were sequenced at three 
and six months compared to the number sequenced at screening/enrolment, it is possible that 
these variants may have persisted at later time-points and were not detected due to small 
sampling size, yet they likely did not gain dominance in the overall population.  Although these 
additional variants were not detected by env-only SGA, we do not believe that this disputes the 
use of env-only SGA for determining multiplicity of infection nor advocates the use of near full-
length genome amplification for this purpose since: (i) within an individual, variants differed only 
by a few nucleotides across the genome and did not represent high diversity, multi-variant 
infection; (ii) amplification of near full-length genomes would not only be more costly, but 
achieving high sequence numbers needed for diversity analyses would be more challenging.  
The results of this study support env-only SGA as a sensitive technique for determining 
multiplicity of infection. 
Early studies have reported a relationship between viral evolution or diversity of HIV-1 and 
clinical disease progression (Wolfs et al., 1990; Lukashov et al., 1995; Wolinsky et al., 1996; 
Ganeshan et al., 1997; Liu et al., 1997; McDonald et al., 1997; Shioda et al., 1997; Markham et 
al., 1998), with the majority investigating only the env gene or regions thereof, and finding an 
association between higher genetic diversity or rate of evolution and slow disease progression.  
Of the five women focused on in this study, viral diversification and evolution was more rapid 
and extensive in rapid progressor CAP63 and intermediate progressor CAP85 compared to the 
other three women.  Interestingly, for participant CAP63, diversification was extensive in env 
and only minimal diversification was seen in the gag and pol genes.  Sequences from viremic 
controller CAP45 displayed the lowest diversity and extent of evolution at three months post-
infection, however this may have been due to low sample number. 
In a more recent study, Herbeck et al. (2011) reported a contraction of viral diversity in near full-
length genomes from 11 subtype B-infected MSM individuals within the first 20-40 days post-
infection (taken as days after onset of clinical symptoms, thus the actual period of infection was 
likely longer), despite continuous viral outgrowth.  The authors hypothesized this to be due to 
viral expansion from a single or limited number of variants, or due to purifying selection 
eliminating hypermutated viruses (Herbeck et al., 2011).  In the current study, a comparison of 
viral diversification between participants showed an increase in sequence diversity in the first 
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three months for four women and a contraction in diversity for one woman.  Furthermore, the 
rate of sequence diversification was higher in the first three months of infection than between 
three and six months, although this difference was not statistically significant.  Interestingly, the 
Herbeck study also reported early selection to be dominant in env and nef.  In the current study, 
evolution was more extensive in env and nef at both three and six months post-infection 
compared to gag, pol, vif and vpr.  Immune selection for these women will be investigated in 
Chapter 3 of this thesis. 
The use of near full-length genomes in this study allowed for comparison of rates of 
diversification and evolution of individual HIV-1 genes.  However, the numbers of sequences 
used in these analyses were limiting for certain individuals/time-points due to challenges 
inherent in full-length genome amplification techniques including sample availability and cost.  It 
is therefore important to note that the rates of diversity and evolution reported may have been 
underestimated for the individuals in this study.  None-the-less, the data provides insight into 
which genes evolve more rapidly and are potentially preferred targets of early immune 
responses, and therefore form a basis for selection of individual genes for which greater depth 
of sequencing would be beneficial. 
This chapter has described the multiplicity of infection and the early viral evolution of subtype C 
t/f viruses in the context of differing disease progression.  Increased diversity and more rapid 
evolution were reported for virus from one rapid disease progressor.  The impact of specific 
immune responses mediated by CD8+ T-lymphocytes and antibodies in acute/early infection will 
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Elucidation of HIV-1 immune escape mutations acquired following infection is a sensitive 
approach to identifying the earliest immune pressures associated with control of viral replication 
in primary infection.  The purpose of this study was to characterize the earliest changes in near 
full-length genomes following infection to better understand early control of viremia. 
Near full-length transmitted/founder and early (first six months of infection) viral sequences from 
five women recruited within two to five weeks of infection (Chapter 2) were analyzed for the 
presence of amino acid mutations associated with cytotoxic T-lymphocyte and neutralizing 
antibody immune selection.  
Fifty-five genome regions were identified with amino acid mutations associated with viral 
adaption to the new host.  The majority of mutations were attributed to CD8+ T-lymphocyte 
pressure (40%), followed by antibody-mediated pressure (35%) and reversion of transmitted 
mutations (16%).  Nine percent of mutations could not be classified.  CD8+ T-lymphocyte 
escape was most frequent in Nef, followed by Pol and Env, and occurred at a higher frequency 
in the first five weeks of infection followed by a decline as viral load declined.  In the majority of 
mutating CD8+ T-lymphocyte epitopes (82%), amino acid shuffling and toggling was observed 
with only 9% reaching fixation in the first six months of infection.   
In conclusion, CD8+ T-lymphocyte-mediated immune pressure was the predominant selective 
force in primary subtype C infection.  Immune escape was rapid and frequently characterized by 













3.2.1 Immune selection in the HIV-1 genome 
HIV replication is highly error prone (Mansky et al., 1995) which enables the virus to rapidly 
escape immune responses through the introduction of amino acid mutations.  Mutations that are 
advantageous to the virus are maintained and become fixed over time within the host and 
therefore represent a form of positive selection (Price et al., 1997). Following transmission 
however, these mutations may not be advantageous in the new recipient and may revert to the 
wild-type form (reversion) (Leslie et al., 2004; Moore et al., 2012).  If escape mutations are 
associated with a loss of viral fitness, they may be compensated by additional mutations at 
proximal or distant sites (Brockman et al., 2007, Crawford et al., 2007).  Sequence changes 
associated with immune selection mediated by CD8+ T-lymphocytes (CTLs) and antibody (Ab) 
responses, as well as reversion and compensatory mutations, have been well described 
(Figure 23).   
 
Figure 23.  The accumulation of mutations associated with immune selection across the genome 
over the course of acute and early HIV-1 infection (illustration taken from McMichael et al., 2010). 
Stages II (viral RNA and p24 antigen positive, but Ab negative) and IV (ELISA positive but Western blot 
indeterminate) of acute infection as defined by Fiebig et al (2003) are indicated corresponding to peak 
viremia and viral load decrease following peak viremia respectively. 
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Selection patterns in viral sequences from other sources such as CD4+ T-cells and natural killer 
(NK) cells are not as well characterized, although polymorphisms associated with escape from 
NK cell pressure mediated by killer immunoglobulin-like (KIR) receptors has been described 
(Alter et al., 2011). 
CTL responses are mediated via HLA Class I molecules which recognize sequences within the 
viral genome and present short peptides to CD8 receptors on the surface of CTLs. CTL escape 
occurs when mutations (i) occur in HLA-binding anchor residues and prevent peptide 
presentation; (ii) obscure recognition by T-cell receptors; or (iii) alter peptide processing within 
an infected cell thereby preventing peptide presentation  (Borrow et al., 1997, Goulder et al., 
1997, Feeney et al., 2004, Draenert et al., 2004; Tenzer et al., 2009).  Mutations associated with 
CTL escape have been extensively characterized (Borrow et al., 1997, Goulder et al., 1997, 
Draenert et al., 2004, Allen et al., 2005, Brumme et al., 2007, Brumme et al., 2008, Brumme et 
al., 2008b, Brumme et al., 2009, Carlson et al., 2012a; Carlson et al., 2012b).  This data, 
together with mapping of HLA Class I genotype associated mutations in population-based 
studies (HLA-associated polymorphisms) (Moore et al., 2002; Kiepiela et al., 2004; Brumme et 
al., 2007; Kiepiela et al., 2007; Brumme et al., 2008; Brumme et al., 2008b; Matthews et al., 
2008; Rousseau et al., 2008; Brumme et al., 2009; Carlson et al., 2012a) have made it possible 
to predict CTL escape through viral sequencing when the HLA type of the individual is known.  
Escape is typically characterized by transitions from high frequency/consensus to low 
frequency/nonconsensus amino acids and may fall within or flank targeted epitopes (Allen et al., 
2004; Liu et al., 2006).  A single amino acid change in a site evolving under positive selection or 
a cluster of mutations in short peptide stretches have both been used as proxies for identifying 
immune selection (de Oliveira et al., 2004; Liu et al., 2006; Kelleher et al., 2001; Jones et al., 
2004; Wood et al., 2009).  APOBEC is a host restriction factors which incorporates nucleic acid 
G-to-A mutations along the viral genome in order to restrict viral replication (Malim and Bieniasz, 
2012).   A study by Wood et al. (2009) showed that APOBEC facilitated immune escape in CTL 
epitopes.   
Antibodies predominantly target the viral envelope glycoprotein spikes which are exposed on 
the outer surface of viral particles, and antibody selection typically presents as gains and losses 
of potential N-linked glycosylation sites (PNGSs) and nucleotide insertions and deletions 
(indels) in the variable loops (Wei et al., 2003; Richman et al., 2003, Rybarczik et al., 2004).  
Addition of PNGSs can result in steric hindrance and thus shielding the virus from antibody 
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binding (Wei et al., 2003). The variable loops also shield the virus from neutralization (Rusert et 
al., 2011) and the introduction of insertions resulting in lengthening of loops may obscure 
access to epitope targets and enhance shielding (Laakso et al., 2007). 
 
3.2.2 Immune selection in acute infection 
CTLs emerge very early in HIV-1 infection and are associated with early control of viremia 
(Koup et al., 1994; Borrow et al., 1994; Ogg et al., 1998).  CTL escape has also been observed 
in the first weeks of infection (Borrow et al., 1997; Jones et al., 2004; Liu et al., 2006; Keele et 
al., 2008; Gray et al., 2009; Salazar-Gonzalez et al., 2009; Goonetilleke et al., 2009; Wood et 
al., 2009; Mlotshwa et al., 2010).  The large majority of early selection identified in acute 
infection studies evaluating full-length genomes was attributed to CTL-mediated pressure, 
although Ab-associated selection and reversion has also been described (Goonetilleke et al., 
2009; Henn et al., 2012). Studies such as these have been limited to subtype B-infected 
individuals (Goonetilleke et al., 2009; Herbeck et al., 2011; Henn et al., 2012).   
In this thesis, a companion study performed in conjunction with a subtype B and C study by Liu 
et al (2013) is described, wherein early immune selection in full-length genome transmitted 
subtype C viruses was characterized.  This required firstly identifying the genome sequence of 
the virus that was transmitted in five subtype C-infected women, followed by longitudinal 
sequencing over acute and early infection (up to six months post-infection) (see Chapter 2).  
The focus of this chapter is the identification of early immune selection in all nine HIV-1 genes.  
Furthermore, the impact of early immune selection on the clinical course of disease remains 
unclear. Since the five women in this study include rapid and intermediate progressors as well 
as a viremic controller, early selection will also be evaluated in the context disease progression. 
Results from this study were published in a manuscript entitled ‘Rapid, complex adaptation of 
transmitted HIV-1 full-length genomes in subtype C-infected individuals with differing disease 






3.3 Research Aim and Objectives 
Aim: To identify immune selection in near full-length genome subtype C HIV-1 sequences 
during acute and early infection 
Objective 1: Analyze longitudinal near full-length genome sequences from five acutely 
infected women for regions containing known HLA Class I-associated 
polymorphisms, clustered amino acid polymorphisms and/or sites evolving under 
positive selection 
Objective 2: Classify evolving sites associated with CTL- and Ab-mediated immune pressure 
or reversion 
Objective 3:  Evaluate immune selection in the context of disease progression 
 
3.4 Rationale 
The correlates of protection from HIV-1 infection are unknown, however are likely to include 
neutralizing and non-neutralizing antibodies to block infection; and cellular immune responses to 
eliminate or contain the initial foci of infection.  Studies of natural infection can provide clues on 
early responses and immune targets associated with control of viral infection.  
 
3.5 Methods and Materials 
Single genome amplification and sequencing of near full-length genomes, as well as derivation 
of t/f sequences, are described in Methods and Materials of Chapter 2.  Supplemental sequence 
data used in analyses for this chapter included four half-genome sequences generated by H. 
Bredell (University of Cape Town); 11 near full-length genomes (amplified by F. Treurnicht, 
University of Cape Town); gag and nef sequences generated by limiting dilution PCR and 
cloning done by D. Chopera and R. Ntale (University of Cape Town) respectively (described in 
Chopera et al., 2011); and env sequences generated by single genome amplification as 
described in Abrahams et al., 2009 as well as additional env SGA sequences generated by G. 
Bandawe (University of Cape Town) (details of supplemental data are provided in Appendix 3).   
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Epitope sequences were generated by targeted direct sequencing of gene-specific amplicons 
generated using limiting dilution PCR.  Of the 390 epitope sequences used, 321 were generated 
as part of this thesis and 69 sequences were contributed by J.Marais, S. Goodier and N. 
Ndabambi. Details for gag, vif and nef limiting dilution PCR are described in Appendix 4. 
 
3.5.1 Sequence analyses 
Sequence alignments and amino acid frequency plots were performed in BioEdit version 7.0.8.0 
(Hall, 1999). Intra-participant sequence alignments were analyzed for the presence of silent and 
non-silent mutations away from the transmitted/founder virus using the Highlighter tool 
(http://www.hiv.lanl.gov/content/sequence/HIGHLIGHT/highlighter).  Subtype C amino acid 
frequencies were calculated based on per gene database alignments obtained from the Los 
Alamos HIV Database (www.hiv.lanl.gov).   
The Hypermut tool (http://www.hiv.lanl.gov/content/sequence/HYPERMUT/hypermut.html) was 
used for the detection of APOBEC-associated G-to-A hypermutation.  Shannon entropies were 
determined using the Entropy One tool 
(http://www.hiv.lanl.gov/content/sequence/ENTROPY/entropy_one).  A high entropy score was 
taken as > 0.25 (Bansal et al., 2005).  Structural and functional motifs/regions within the 
genome were identified using the HIV landmark map from the Los Alamos Database 
(http://www.hiv.lanl.gov/content/sequence/HIV/MAP/landmark). 
 
3.5.2 Classification of immune selection 
Mutations from high frequency/consensus to low frequency/non-consensus amino acids within 
known class I HLA-restricted CTL epitopes were classified as CTL-mediated selection (Allen et 
al., 2005, Liu et al., 2006, Li et al., 2007, Brumme et al., 2008).  Known class I HLA-associated 
epitopes and polymorphisms associated with CTL-escape and compensation of escape were 
identified using the Los Alamos HIV Molecular Immunology Compendium 
(http://www.hiv.lanl.gov/content/immunology/compendium.html) and Matthews et al., 2008.  
Predicted CTL epitopes were identified using Epitope Location Finder (ELF) 
(http://www.hiv.lanl.gov/content/sequence/ELF/epitope_analyzer) and NetMHCpan 2.2 
(http://www.cbs.dtu.dk/services/NetMHCpan).   
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Mutations from low frequency/non-consensus to high frequency/consensus amino acids were 
classified as reversion (Allen et al., 2005, Li et al., 2007, Brumme et al., 2008).  Mutations 
resulting in gains or losses of potential N-linked glycosylation sites (PNGSs) or which altered the 
length of hypervariable loops within the envelope gene were classified as Ab-mediated selection 
(Wei et al., 2003).  PNGSs were identified using the N-GlycoSite tool 
(http://www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html).  
 
3.5.3 Positive selection analyses 
The MG94xHKY85 codon model (Kosakovsky Pond et al., 2005) implemented in HyPhy (Pond 
et al., 2005) was used to calculate non-synonymous/synonymous substitution (dN/dS) rate 
ratios.  Allowance was made for dS to vary across codon sites with use of the Dual model which 
accounts for dS varying independently of dN (Pond and Muse, 2005).  For genomic regions 
separated by recombination breakpoints, the use of correct phylogenetic relationships was 
ensured (Scheffler et al., 2006).  Supplemental clonal and SGA sub-genomic sequences were 
included in these analyses. Dr Nobubelo Ngandu (University of Cape Town) assisted with 
positive selection analyses. 
 
3.5.4 Statistical tests 
Fisher’s exact two-tailed tests (http://www.graphpad.com/quickcalcs) were used to perform 
categorical statistical tests.  
 
3.6 Results 
3.6.1 Identification of early immune selection in HIV-1 subtype C near full-length 
genomes 
Longitudinal near full-length genome sequences (n=113) generated from five acutely infected 
women over the first six months of infection were analyzed for mutations associated with 
immune selection.  Eleven near full-length and four half-genomes were also included from 
additional time-points (Appendix 3).  All women were HIV-1 subtype C-infected and were 
recruited into the study within two (CAP45, CAP63 and CAP210) to five (CAP85 and CAP239) 
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weeks post infection.  The sequence of their t/f near full-length genome virus/es were derived 
(Chapter 2), and changes over time were characterized to identify the timing, type and location 
of the earliest immune selective pressures acting on the t/f genome.   
CTL-escape mutations were identified as mutations from high frequency/nonconsensus to low 
frequency/consensus amino acids in or flanking known or predicted HLA Class I-restricted 
epitopes (see section 3.5.2) or which corresponded to known HLA-restricted polymorphisms 
(Allen et al., 2005, Liu et al., 2006, Li et al., 2007, Brumme et al., 2008, Matthews et al., 2008).  
Conversely, mutations from low frequency/nonconsensus to high frequency/consensus amino 
acids in epitopes not targeted by the individuals HLA were classified as reversion (Allen et al., 
2005, Li et al., 2007, Brumme et al., 2008).  Mutations in env resulting in gains or losses of 
PNGSs and indels in variable loops were classified as Ab-mediated selection (Wei et al., 2003; 
Richman et al., 2003, Rybarczik et al., 2004).  Furthermore, mutational clusters in amino acid 
nine-mers (Kelleher et al., 2001; Jones et al., 2004) containing sites evolving under positive 
selection (de Oliveira et al., 2004; Liu et al., 2006) were classified as immune pressure.   
Mutations conforming to the aforementioned criteria were identified in a total of 55 genome 
regions of viruses from the five women (Figures 24 to 28). Of the 55 regions, 22 were classified 
as evolving under CTL-mediated selection (Table 4), 19 as evolving under Ab-mediated 
selection (Table 5), nine as reverting (Table 6), and finally selection in five regions (with 
clustered mutations) could not be classified (Table 7).  Positive selection (dN/dS>1) was 
identified in a total of 55 amino acid sites, of which 84% (46/55) fell within the 55 genome 
regions identified as evolving under immune selection (Figure 24B to 28B).  A total of 30 sites 
under positive selection were identified in env, representing the majority, followed by Gag (n=9), 
Pol (n=7), Nef (n=5), Rev (n=3) and Tat (n=1). 
Of the 22 genome regions identified as evolving under CTL-mediated selection, 19 spanned 
known class I HLA-restricted CTL epitopes (Table 4), two spanned epitopes predicted to be 
bound by class I HLA types identified in the participant, and finally one region contained neither 
a known nor a predicted epitope but was found to induce a response in IFN-  ELISPOT assays 
in a companion study by Liu et al. (2013) which tested responses to autologous peptides from 
participants CAP45, CAP210 and CAP239.  This reactive peptide was located at the beginning 
of Pol (FFRENLAFPEGEARELPS) and may contain a novel CTL epitope.  All 11 evolving CTL 
epitopes (known and predicted) identified for participants CAP45, CAP210 and CAP239 were 
likewise confirmed to induce an immune response by IFN-  ELISPOT (Liu et al., β01γ), as well 
69 
 
as three of the 11 epitopes identified for participants CAP63 and CAP85 (Liu et al., unpublished 
data, personal communication).  For CAP63 one epitope in Pol (QLTEAVHKI), which was 
predicted to be HLA-A*02:01-targeted, and another in Gp41 (LLDSIAITV) were reactive in IFN-  
ELISPOT, and for participant CAP85 one epitope in Nef (KAAVDLSFF) was reactive. Therefore 
in total 14 sites predicted by sequence data to be evolving under CTL-mediated selection were 
confirmed by elispot as responsive, and responses could not be confirmed to the remaining 
eight evolving epitopes.   
Of the nine genome regions identified with reverting mutations (Table 6), four contained known 
Class I HLA-targeted epitopes in Gag, Gp41 and Nef, and may represent reversion of 
transmitted escape mutations from the donor.  In the remaining five regions, changes from 
uncommon (identified in 0.19% to 19% of subtype C database sequences) to common 
(identified in 48% to 98% of subtype C database sequences) were observed but could not be 
associated with reversion of escape in known HLA-restricted epitopes. 
Of the five genome regions for which immune selection could not be classified (Table 7), one 
genome region in Nef (SLHGMEDTEREVLQWKFD), in participant CAP210, overlapped with a 
known CD4+ T-cell peptide (PEREVLEWRFDSRLAFHH) reported to be targeted by multiple 









Figure 24.  Early selection in the transmitted/founder (t/f) virus of participant CAP45. (A) A 
Highlighter plot of synonymous (green) and non-synonymous (red) changes from the t/f virus over time, 
and (B) amino acid sites across the genome under positive selection given as the posterior probability of 
a dN/dS ratio >1 for each site.  Pale grey bars = putative CD8+ T-lymphocyte escape sites and blue bars 
= sites under putative antibody-mediated pressure.  Horizontal grey bars indicate deletions/missing data 





Figure 25.  Early selection in the transmitted/founder (t/f) virus of participant CAP63.  (A) A 
Highlighter plot of synonymous (green) and non-synonymous (red) changes from the t/f virus over time, 
and (B) amino acid sites across the genome under positive selection given as the posterior probability of 
a dN/dS ratio >1 for each site.  Shaded bars indicate where mutating sites in the Highlighter plots 
correspond to sites under positive selection.  Pale grey bars = putative CD8+ T-lymphocyte escape sites, 
dark grey = sites reverting to consensus, and blue bars = sites under putative antibody-mediated 
pressure.  A 
#  
indicates that mutations were found to arise earlier than indicated on the  Highlighter plot 




Figure 26.  Early selection in the transmitted/founder (t/f) virus of participant CAP85.  (A) A 
Highlighter plot of synonymous (green) and non-synonymous (red) changes from the t/f virus over time, 
and (B) amino acid sites across the genome under positive selection given as the posterior probability of 
a dN/dS ratio >1 for each site.  Pale grey bars = putative CD8+ T-lymphocyte escape sites, dark grey = 
sites reverting to consensus, blue bars = sites under putative antibody-mediated pressure, and green 
bars = sites with changes which could not be classified.  Horizontal grey bars indicate deletions/missing 




Figure 27.  Early selection in the transmitted/founder (t/f) virus of participant CAP210.  (A) A 
Highlighter plot of synonymous (green) and non-synonymous (red) changes from the t/f virus over time, 
and (B) amino acid sites across the genome under positive selection given as the posterior probability of 
a dN/dS ratio >1 for each site.  Pale grey bars = putative CD8+ T-lymphocyte escape sites, dark grey = 
sites reverting to consensus, blue bars = sites under putative antibody-mediated pressure, and green 




Figure 28.  Early selection in the transmitted/founder (t/f) virus of participant CAP239.  (A) A 
Highlighter plot of synonymous (green) and non-synonymous (red) changes from the t/f virus over time, 
and (B) amino acid sites across the genome under positive selection given as the posterior probability of 
a dN/dS ratio >1 for each site.  Pale grey bars = putative CD8+ T-lymphocyte escape sites, dark grey = 
sites reverting to consensus, blue bars = sites under putative antibody-mediated pressure, and green 
bars = sites with changes which could not be classified.  Horizontal grey bars indicate deletions/missing 
data within the genome.  A 
#  
indicates that mutations were found to arise earlier than indicated on the 
Highlighter plot by subsequent targeted epitope sequencing. 
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*Bold amino acids indicate sites undergoing mutation, ** Predicted epitopes obtained using Net MHCPan2.0 (www.cbs.dtu.dk/services/NetMHCPan)
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Table 5.  Genome regions evolving under antibody-mediated immune selection 
Participant ID ORF Genome region sequence*  
(18 to 20-mer) 
HXB2 
position 
Time of first mutation 






















































































*Bold amino acids indicate sites undergoing mutation; underlined amino acids indicate sites evolving under positive 
selection; highlighted amino acids indicate sites mutating to result in a change within, or gain/loss of a potential N-
linked glycosylation site gain/loss (NXS/Tx, where x is not Proline); 
#







Table 6.  Genome regions containing mutations associated with reversion 
Participant 
ID 


























V to I 
(0.9% to 97.85%) 




























N to T 
(10% to 85%) 
A to S 
(4.4% to 54%) 
E to D 
(31.72% to 
68.04%) 
T to A 






























D to N 
(1.5% to 98%) 
F to L 
(19% to 80%) 
K to R 
(8.5% to 88%) 
I to V 








CAP239 Gp120 NDMVDQMHKDIISLWDQS 
 
98-115 K to E 
(0.19% to 93.2%) 
11-22 
*
Only mutations associated with reversion are indicated (shown in bold).  Known Call I HLA-targeted epitopes (based 
on Matthews et al., 2008 and the HIV Molecular Immunology Compendium (www.lanl.hiv.gov )) are underlined. 
Genome regions may also contain changes from high to low frequency amino acids not associated with known CTL-
escape. 
**
Participant A*02:01/A*23:01 HLA association according to Los Alamos HIV Molecular Immunology 
Compendium (http://www.hiv.lanl.gov).  
#
Amino acid frequencies according to Los Alamos subtype C database 
sequences for each gene (http://www.lanl.gov). 
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(18 to 20-mer) 
CAP85 
Gp120 RPGGGDMKDNWRSELYKY 469-486 0-5 Yes 
CD4 binding 
region 
Nef GVGAASQDLGKYGALTSS 29-46 0-5 Yes None/unknown 
CAP210 Nef SLHGMEDTEREVLQWKFD 169-186 5-12 No None/unknown 
CAP239 
Gag SNPSGPKRPIKCFNCGRE 382-399 2-5 Yes 
Start of zinc 
knuckle 
Rev GRPAEPVPFQLPPIERLH 65-82 2-5 Yes None/unknown 
*Bold amino acids indicate sites undergoing mutation, and underlined amino acids indicate sites evolving 
under positive selection; 
#
Structural and functional genomes regions were identified using the Los Alamos 
HXB2 annotation spreadsheet (http://www.hiv.lanl.gov/content/sequence/HIV/MAP/annotation.html). 
 
3.6.2 Frequency and timing of early CTL-mediated selection and reversion 
Mutations associated with CTL-mediated selection or reversions (possibly of transmitted CTL-
escape) were analyzed more closely to determine how early in acute infection these mutations 
arose and the frequency of their location within the genome.  In order to more precisely time the 
appearance of mutations, supplemental sequence data from clonal and SGA sub-genomic 
sequences (Appendix 3) as well as from targeted epitope sequencing (Appendix 4) from 
additional time-points within the six month period of infection were included in these analyses.  
CTL-mediated selection was most frequently identified in Nef (n=6 mutating epitopes), followed 
by Pol and Env (n=5 mutating epitopes each), Gag and Vif (n=2 mutating epitopes each) and 
Rev, Tat and Vpr (n=1 mutating epitope each) (Figure 29A).  Even when accounting for protein 
length, since longer proteins may contain a greater number of epitope targets or mutational 
clusters, Nef remained the protein with the highest frequency of mutating epitopes. 
The earliest mutations associated with putative CTL-mediated selection were detected at two 
weeks post-infection in the Gag HLA B*58:01-restricted TW10 epitope and in the Nef HLA 
B*45:01-restricted EV11 epitope.  Thirty-six percent of mutations were identified in the first five 
weeks of infection and were located in Gag, Pol, Env and Nef, and 32% were identified between 
five and 12 weeks and included mutations in accessory genes Tat, Rev and Vpr (Figure 29B, 
Table 4).  The frequency of mutation was calculated as 1.6 putative escapes/week for the first 
five weeks of infection, followed by a reduction to 0.9 putative escapes/week between weeks 
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five and three months, and a further reduction to 0.4 putative escapes per week between three 
and six months (up to 29 weeks post-infection). 
 
 
Figure 29.  Frequency and timing of CTL-mediated immune selection in five acutely subtype C-
infected women.  (A) The number of CTL epitopes (total and total per 100 amino acids) putatively 
undergoing escape from CTL-mediated pressure across the HIV-1 genome, and (B) number of putative 




Genome regions containing mutations classified as reversion were most frequent in Vpu 
(n=3), followed by Gag, Env and Nef (n=2 each) (Table 6).  Four of the nine reversions were 
rapid and occurred within the first five weeks of infection, while the remaining reversions 
occurred between 13 and 29 weeks post-infection. The reverting sites in Vpu were all within 
the first 26 amino acids (according to HXB2 numbering), and did not overlap with another 
open reading frame.  
 
3.6.3 Frequency and timing of early Ab-mediated selection 
Mutations associated with Ab-mediated selection in Env were identified as mutations within 
PNGSs and hypervariable loops (substitutions or indels).  It was of interest to determine how 
early in acute infection Ab-mediated selection was observed, and also whether early 
selection was more frequent in specific areas of this structural gene.  Env SGA sequences 
were used to supplement sequence numbers at screening/transmission and additional time-
points where available (see Table 3, Chapter 2), and to increase sensitivity for timing of 
selection.  
Mutations in seven of the 19 genome regions (37%) that were classified as evolving under 
Ab-mediated selection were identified in the first five weeks of infection in all participants 
with the exception of CAP210 (Table 5).  Earlier studies investigating nAb responses and 
escape in women from the CAPRISA 002 AI cohort reported, for the five women in this 
thesis, that the earliest nAb responses were detected at nine weeks post-infection (in 
participant CAP45) and the latest at 46 weeks post-infection (in participant CAP210) (Moore 
et al., 2008; Moore et al., 2009).  It would therefore seem unlikely that these early mutations 
were associated with nAb selection.  However, in participant CAP45, sites undergoing early 
mutation in the V5 loop coincided with sites in which neutralization escape was reported to 
later occur (mutations K460D and D462G) (Table 5) (Moore et al., 2009), potentially 
indicating the earlier presence of nAbs that were not detected.  This was the only participant 
of the five in which very early mutations could be associated with nAb responses. 
 
3.6.4 Mutational pathways in genome regions evolving under immune selection 
To evaluate the pathways to escape in genome regions evolving under CTL-mediated 
selection, additional near full-length genome sequences generated from SGA and limiting 
dilution PCR, as well as targeted epitope sequences were analyzed (Appendix 3 and 4).  
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In 82% (18/22) of evolving CTL epitopes, mutations were seen to shift between different 
amino acid positions within the epitope (shuffling) and/or between different amino acids at 
the same position (toggling).  This is illustrated for Nef epitope EV11 restricted by 
HLA*B45:01 in participants CAP63 and CAP85 (Figure 30A).  In the case of participant 
CAP63, by 37 weeks post-infection only one variant was observed in all sequences sampled 
(due to low sequence numbers complete fixation of this variant cannot be assumed), 
whereas in the case of CAP85 more than one mutant variant was still present as late as 55 
weeks post-infection.   
The extent of variation within evolving CTL epitopes in acute and early infection was 
expressed as the number of mutant variants per epitope at each time-point (Figure 30B).  
With the exception of participant CAP239, the number of variants per epitope increased in all 
women over the first three months of infection.  For CAP63 and CAP210, variation continued 
to increase over the subsequent three months, whereas for CAP85 the number of variants 
reached a plateau by six months and thereafter decreased.  The number of variants per 
epitope decreased for CAP63 after six months.  In the case of CAP239, an increase in 
variants per epitope was seen very early (between two and five weeks); however numbers 
reached a plateau by three months and decreased thereafter. The decrease in variants was 
in part owing to fixation of mutant variants. Shuffling/toggling was also seen in four of the five 
genome regions with unclassified selection.  Fixation was observed in only 9% of mutating 
CTL epitopes by six months post-infection and 7% when including genome regions evolving 
under unclassified selection. 
In order to determine whether shuffling/toggling of mutations was more frequent in variable 
regions of the genome, Shannon entropy scores of mutating epitopes were calculated using 
database subtype C sequences (www.hiv.lanl.gov).  While 12 of the 18 (67%) CTL epitopes 
with shuffling/toggling corresponded to high entropy epitopes (>0.25) (Bansal et al., 2005), 
shuffling/toggling was not significantly more frequent in high entropy epitopes compared to 




















Figure 30.  Mutational variation in epitopes evolving under CTL-mediated immune selection.  (A) Shuffling and toggling of amino acid mutations in the 
B*45:01-restricted Nef EV11 epitope in participants CAP63 (left) and CAP85 (right), (B) the number of mutant variants within evolving CTL epitopes for each 
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Next we investigated whether shuffling/toggling may be a result of immune selection within 
structurally or functionally essential regions of the genome, and that the virus therefore 
struggles to incorporate mutations due to detrimental effects on viral fitness.  The proportion 
of CTL epitopes with shuffling/toggling was however not greater in genome regions of 
structural or functional importance compared to the proportion in regions with no known 
structural or functional importance (p=1, Fisher’s Exact categorical test).  This analysis was 
repeated with inclusion of the five genome regions with evidence of immune selection that 
could not be classified, however the comparison remained statistically non-significant (p=1, 
Fisher’s Exact categorical test).  In addition, APOBEC G-to-A hypermutation was identified in 
36% (8/22) of escaping CTL epitopes, and overall in 25% (13/55) of all genome regions 
identified as evolving under selection (Figure 30C). 
 
3.6.5 Early immune selection and clinical disease progression 
To determine whether the extent of mutation associated with selection was associated with 
disease progression, the numbers of genome regions identified as evolving under selection 





























































Figure 31.  Intraparticipant quantitative analysis of genome regions/codon sites evolving under 
selection.  The number of genome regions evolving under CTL- or Ab- mediated immune selection or 
reversion is indicated.  Positive selection data is reported as the total number of evolving codon sites. 
Sequences from rapid progressor CAP63 contained the highest number of genome regions 
evolving under positive (n=31), CTL-mediated (n=7) and Ab-mediated (n=9) selection. Rapid 
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progressor CAP210 had the highest number of genome regions with reversion (n=4).  
Viremic controller CAP45 had the lowest number of genome regions evolving under positive 
(n=1) and Ab-mediated (n=1) selection and had no reverting sites, however sequence data 
for this individual was lacking at six months post-infection and additional evolving sites may 
have arisen between three and six months. 
 
3.7 Discussion 
Elucidation of responses associated with early virological control provides information on the 
types of responses needed to be elicited through vaccination.  Sequencing of t/f and early 
evolving viruses allows the identification of targets of these earliest immune responses.  
Further, these changes can potentially alter viral phenotype and the clinical course of 
disease.  Four studies to date have characterized early viral evolution of near full-length viral 
genomes in the context of subtype B infection (Salazar-Gonzalez et al., 2009; Goonetilleke 
et al., 2009; Herbeck et al., 2011; Henn et al., 2012), while studies of the globally dominant 
subtype C strain are lacking.  In this study, peptide regions evolving under selection in near 
full-length genomes from five subtype C-infected women in acute and early infection were 
identified, and the immune pressures driving the observed changes within these regions 
were predicted.  Furthermore, the timing, frequency and pattern of early changes were 
described.  Our sequence data illustrates the dominant role of early CTL responses in 
moulding viral evolution, and together with published studies evaluating early immune 
responses (Bernardin et al., 2005, Brumme et al., 2008, Salazar-Gonzalez et al., 2009, 
Goonetilleke et al., 2009), provide strong support for CD8+ T-cell responses as being the 
most important for virus control following infection. Some of these results were published in 
Abrahams et al., 2013 and Liu et al., 2013.   
Selective pressure from CD8+ cytotoxic T-lymphocytes (CTLs) was predicted to account for 
the majority (40%) of early changes across the genome.  Sixty-four percent of epitopes that 
were predicted to be evolving under CTL selection based on sequence data, were confirmed 
by IFN-  ELISPOT (Liu et al., β01γ and Liu personal communication), providing confidence 
that the CTL escape prediction approach was robust.  For the remaining 36% of epitopes 
(n=8), seven were identified in participant CAP63 whose cells had poor viability and 
therefore peptide CTL reactivity could not be confirmed.  For the eighth putative epitope (in 
CAP85), CTL responses were tested at a time-point after escape had already occurred. 
Therefore a higher percentage of the epitopes predicted by sequence data was likely 
ELISPOT reactive.  This finding for subtype C sequences is in keeping with subtype B 
studies which reported the majority of early selection to be due to CTL-mediated pressure 
85 
 
(Bernardin et al., 2005, Brumme et al., 2008, Salazar-Gonzalez et al., 2009, Goonetilleke et 
al., 2009, Herbeck et al., 2011).  
Analysis of the timing and frequency of CTL-mediated selection revealed a higher frequency 
of mutations associated with CTL-escape in the first five weeks of infection and that the 
frequency of new mutations decreased four-fold over the six month period investigated.  The 
earliest CTL-escape mutation was identified in a Gag epitope, TW10, which is targeted by 
the immunodominant HLA-B*58:01 response.  Rate of escape is reported to be influenced 
by a hierarchy of responses of varying immunodominance (Liu et al., 2013), wherein more 
immunodominant responses exert strong selection very soon after infection resulting in early 
change.  In addition, immunodominant responses in early infection were reported to more 
frequently target high entropy epitopes (Liu et al., 2013) which mutate and escape rapidly, 
whereas more conserved epitopes escape at slower rates (Ferrari et al., 2011).  In line with 
these findings, for the five women in this study, in the first 12 weeks of infection, 67% of 
escape occurred in high entropy genome regions compared to only 29% in late infection. 
CTL escape mutations were identified most frequently in Nef.  This finding confers with that 
of a subtype B sequencing study which reported early selection to predominate in Nef and 
Env (Herbeck et al., 2011).  While numerous studies have reported Nef to be one of the 
most immunogenic HIV proteins (Addo et al., 2003; Frahm et la., 2004; Brumme et al., 2007; 
Wang et al., 2009; Mlotshwa et al., 2010, Bartha et al., 2013, Liu et al., 2013), it should be 
noted that three of the five women in this study shared the B*45:01 HLA allele which is 
reported to target the Nef EV11 epitope (Matthews et al., 2008).  Selection was identified in 
this epitope for all three women, possibly accounting for the observed higher frequency of 
escape in Nef.  However, other reasons for more frequent immune targeting of Nef may 
include that it is expressed early in the virus life cycle, and at higher abundance compared to 
Gag, Pol and Env which are expressed later (Karn and Stoltzfus, 2012).  Due to the major 
structural and enzymatic roles of Gag, Pol and Env, genome regions encoding these 
proteins are also likely to be less tolerant of mutations which may have a negative impact on 
their function.  
Ab-mediated selection was predicted to account for 35% of evolving genome regions 
identified in the five women.  In an unexpected finding, mutations typical of Ab selection 
were identified as early as two weeks post-infection.  Since nAb pressure is generally 
reported to arise only some months after infection (Wei et al., 2003; Gray et al., 2007; Yeh et 
al., 2010) and the earliest autologous nAb response for the five women in this study was 
reported at nine weeks (Moore et al., 2009), these changes were initially postulated to be a 
result of stochastic change, reversion of transmitted Ab escape in the donor, pressure from 
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non-neutralizing binding Abs, or antibody-dependent cell-mediated cytotoxicity (ADCC).  
However, a study by Bar et al. (2012) reported evidence of low-level nAb responses not 
detected by routine assays.  Furthermore, for participant CAP45, early changes in the V5 
loop identified in this study were found to coincide with sites at which nAb escape was 
reported for later in infection in a separate study (Moore et al., 2009).  Thus the possibility 
exists that these early changes were a consequence of very early, low titre nAb responses. 
Reversion of transmitted mutations accounted for 16% of changes in sites evolving under 
selection.  Transmitted CTL escape mutations from the donor possibly accounted for 44% of 
reverting genome regions, however this is not conclusive in the absence of donor HLA or 
donor viral sequence information. One third of reversions identified were in a common amino 
acid stretch in Vpu.  These genome regions did not correspond with known CTL epitopes 
and contained no known functional or structural motifs, and therefore cannot be postulated 
to have been a result of transmitted escape or to have been fitness related.  The explanation 
for the higher frequency of reversion in Vpu in this study is unknown. In a study by Li et al 
(2007), reversions were reported to arise significantly earlier than escape mutations; 
however this was not found to be the case for this study as well as similar studies by 
Goonetilleke et al. (2009) and Herbeck et al. (2011) which analyzed early selection across 
the genome of t/f viruses from three subtype B-infected individuals using SGA.  This may be 
owing to differences in methodology.  The derivation of t/f virus sequences together with the 
sensitivity of SGA of circulating RNA virus, represent a more accurate approach to identify 
changes to the viral genome compared to the approach used by Li et al. who amplified from 
proviral DNA using limiting dilution PCR and population sequencing of pooled PCR products, 
and who did not have the t/f virus sequence as a point of reference. 
Finally, the pressure driving changes in 9% of genome regions predicted to be evolving 
under selection could not be classified.  Changes may represent compensation of the 
escape mutations identified, or may have been a consequence of pressure from NK cells, 
CD4+ T-cells, ADCC, non-neutralizing binding Abs, or perhaps have been related to 
evolutionary drift or enhancement of viral fitness.  These were not investigated further in this 
study; however they highlight that more remains to be understood regarding selection in 
early HIV infection and potential barriers to disease control and vaccine efficacy.  
An increasing number of studies propose that epitopes which are stable and conserved, and 
which subsequently escape slowly, would represent good vaccine targets (Davenport et al., 
2008; Matthews et al., 2008; Goonetilleke et al., 2009).  A subtype B study by Goonetilleke 
et al. (2009) reported the presence of multiple mutant variants in 15 of 18 (83%) early 
escaping CTL epitopes.  In the current study, 82% of mutating CTL epitopes displayed 
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extensive shuffling and toggling of amino acid mutations within evolving genome regions.  It 
may be that such variation is seen in  regions of the genome that are not able to tolerate 
change due to potential costs to viral fitness as proposed in a recent study (Herbeck et al., 
2011), however no evidence was found to indicate more frequent shuffling/toggling in 
genome regions of known functional or structural significance.  Alternatively, the opposite 
could be proposed, that such variation is seen since these regions can tolerate extensive 
mutation.  This is supported by the fact that 61% of epitopes with shuffling/toggling 
corresponded to high entropy database epitopes.  Henn et al. (2012) performed a detailed 
sequencing study of viral evolution in one participant, and also observed mutational 
shuffling/toggling in targeted epitopes, which they proposed could be a pattern which persist 
until such time that a mutation is introduced which facilitates complete viral escape that will 
subsequently become fixed.  This would however need to be tested in vitro.  
Furthermore, in this study it was found that APOBEC-mediated hypermutation contributed to 
the evolution and potentially to the escape of a significant portion (25%) of genome regions 
evolving under selection (36% of CTL epitopes).  While the viral protein Vif functions to 
counteract the activity of APOBEC (Malim and Bieniasz, 2012), it would appear that the virus 
has evolved to use activity of this host-restriction factor to its advantage. 
One advantage of this study is that the five participants display differential disease 
progression, which allows the description of immune selection ‘profiles’ in the context of 
viremic control, and rapid and intermediate progression.  Virus from one rapid progressor, 
participant CAP63, who was referred to ARV treatment by nine months post-infection, had 
the highest number of genome regions evolving under selection.  One may expect that a 
greater breadth of immune targeting would place more constraints on viral replication and 
would thus not be associated with a more rapid disease progression, unless targeting 
frequently resulted in immune escape.  Supporting this, studies by Gray et al. (2009) and 
Mlotshwa et al. (2010) which examined the relationship between breadth of CTL responses 
and disease progression in women form the CAPRISA 002 cohort, reported a trend for 
increased breadth of CTL responses in rapid progressors, but a significant difference in 
retention of responses between rapid progressors and viremic controllers, wherein 
responses were lost more frequently in rapid progressors.  Due to low participant numbers, 
the associations between breadths of overall positive, CTL- or Ab-mediated selection with 
set-point viral load or CD4 count at 12 months post-infection, both of which are predictors of 
disease progression (Mellors et al., 1997; Lyles et al., 2000), could not be tested.  
In summary, this study reports early immune selection across the subtype C genome to be 
predominantly attributed to CTL-mediated immune pressure, that nAb-mediated pressure 
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may be prevalent earlier than expected, and that the mutational pathway to immune evasion 
or adaption is dynamic and complex.  In the chapter to follow, the impact of early CTL 
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Studies evaluating the impact of CTL escape mutations on viral replicative fitness typically 
introduce mutations into a viral backbone that does not match the naturally occurring 
cognate virus.  This approach is limited as it does not take into consideration co-evolving 
mutations that may restore viral function.  In this chapter we investigate the impact of early 
CTL escape mutations on viral replication fitness introduced into infectious molecular clones 
encoding the cognate transmitted/founder virus sequence. 
Four transmitted/founder infectious molecular clones were available, and a fifth was 
constructed as part of this thesis.  CTL escape mutations that evolved in HLA-B-restricted 
epitopes in the first six months of infection were introduced into four of the clones by site-
directed mutagenesis.  The replication capacities of transmitted/founder and mutant viruses 
were compared in parallel replication assays in peripheral blood mononuclear cells. 
The transmitted/founder virus from a rapid progressor, CAP63, had the highest replication 
capacity (p<0.0001).  In two individuals, HLA-B associated escape mutations did not affect 
replication fitness.  In the third individual (CAP210), introduction of a rare mutation (A146T) 
in the B*15:10-restricted VL10 epitope situated in the Gag p24 capsid, together with a V85A 
mutation in the Vif WI9 epitope, resulted in a significant loss in viral replicative fitness relative 
to the cognate transmitted/founder virus (p=0.0004).  In the fourth individual (CAP239), a Pol 
E343K mutation together with the well-described T242N p24 capsid mutation significantly 
enhanced viral replication fitness relative to the cognate transmitted/founder virus 
(p=0.0072).  The CAP239 transmitted/founder virus harboured compensatory mutations 
H219Q and I223V, which when reversed resulted in the lowering of viral replicative capacity 
of the virus containing the T242N and E343K mutations to below that of the 
transmitted/founder virus (p=0.0015).  
This study showed that cognate sequence information can significantly influence the 
interpretation of the effect of escape mutations on viral replicative capacity, as illustrated in 
this instance by CTL-escape mutations which increased replication fitness due to pre-








Viral fitness is defined as the ability of a virus to survive and propagate in a given 
environment (reviewed in Domingo et al., 1997).  It has been proposed that, within an 
infected individual, viral fitness increases with increasing viral load over the course of HIV 
infection (Troyer et al., 2005; Arien et al., 2007).  Increasing fitness may be a result of the 
accumulation of immune escape mutations over time (Richman et al., 2003; Allen et al., 
2005) or evolution of variants to the more virulent CXCR4 receptor-utilizing phenotype 
(Shankarappa et al., 1999; Troyer et al., 2005).   
However, the accumulation of immune escape mutations, such as those selected by CTL 
pressure, can also reduce viral replication fitness when arising in functionally conserved 
regions of the viral genome (Martinez-Picardo et al., 2006).  The identification and 
characterization of such mutations furthers our knowledge of the vulnerabilities of HIV and of 
potential vaccine targets.  This study examines the impact of CTL escape mutations in 
cognate full-length genome t/f virus backbones on replicative fitness.  This approach 
provides an advantage over most published replicative fitness studies which have almost 
exclusively been done in recombinant backbones which do not include potential 
compensatory mutations that could restore fitness.   
 
4.2.1 Assaying viral replicative fitness  
To evaluate differences in replication capacity, viruses are either competed against each 
other following co-infection of cell culture, or their growth kinetics is compared independently 
in parallel cultures under standardized conditions (reviewed in Quinones-Mateu and Arts, 
2002 and Dykes and Dementer, 2007).  While competition assays are reported to be more 
sensitive for detecting subtle fitness differences (Collins et al., 2004; Prado et al., 2004), 
recombination between the competing viruses is a major confounder (Jetzt et al., 2000; Jung 
et al., 2002).  Song et al. (2012) reported recombination as early as three to four days post 
culture co-inoculation.   An additional drawback of competition assays is that they require 
expensive methods of quantification such as deep sequencing or real-time PCR to 
distinguish between viruses.  Parallel growth kinetics assays, monitored using rapid and less 
costly quantitative assays such as by p24 ELISA or flow cytometry (reviewed in Quinones-
Maeu and Arts, 2002 and Dykes and Dementer, 2007), have successfully been used to 
detect fitness costs conferred by CTL escape mutations (Brockman et al., 2007; Chopera et 
al., 2012; Boutwell et al., 2013), and are used in this study. 
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The cells used to evaluate replicative capacity can affect assay results.  CD4+ T-cell-lines 
are frequently used as the target cells and proliferate rapidly in culture, are relatively 
homogeneous, and are designed to be readily infected by HIV through enhanced expression 
of CD4 and CCR5/CXCR4 cellular receptors.  While cell-lines provide a standardized 
environment for comparing virus replication, and allow for more rapid assaying of viral 
fitness, they do not necessarily provide a realistic reflection of how viruses expand within the 
complex cellular environment of an infected individual. Furthermore, depending on the assay 
used, fitness differences may be detected in some cell-lines but not in others (Brockman et 
al., 2007).  For these reasons, donor-derived peripheral blood mononuclear cells (PBMCs), 
which consist of a mixture of cells including CD4+ T-cells, CD8+ CTLs and macrophages, 
and are utilized for more in vivo-relevant fitness assays, were used in this study. 
The impact of genetic mutations on viral replicative fitness is evaluated by the introduction of 
these mutations into a viral genetic backbone cloned into a DNA plasmid vector, known as 
an infectious molecular clone (IMC) (Adachi et al., 1986; Mochizuki et al., 1999; Salminen et 
al., β000; Ndung’u et al., β001).  These constructs express viral genes for packaging of 
infectious virions in mammalian cells and can therefore be used to study viral replication. 
The introduction of mutations into IMCs containing full-length cognate viral genomes permits 
evaluation of the true impact of these mutations in the host in which they were identified.  
While the generation of such IMCs is challenging and costly, the resulting constructs 
represent valuable research tools, not only for fitness studies but also for immunological and 
transmission studies among others.  
 
4.2.2 Fitness of the transmitted virus and disease progression 
While genome-wide association studies (GWAS) have reported clinical outcome to be 
largely dictated by Class I HLA genotype, in particular HLA-B (Fellay et al., 2007, Fellay et 
al., 2009, Pereyra et al., 2010, Bartha et al., 2013), an increasing number of reports indicate 
a greater than previously appreciated contribution of the genotype of the transmitted virus 
(Yue et la., 2012; Lingappa et al., 2013; Fraser et al., 2014).  For example, the transmission 
of CTL-escape mutations in epitopes targeted by advantageous HLA types, such as  
B*58:01,  has been shown to afford a degree of disease control when transmitted to 
recipients with mismatched HLA types if they do not revert (Chopera et al., 2008, Goepfert et 
al., 2008).  This may be owing to the effect of these mutations on viral replicative fitness. 
Replicative capacity has also previously been correlated with disease progression.  For 
example, viruses (both viral isolates and chimera viruses derived from IMCs) from clinical 
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progressors were reported to display greater replicative capacity than those of long-term 
survivors, and viral load was correlated with viral replication capacity (Blaak et al., 1998, 
Quinones-Mateu et al., 2000, Campbell et al., 2003, Trkola et al., 2003, Troyer et al., 2005, 
Miura et al., 2009).  In two separate studies using gag-pro recombinant NL4-3 constructs, 
viruses from individuals with protective HLA-alleles B*57/58:01, B*13 and B*81 were found 
to have lower replication capacities (Brockman et al., 2010, Wright et al., 2011) indicating a 
link between disease control and lower replication fitness.  Prince et al. (2012) showed that 
the replicative fitness of viruses expressed from chimera backbones encoding transmitted 
gag sequences from a large Zambian cohort was positively correlated with set-point viral 
load.  However, other studies investigating a relationship between disease progression and 
replication fitness of gag-pro chimeras (Wright et al., 2011) and viral isolates (Arnott et al., 
2010) derived from acute/early infection did not find a correlation with viral load.   
Recently, the loss of replication capacity incurred by CTL-escape mutations was reported in 
a comprehensive study of mutations commonly identified in Gag epitopes, for example those 
in protective HLA-restricted epitopes KF11 (A136G), IW9 (A146P and I147L) and TW10 
(T242N and G248A) (Boutwell et al., 2013).  In a separate study, a significant association 
between a number of these escape mutations, including T242N, G248A and I147L with 
lower plasma viral loads was identified (Bartha et al., 2013).  Compensation of these escape 
mutations has been demonstrated to effectively restore viral replicative capacity (Brockman 
et al., 2007; Crawford et al., 2007; Brockman et al., 2010). 
In this chapter, replication capacity of viruses produced from IMCs representing the cognate 
t/f virus of five subtype C-infected women focused on in this study.  IMCs were mutated in 
order to evaluate the impact of early CTL immune escape on viral fitness in parallel 
replication kinetics assays.  Mutations introduced were selected based on their presence in 
known Class-I HLA-B-restricted epitopes and their being fixed or gaining dominance within 
the first six months of infection (immune selection data is described in Chapter 3).  In 
addition, the replication fitness of the t/f viruses was compared in the context of disease 
progression profile.   
 
4.3 Research Aim and Objectives 
Aim: To determine the relationship between replication capacity (RC) of t/f viruses and viral 
load set-point, and the effect of early CTL-escape mutations on RC. 
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Objective 1: Characterize and compare RC of t/f viruses in the context of disease 
progression profile 
Objective 2: Introduce selected CTL-escape mutations into IMCs of four women by site-
directed mutagenesis and compare the RC of t/f and early CTL-escape 
mutant viruses in parallel replication kinetics assays 
 
4.4 Rationale 
To further our understanding of determinates of disease control, this study evaluated the 
replicative fitness of t/f viruses and the effect of early immune selection on replication.  IMCs 
generated as part of this study provide a valuable biological resource for characterizing viral 
pathogenesis. 
 
4.5 Methods and Materials 
The IMCs containing t/f viruses of participants CAP45, CAP63, CAP210 and CAP239 were 
generated by F. Treurnicht (University of Cape Town) and H. Ding (University of Alabama at 
Birmingham) in the laboratories of Prof. Carolyn Williamson and Dr. John Kappes. 
The CAP200 t/f virus IMC was constructed as part of this thesis. 
 
4.5.1 Design and construction of the CAP200 t/f virus IMC (pCAP200.t/f) 
4.5.1.1 Determination of the complete LTR sequence 
A consensus of SGA near full-length viral genome sequences amplified from viral RNA from 
plasma drawn at approximately two weeks post-infection for participant CAP200 was 
previously derived by S. Goodier (University of Cape Town). These sequences contained 
partial LTR sequences at either end since complete LTRs may only be amplified from 
proviral DNA. The 5’ end of the amplified sequence contained the complete LTR U5 region 
and the γ’ end contained the complete Uγ and R regions. The complete Uγ-R-U5 LTR 
sequence could thus be pieced together for both ends of the genome. Los Alamos HIV 





4.5.1.2 Restriction enzyme digestion and cloning 
Restriction enzyme sites within the CAP200 viral genome were identified using NEBcutter 
2.0 (Vincze, Posfai and Roberts, 2003; http://tools.neb.com/NEBcutter2/index.php) and the 
Web Map Preferences tool at http://pga.mgh.harvard.edu/web_apps/web_map/start by S 
Goodier.  Genome fragments were synthesized and cloned into pUC57 by GenScript, NJ, 
USA.  Fragments digested from pUC57 were cloned into the pBR322 vector (Promega, WI, 
USA).   
For each digestion, approximately 3-7 µg of plasmid DNA was digested using NEB 
restriction enzymes (New England BioSciences, UK) according to manufacturer instructions 
for 3 hours or overnight. Digested insert and vector bands were gel-purified using the Qiagen 
Gel Extraction Kit (Qiagen, Limburg, Netherlands) according to manufacturer instructions 
and ligated overnight at 16°C using T4 ligase (Thermo Scientific, MA, USA) in a 20 µl final 
reaction volume.  A volume of 5 µl of ligation reaction was transformed into One Shot Stbl3 
chemically competent cells (Invitrogen, CA, USA) according to manufacturer instructions, 
with one exception: after heat shocking, cells were incubated in 250 µl Luria broth instead of 
500 µl SOC medium followed by centrifugation at 4 000 g for 5 minutes to pellet cells and all 
cells were resuspended in 100 µl and plated. Cells were plated onto ampicillin-containing LB 
agar (0.1mg/ml final concentration) and incubated at 32°C overnight or at room temperature 
for three days. Colonies were screened by restriction enzyme digestion following small-scale 
plasmid DNA isolation using the Qiagen Plasmid Mini Kit (Qiagen, Limburg, Netherlands) 
according to manufacturer instructions.  
The In-Fusion HD Cloning Kit (Clontech, CA, USA) was used according to manufacturer 
instructions to clone genome fragment II into pBR322 containing fragments I and III. Primers 
were designed to amplify fragment II, with the forward primer designed to incorporate a 15 
base pair overlap with the γ’ end of fragment I and the reverse primer designed to 
incorporate a 15 base pair overlap with the 5’ end of fragment III.  Using these primers, 
fragment II was PCR amplified from pUC57 using Platinum Taq DNA Polymerase High 

















dH2O 15.3  94 2 min  
10 X High Fidelity Buffer 2  94 15 sec 
25 MgSO4 (50 mM) 0.8  55 30 sec 
dNTPs (10 mM) 0.4  68 4 min* 
CAP200T/F_F2_For  (20µM) 0.2  68 20 min  
CAP200T/F_F2_Rev (20µM) 0.2  4 Hold  
Platinum Taq High Fidelity 0.1     
pUC57_Fragment II (10 ng/ul) 1     
Total 20     
*An additional 15 sec of template elongation time was added on per cycle 
The resulting PCR product was gel-purified as described earlier.  A volume of 3 µl (66 ng) 
purified PCR product was combined with 4 µl of PflFI/BstBI-digested pBR322 containing 
fragments I and III (50 ng) and 2 µl In-Fusion HD Enzyme Premix and incubated at 50°C for 
15 minutes followed by 4°C until transformation. A volume of 2.5 µl of the In-Fusion reaction 
was transformed into One Shot Stbl3 chemically competent cells (Invitrogen, CA, USA) as 
described earlier. 
 
4.5.2 Site-directed mutagenesis 
Nucleic acid mutations were introduced into IMC backbones by PCR using the QuikChange 
II XL Site-Directed Mutagenesis Kit (Agilent Technologies, CA, USA) according to 
manufacturer instructions. Unique forward and reverse mutagenesis PCR primers, which 
overlapped the participant-specific epitope to be mutagenized and which incorporated the 
desired nucleic acid mutation, were designed using the on-line QuikChange Primer Design 
Program (www.agilent.com/genomics/qcpd). Where necessary, primer lengths were 
modified so as to have a guanine or cytosine residue at the 5’ and γ’ termini to facilitate 
efficient primer binding, while ensuring that the desired mutation remained centralized within 
the primer sequence.  
Mutagenized PCR products were transformed into XL-Gold Ultracompetent cells provided 
with the QuikChange II XL Site-Directed Mutagenesis Kit according to manufacturer 
instructions, with the exception that cells were incubated in LB Broth and not NZY+ broth, or 
into One Shot Stbl3 chemically competent cells (Invitrogen, CA, USA) as described in 
section 4.4.1. Small and medium-scale DNA preparations from bacterial cultures were 
carried out using the Qiagen Plasmid Mini and Midi Kits (Qiagen, Limburg, Netherlands) 
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respectively according to manufacturer instructions. The full genome of all constructs were 
screened by sequencing at the Stellenbosch Central Analytical Facility using an ABI 3000 
genetic analyser (Applied Biosystems, Foster City, CA, USA) and BigDye terminator 
reagents to confirm the presence of desired mutation and that no unwanted mutations were 
introduced by the PCR. 
 
4.5.3 Generation of virus stocks 
IMC DNA was transfected into HEK293T cells (ATCC CR-L11268) for the production of virus 
using PolyFect Transfection Reagent (Qiagen, Limburg, Netherlands). HEK293Ts are 
immortalized human embryonic kidney cells which are highly transfectable (Graham et al., 
1977). Cells were maintained at 37°C with 5% CO2 in Dulbecco’s Minimal Essential Medium 
(D-MEM) 4.5g/L Glucose (Lonza, Basel, Switzerland) supplemented with 10% Fetal Calf 
Serum (Biochrom GmBH), 50 µg/ml Gentamicin antibiotic (Lonza, Basel, Switzerland) with 
passaging at 80-100% confluency. The PolyFect reagent is positively charged and 
associates with the negatively charged DNA molecules to form complexes which are taken 
up by the HEK293T cell membranes, followed by expression of viral proteins and packaging 
of virus particles within the cells. 
A total of 5 x 105 cells were seeded per well of a 6-well cell culture plate and incubated 
overnight at 37°C with 5% CO2. The following day, the medium in each well was replaced 
with 1.5 ml of fresh supplemented D-MEM. For each virus to be produced, a total of 2.5-5 µg 
of IMC DNA was combined with 100 µl of unsupplemented D-MEM and 20 µl PolyFect 
Transfection Reagent (Qiagen, Limburg, Netherlands) in a 15 ml conical tube, vortexed for 
10 seconds and incubated for 10 minutes at room temperature to allow formation of DNA-
Polyfect complexes. A volume of 600 µl of supplemented D-MEM was then added to the 
mixture followed by gentle mixing and slow drop-wise addition of the complexes to a single 
well of HEK 293T cells for each virus to be produced. Cells and DNA complexes were then 
incubated for 72 hours at 37°C with 5% CO2. Viruses were harvested following aspirating of 
medium from each well and centrifugation at 1 500 rpm for 10 minutes to pellet cells. 
Supernatants containing virus particles were aliquoted into cryovials and stored at -80°C. 
 
4.5.4 Viral titration 
The titre of each virus batch harvested was determined by infection of TZM-bl cells (NIH 
AIDS Research and Reagent Program, Division of AIDS, NIAID, NIH, from Dr John Kappes, 
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Dr Xiaoyun Wu and Tranzyme Inc., catalogue number 8129).  TZM-bl cells are a HeLa cell-
line engineered to express luciferase and -galactosidase under the control of a Tat-
inducable HIV LTR promoter, and stably express receptors CD4+ and CCR5 for HIV 
infection (Platt et al., 1998; Wei et al., 2002). Infection of cells can thus be measured by 
either luminescence or -galactosidase staining. Cells were maintained at 37°C with 5% CO2 
in Dulbecco’s Minimal Essential Medium (D-MEM) 4.5 g/L Glucose (Lonza, Basel, 
Switzerland) supplemented with 10% Fetal Calf Serum (BioChrom GmBH), 50 µg/ml 
Gentamicin antibiotic (Lonza, Basel, Switzerland) with passaging at 80-100% confluency. 
A virus aliquot from each batch was first subjected to a single freeze/thaw cycle in order for 
the titre to be reflective of stored vials of frozen virus from the same batch. A volume of 100 
µl of supplemented D-MEM containing Dextran (40 µl per 10 ml D-MEM; the optimal 
concentration of Dextran used was determined based on batch serial dilution and toxicity 
testing) was added to each well of the first four rows of a 96-well cell culture plate. Dextran is 
a polysaccharide that enhances the permeability of cellular membranes thereby allowing for 
easier uptake of viral particles into cells. To each of the four wells in column 1, a volume of 
25 µl of virus was added followed by thorough mixing. Using a multi-channel pipette, 25 µl of 
virus from column 1 was transferred to column 2 and this was repeated across the plate until 
column 11 to produce a quadruplicate 1:5 dilution series, with thorough mixing and changing 
of tips between transfers. The 25 µl excess from column 11 was discarded and column 12 
was left as a negative column with no virus added. A volume of 100 µl of TZM-bl cells at a 
concentration of 1 x 105 cells/ml in supplemented D-MEM containing Dextran (40 µl per 10 
ml D-MEM) was then added to each well of the four rows. The titration plate was then 
incubated at 37°C with 5% CO2 for 48 hours.  
A volume of 100 µl of medium was removed from each well and discarded. To the remaining 
cells and media, 100 µl of Bright-Glo luciferase substrate (Promega, CA, USA) was added 
per well followed by an incubation step of two minutes at room temperature to allow for cell 
lysis and the interaction of luciferase released from infected cells with substrate. Luciferase 
expression was measured on a luminometer as Relative Light Units (RLU). Viral titre was 
taken as the viral dilution at which 50% of wells were infected (infected wells were 
determined based on RLU values at least 2.5 times above background), known as TCID50 






4.5.5 Parallel replication kinetics assays 
PBMCs from three HIV-negative donors were stimulated for 72 hours with the IL-2 cytokine 
(Gentaur, Belgium) (200 U/ml final concentration) and phytohemagglutinin-P (PHA-P) lectin 
(Remel, Thermo Scientific, MA, USA)(0.5 µg/ml final concentration) in RPMI 160 medium 
with 25 mM HEPES (Lonza, Basel, Switzerland) supplemented with 10% Fetal Calf Serum 
(Biochrom GmBH), 50 µg/ml Gentamicin antibiotic (Lonza, Basel, Switzerland) and 2mM L-
glutamine (Lonza, Basel, Switzerland) at 37°C with 5% CO2. The IL-2 and PHA-P activate 
cells and stimulate cellular proliferation.  
Stimulated PBMCs from each donor were CD8-depleted using Dynabeads CD8 (Invitrogen, 
CA, USA) according to manufacturer instructions. For these assays, it is necessary to 
deplete PBMCs of CD8+ CTLs prior to infection to prevent in vitro CTL-directed killing of HIV-
infected cells and exertion of immune pressure resulting in de novo escape mutations 
evolving in vitro.  Briefly, 8 x 106 to 1 x 107 cells from each donor were incubated in isolation 
buffer (PBS without calcium and magnesium, 0.1% BSA and 2 mM EDTA) with 1 x 107 
magnetic beads coated with monoclonal anti-CD8 membrane antigen antibodies which bind 
human CD8+ T-lymphocytes. By applying an EasySep magnet (Stemcell Technologies, 
Canada), bead-bound cells were sequestered while the remaining non-CD8+ cells were 
poured off and pelleted by centrifugation at 2 000 rpm for 8 minutes. Equal amounts of CD8-
depleted PBMCs from each donor were then combined and diluted to a final concentration of 
750 000 cells/ml in supplemented RPMI 160 containing IL-2 (200 U/ml) referred to as IL-2 
medium. 
Each virus was used to infect cells in triplicate wells of a 96-well cell culture plate at a 
multiplicity of infection of 0.001 (75 TCID50 in 75 000 PBMCs) in a final volume of 200 µl.  
As a virus inoculum-only background control, 75 TCID50 of virus was added to an additional 
well containing only medium and no cells.  Cultures were incubated at 37°C with 5% CO2 
and 50 µl of medium was removed with replacement on day five post-infection and thereafter 
every two days for two weeks and frozen at -20°C.  No fresh cells were added over the 
course of the assay.  The virus inoculum control wells were treated in the same manner.  
The Gag p24 concentration of virus supernatant was measured using a p24 sandwich ELISA 
described in section 4.4.6. The virus inoculum control p24 concentration was subtracted 
from p24 concentrations of infected cell cultures so as to determine the amount of new p24 
produced as a result of viral expansion over time. 
A replicative capacity (RC) score was calculated for each replicate infection growth curve 
using two methods:  (i) the rate of viral expansion in ng p24 per day up to the point of peak 
p24 concentration was determined and (ii) the slope of replication was determined for day 0 
100 
 
to each subsequent sampling day up to the p24 concentration plateau/decrease and 
averaged as according to the method described by Weber et al., 2011. 
 
4.5.6 Gag p24 antigen ELISA 
An HIV-1 p24 sandwich ELISA used for measuring viral expansion in culture was modified 
from that originally described by Moore et al. (1990) and McKeating et al. (1991) and 
adapted by Dr A Trkola.  In this protocol, p24 antigen from the viral lysates is bound to a 
polyclonal anti-HIV-1 p24 antibody immobilized on the surface of an ELISA assay plate. A 
monoclonal secondary anti-HIV 1 p24 antibody with an alkaline phosphatase conjugate is 
then bound to the p24 antigen. Finally, an alkaline phosphatase chemiluminescent substrate 
is added and p24 concentration is measured by light emission in relative light units (RLU).  
Details of the protocol used are as follows: 
White, opaque high-binding 96-well ELISA plates (Porvair Sciences, United Kingdom) were 
coated with 100 µl/well D7320 sheep polyclonal anti-HIV-1 p24 antibody (Aalto Bio reagents, 
Dublin, Ireland) dissolved in 0.1M NaHC03 buffer pH 8.5 to a final concentration of 33.3 
µg/ml and incubated overnight at room temperature.  Plates were washed three times with 1 
x Tris-buffered saline (TBS) and left to dry before freezing at -20°C. Virus supernatants were 
inactivated by 1:10 dilution in 1,1% Empigen detergent (Sigma-Aldrich, MO, USA) in 1 x TBS 
for one hour at room temperature. This incubation allowed for release of p24 antigen from 
virus particles.  Further dilution of lysed virus particles was carried out using 10% IL-2 
medium (as described in section 4.4.5), 1% Empigen in 1 x TBS.  A volume of 100 µl of 
diluted sample was loaded onto wells of pre-coated ELISA plates.  For generation of a 
standard curve from which to derive sample p24 concentrations, a seven-step 1:2 dilution 
series of recombinant HIV-1 p24 antigen standard (Aalto Bio Reagents, Dublin, Ireland) 
starting at 12.5 ng/ml was prepared and loaded in duplicate onto each ELISA plate (100 
µl/well).  Plates were incubated for two hours at room temperature to allow for binding of p24 
to antibody coated on the surface of the wells and  thereafter washed three times with 1 x 
TBS.  A volume of 100 µl of BC 1017-AP anti-HIV-1 p24 secondary conjugate antibody 
(Aalto Bio Reagents, Dublin, Ireland) diluted 1:12 500 in 0.1% Tween-20 in 1 x TBS was 
then added to each well followed by incubation at room temperature for one hour and 
thereafter four washes with 1 x TROPIX buffer (0.2 M Tris, 10 mM MgCl2, pH 9.8 with 1M 
HCL) containing 0.1% Tween-20.  A volume of 100 µl of CPD-Star with Sapphire II enhancer 
substrate (Applied Biosystems, CA, USA) diluted 1:10 in 1 x TROPIX buffer was added to 
each well and incubated at room temperature for 30 minutes away from light.  Luminescence 
of each well was measured in RLU using a Glomax luminometer (Promega, MA, USA). 
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Concentrations of p24 for all samples were extrapolated using the linear range of standard 
curve concentrations plotted on a log-log scale and fitted with a power regression trendline 
and equation. Viral replication kinetics curves were plotted as average p24 concentration 
(ng/ml) over time. 
 
4.5.7 Statistical tests 
Replicative capacity scores were compared using two-tailed unpaired Student’s t-tests and 
one-way ANOVA tests with Bonferroni correction for multiple comparisons. All statistical 
tests were run using GraphPad Prism version 5 (www.graphpad.com).  
 
4.6 Results 
4.6.1 Viral replicative fitness of t/f viruses 
IMCs were generated from individuals classified as infected with a single t/f env variant (see 
Chapter 2 and Appendix 1), of which four were provided (F. Treurnicht and J. Kappes) and 
one (pCAP200.t/f) was constructed for this thesis (see Appendix 5 for details).   IMCs were 
sequenced to ensure a match to the derived t/f full-length genome sequence (Chapter 2).  
For participant CAP63, who was infected with a second, minor variant, both t/f variant IMCs 
were available, however only the dominant variant was used for replication assays as the 
minor variant was not identified at later time-points. 
T/f viruses were generated by transfection of IMCs into HEK293 cells.  Replication kinetics 
was evaluated following infection of CD8+ T-cell-depleted, pooled PBMCs derived from 
three HIV-negative donors at an m.o.i. of 0.001.  Replication was monitored every two days 
from day five to 15 post-infection by harvesting of viral supernatant and measuring Gag p24 
antigen content. Replication capacity (RC) was expressed as the rate of increase of p24 
concentration per day until peak p24 concentration or the mean of slope derived from day 0 
to each day of sampling up to the p24 concentration plateau/decrease (Weber et a., 2011).  
T/f viruses from participants CAP63 and CAP239 expanded more rapidly than the other 
three viruses and plateaued earlier (by day 13) than viruses from participant CAP45 and 
CAP210 which continued to expand over the full two weeks.  The t/f virus from participant 





The RC of t/f viruses from participants CAP45, CAP63, CAP200, CAP210, CAP239 were 
compared (Figure 32A).  On average, CAP63.T/F had a 2.5-fold greater rate of expansion 












Figure 32.  Replication kinetics of CAPRISA t/f viruses.  (A) Gag p24 antigen concentrations of 
viral supernatants from infected PBMCs (pooled form three donors) sampled every two days from day 
5 post-infection are illustrated.  PBMCs were infected at an equal TCID50 m.o.i. for all viruses of 
0.001.  Mean p24 concentrations of triplicate infections are plotted with error bars indicating standard 
deviations. (B) Mean slopes of viral expansion from replicate infections with t/f viruses from the five 
women are plotted.  Asterisks indicate the level of significance of differences in mean RC values 
obtained from unpaired parametric Student’s t-tests (*** = p<0.001).    Viruses are colour-coded 
according to disease progression profile: grey = viremic control, black = intermediate, red = rapid 
progression.   
CAP45.T/F, CAP200.T/F, CAP210.T/F and CAP239.T/F displayed similar rates of increase 
to peak p24 concentration of 8.4, 8.68, 9.6 and 8.61 ng p24/day respectively, while 
CAP63.T/F had the highest rate of 21.6 ng p24/day. The difference in RC, as determined by 
both rate to peak p24 and mean slope of expansion, between CAP63.T/F and each of the 
other four viruses was highly significant [one-way analysis of variance (ANOVA) test 
revealed the difference in p<0.0001], even after correcting for multiple testing.  CAP45.T/F 
had the lowest replication capacity but this was not significantly different to viruses other 
than CAP63.    
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When considering the RC of t/f viruses in the context of disease progression, the woman 
with the most replication competent virus, CAP63, progressed to CD4+ counts <200 cells/µl 
in the first year of infection, after which she initiated therapy according to prevailing 
guidelines (National Department of Health South Africa, 2004).   
 
4.6.2 Selection of CTL-escape mutations for introduction into cognate t/f IMCs 
For participants CAP45, CAP63, CAP210 and CAP239, t/f IMCs were available at the time of 
initiation of this study.  HLA-B has been identified as the strongest determinant of HIV 
disease progression (Fellay et al., 2007, Fellay et al., 2009, Pereyra et al., 2010, Bartha et 
al., 2013) and longitudinal sequence datasets from these women were analyzed for 
evidence of polymorphisms presenting in Class I HLA-B targeted epitopes during the first six 
months of infection (Chapter 2).  Nine putative escape mutations were identified and seven 
of the nine mutations were selected for introduction into t/f IMCs (Table 8A-D) based on 
fixation or gain of dominance of the escape variant within the population by six months post-
infection. 
An escape mutation, D78A, in one epitope from participant CAP45 (Vif DWHLGHGVSI) was 
excluded since no sequence data was available between 12 and 65 weeks in order to 
evaluate the frequency of the mutant population at six months.  An additional mutation, 
A86G, in the Nef KAAVDLSFF epitope from CAP239, was excluded based on conflicting 
reports regarding which of the two amino acids represented the consensus form, with some 
studies reporting Glycine (G) to be consensus (Novitsky et al., 2002, Kiepiela et al., 2004, 
Brumme et al., 2007), and others reporting G to be the escape amino acid and A to be the 
consensus (Matthews et al., 2008, Brumme et al., 2009, Carlson et al., 2012a).  This may 
represent an instance of frequent transmission and fixation of the escape variant as a result 
of HLA adaption. 
 
CTL-escape mutations identified in participants CAP45, CAP63, CAP210 and CAP239, were 
introduced by site-directed mutagenesis into their cognate t/f IMCs (pCAP45.c, pCAP63.c, 
pCAPβ10.c and pCAPβγ9.c, where ‘p’ refers to plasmid and ‘c’ to subtype C) in order to 







Table 8A.  Selected CTL escape mutations for introduction into pCAP45.c t/f IMC 


































































































































Table 8B. Selected CTL escape mutations for introduction into pCAP63.c t/f IMC 
















































































Table 8C. Selected CTL escape mutations for introduction into pCAP210.c t/f IMC 
























































































































































































Table 8D. Selected CTL escape mutations for introduction into pCAP239.c t/f IMC 



































































































































4.6.3 The impact of early CTL selection on viral replicative capacity 
Mutant viruses were produced and parallel replication kinetics assays performed following 
infection of PBMCs at equal m.o.i. as described in section 4.6.2.  Replication kinetics of t/f 
and mutant viruses were compared.  The fold-difference in RC values between t/f and 
mutant viruses as determined by the rate of expansion to peak p24 and mean slope 
respectively are listed in Table 9.   
 
Table 9. RC comparisons between t/f and CTL escape mutant viruses 














CAP45.T/F CAP45.L60F/E64G 1.3 0.0549 1.23 0.0653 
CAP63.T/F CAP63.E65D 0.8 0.0269 1.06 0.6146 
CAP210.T/F CAP210.A146T/V85A 1.8 0.0004 1.81 <0.0001 
CAP239.T/F CAP239.T242N/E343K 0.5 0.0072 0.5 0.0074 
*Fold differences calculated as t/f divided by mutant virus. 
The CAP45.T/F and CAP45.L60F/E64G, differing at a single amino acid site in Rev and Nef 
respectively, expanded similarly in culture from day 5 to 11, after which CAP45.T/F 
expanded towards a higher-level plateau (Figure 33A).  The average rate of expansion of 
CAP45.T/F was 1.3-fold greater than that of CAP45.L60F/E64G and the mean slope was 
1.2-fold greater; however the difference in RCs between the two viruses did not reach 
statistical significance (see Table 10).   
For CAP63, the t/f (CAP63.T/F) and mutant (CAP63.E65D) viruses differed only by a single 
amino acid position in Nef.  Both viruses expanded rapidly in culture, with the CAP63.T/F 
expanding slightly faster in the first nine days of infection and reaching a plateau thereafter, 
while CAP63.E65D continued to expand up to day 11 (Figure 33B).  At day 5, the average 
p24 concentration of CAP63.T/F was 3.8-fold greater than that of CAP63.E65D indicating 
that this virus expanded more rapidly very early in the infection and possibly explains its 
earlier plateau.   However, despite slower expansion early on, CAP63.E65D proceeded to 
exceed the peak p24 concentration of the t/f virus from day 9 onwards.  The rate of 
expansion of CAP63.E65D was significantly higher (1.3-fold) than that of CAP63.T/F 
(p=0.0269) (Table 10), however the mean slopes of replication between the two viruses did 




Figure 33. Replication kinetics of t/f and CTL-escape mutants from CAP45 and CAP63.  
Expansion of t/f (black) and CTL-escape mutant (red) viruses were compared in parallel PBMC 
infection assays.  CD8-depleted, pooled PBMCs were infected at an m.o.i. of 0.001.  Gag p24 antigen 
concentrations of viral supernatants sampled every two days from day 5 are plotted as a function of 
time post-infection for t/f and escape mutant pairs from CAP45 (A) and CAP63 (B).  Error bars 
represent the standard deviation of p24 concentrations for triplicate infections.  
In participant CAP210, the presence of B*15:10-associated escape mutations in each of Gag 
(A146T) and Vif (V85A) significantly reduced the RC of the t/f virus (1.8-fold reduction in RC 
as determined by both mean slope and rate of expansion, p=0.0004) (Figure 34A), and 
conversely in participant CAP239, early B*58:01-associated escape mutations T242N in Gag 
and E343K in Pol, significantly increased RC (Figure 34B, Table 9).  In the case of 
participant CAP210, more rapid expansion of the CAP210.T/F was observed from day 7 




Figure 34. Replication kinetics of t/f and CTL-escape mutants from CAP210 and CAP239.  
Expansion of t/f (black) and CTL-escape mutant (red) viruses were compared in parallel PBMC 
infection assays. CD8-depleted, pooled PBMCs were infected at an m.o.i. of 0.001.  Gag p24 antigen 
concentrations of viral supernatants sampled every two days from day 5 are plotted as a function of 
time post-infection for t/f and escape mutant pairs from CAP210 (A) and CAP239 (B).  Error bars 
represent the standard deviation of p24 concentrations for triplicate infections.  
Virus CAP239.T242N/E343K expanded almost twice as fast as CAP239.T/F from day 7 to 
day 11 after which a large decrease in p24 concentration to a similar level as that of 
CAP239.T/F was seen by day 13 and 15, at which point expansion of both viruses had 
plateaued.  This was unexpected since the Gag T242N mutation is reported to significantly 
reduce RC (Martinez-Picardo et al., 2006; Brockman et al., 2007; Miura et al., 2009; 
Chopera et al., 2012; Song et al., 2012).  The t/f virus sequence of CAP239 contained both 
the H219Q and I223V polymorphisms associated with compensation of T242N and 
associated with restoration of viral replicative fitness (Brockman et al., 2007).  Although 
participant CAP239 is a B*58:01 positive individual herself, these polymorphisms in the 
derived t/f virus were present prior to acquisition of the T242N mutation, and are likely to 
have been in the virus transmitted from the donor. 
111 
 
These transmitted polymorphisms were back-mutated to evaluate their impact on 
CAP239.T242N/E343K replication.  The Q219H and I223V mutations were introduced into 
the pCAP239.c escape mutant IMC by site-directed mutagenesis.  The virus generated by 
transfection of this IMC, CAP239.T242N/E343K/Q219H/V223I, was used to infect the same 
pooled donor PBMCs as used for previous infections reported here, at the same m.o.i. of 
0.001 in parallel with CAP239.T/F and CAP239.T242N/E343K.  The replication kinetics of 
the three viruses was compared (Figure 35A).   
 
Figure 35. The impact of reversal of T242N compensatory mutations on RC of 
CAP239.T242N/E343K. Replication kinetics (A) and RC comparisons (B) of CAP239.T/F, 
CAP239.T242N/E343K and CAP239.T242N/E343K/Q219H/V223I (escape mutant with compensatory 
polymorphisms reversed) following parallel infections of CD8-depleted, pooled donor PBMCs at an 
m.o.i. of 0.001.  Error bars represent the standard deviation of p24 concentrations for triplicate 
infections.  Asterisks indicate the level of significance of differences between mean RC values 
obtained from unpaired parametric Student’s t-tests (** = <0.01 but >0.001).  
In the absence of the compensatory polymorphisms, the RC (mean slope) of the escape 
mutant was significantly reduced compared to both CAP239.T/F and 
CAP239.T242N/E343K/Q219H/V223I viruses (Figure 35B) [ANOVA p=0.001 with correction 
for multiple comparisons].  The expansion of CAP239.T242N/E343K/Q219H/V223I was slow 
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with the first detectable p24 antigen observed at day 9 post-infection.  The mean slope RC 
and rate of expansion to peak p24 of this virus were 2.1- and 1.94-fold lower than that of 
CAP239.T/F respectively, confirming that the presence of the escape mutations did indeed 
confer a loss of fitness, and 3.9- and 3.7-fold lower than that of CAP239.T242N/E343K 
respectively indicating the extent of enhancement of replicative capacity resulting from 
compensation.  These results show that polymorphisms associated with compensation of 
escape can carry a fitness cost, and that the introduction of the detrimental mutations can 
restore relative viral fitness.  
 
4.7 Discussion 
This study characterizes the replication capacity of full-length cognate t/f viruses in the 
context of differential clinical progression and reports the impact of early Class I HLA-
mediated immune escape on replicative fitness of cognate subtype C viruses.  We found that 
the participant with extremely rapid disease progression was infected with a virus which had 
significantly higher replication capacity compared to viruses from the other women, using a 
single-round, parallel PBMC infection assays with low viral multiplicity of infection (0.001).  
Furthermore we identify novel B*15:10-restricted escape mutations in p24 Gag and Vif which 
conferred a cost to replicative fitness.  Counterintuitively, we found that introduction of the 
well-described T242N mutation as well as a Pol E343K mutation into the cognate t/f virus 
from one woman resulted in an increase in replicative fitness.  This was due to pre-existing 
compensatory polymorphisms associated with T242N in the transmitted virus.   
The influence of the replicative fitness of viruses overcoming the mucosal transmission 
bottleneck and establishing clinical infection on the rate of progression of disease is not well 
characterized.  A recent review estimates up to 33% of variation in clinical disease to be a 
consequence of the transmitted virus (Fraser et al., 2014).  We investigated viral fitness of t/f 
viruses from one viremic controller, two rapid progressors and two intermediate progressors.  
It was found that the replication capacity of the t/f virus from one rapid progressor, CAP63, 
was significantly greater than that of viruses from the other four women whose viruses had 
similar replication capacities.  This woman represents a unique case since she progressed 
to CD4 count levels associated with AIDS-defining illness within approximately nine months 
of infection.  It is possible that viral replication fitness contributed to this disease phenotype, 




Many studies have evaluated the impact of immune escape mutations on viral replication in 
recombinant or chronic lab-adapted viral backbones (Brockman et al., 2010, Wright et al., 
2010, Wright et al., 2011, Boutwell et al., 2013), however only two studies to date have 
investigated the impact of immune escape mutations in cognate t/f viral backbones, both of 
which were in subtype B (Song et al., 2012; Song et al., 2014).  In two of the four women 
(CAP210 and CAP239), CTL-escape was found to negatively impact viral replication 
capacity.  Since parallel replication assays are less sensitive to the detection of more subtle 
replicative fitness differences, the possibility exists that differences in replication capacities in 
viruses from the other two women (CAP45 and CAP63) were not detected as a result of the 
assay used.  
In the case of CAP210 viral replication capacity was reduced after introduction of the 
B*15:10-associated Gag A146T and Vif V85A mutations.  Mutations at position 146 have 
previously been associated with HLA-B*57/58, B*13, A*25 and B*15:10-restriction (Draenert 
et al., 2004; Honeyborne et al., 2007; Troyer et al., 2009; Prince et al., 2012).  A146P was 
identified as a processing mutation flanking the B*57/58-restricted ISW9 epitope (Draenert et 
al., 2004), and has been shown to cause a loss of viral replication capacity (Troyer et al., 
2009; Boutwell et al., 2013).  Conversely, an A146S mutation has also been reported to 
enhance viral replication (Prince et al., 2012).  In CAP210 we found that at 43 and 80 weeks, 
the A146T variant was replaced by A146P and A146S variants (see Table 9).  Since a 
Threonine at position 146 is rare (present in <1% of subtype C database sequences), it is 
possible that variation at this site later in infection was due to the virus attempting to 
incorporate a more favourable amino acid while maintaining the escape phenotype.  The 
V85A mutation in Vif is not known to be associated with a loss of fitness and is neither rare 
nor situated within a structural or functional domain of the genome.  Based on the literature, 
it is likely that the Gag A146T mutation resulted in the loss of viral fitness observed, however 
a role for the V85A mutation needs to be tested in isolation to determine its individual 
contribution. 
In the case of participant CAP239, replication capacity was significantly enhanced following 
introduction of B*58:01-associated Gag T242N and Pol E343K mutations into the t/f virus 
backbone.  It is well established that the T242N mutation in the Gag TW10 B*57/58:01-
targeted epitope reduces viral replication (Martinez-Picardo et al., 2006; Brockman et al., 
2007; Miura et al., 2009; Chopera et al., 2012; Song et al., 2012).  This has been attributed 
to interruption of viral capsid binding to host Cyclophilin A which is required for productive 
infection (Schaller et al., 2011); however compensatory mutations in the Cyclophilin A 
binding loop of the virus have been shown to restore replication fitness (Brockman et al., 
2007).  The presence of compensatory polymorphisms (H219Q and I223V) in the t/f virus 
114 
 
appeared to be detrimental to replication in the absence of T242N.  When these viruses 
were back-mutated, the T242N-mutant replication was severely impacted.   This likely 
indicates that the compensatory mutations are beneficial only in the context of escape and 
that independently they are not desirable for viral replication.  These compensatory 
polymorphisms are accumulating in circulating subtype C viruses in southern Africa 
(Matthews et al., 2008) and the enhanced replication fitness associated with escape may 
explain why there is not a strong benefit associated with HLA-B*57.  Recent studies have 
shown that compensatory mutations associated with T242N were found to be significantly 
more frequent in B*57/58:01 progressors compared to long-term non-progressors with these 
alleles (Gijsbers et al., 2013).  In this same study, the H219Q mutation together with T242N 
and no additional compensatory mutations significantly enhanced replication capacity, 
however this was not the case for I223V (Gijsbers et al., 2013).  Since the level of 
enhancement of replicative capacity is reported to increase as the numbers of compensatory 
mutations increase (Brockman et al., 2010, Gijsbers et al., 2013), the I223V mutation may 
have had an additive role in enhancing viral replication in the current study.   
Ours is the first study to our knowledge to demonstrate that T242N escape can facilitate 
superior replication capacity to that of the wild-type virus counterpart.   Interestingly, a study 
by Rolland et al. (2010) which identified co-varying amino acid sites in subtype C Gag from 
individuals in Durban, South Africa found that individuals with deleterious escape and 
compensatory mutation pairs at co-varying sites had higher viral loads than individuals with 
consensus mutations at these sites, thus supporting the potential enhancement of viral 
fitness to above ‘wild-type’ levels in the presence of compensation.  It is possible however 
that in our study, the E343K mutation also contributed to enhanced viral replication capacity. 
Furthermore, in a recent study, Song et al. (2012) were unable to detect a fitness difference 
between a subtype B cognate t/f and T242N mutant virus in a parallel infection assay using 
primary CD4+ T-cells.  The authors proposed that more subtle fitness differences may only 
be detected through competition assays with multiple passaging of viruses (Song et al., 
2012).  In this thesis, a significant difference between the CAP239.T/F virus and 
CAP239.T242N/E343K mutant in the absence of compensation was detected in a parallel 
assay.  However, the parallel assay used by Song et al. (2012) was carried out over a 5-day 
period compared to the 15-day assay used in this thesis which only detected p24 from day 
five post-infection onwards; therefore observed differences may be due to differences in 
assay conditions.  In addition, the CAP239 escape mutant virus also contained a Pol E403K 
mutation in a B*58:01-targeted epitope.  This mutation may have contributed to the reduced 
replication fitness observed.   
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An early escape mutation in the Nef EV11 epitope identified in viruses from both rapid 
progressor CAP63 and viremic controller CAP45 was introduced into the t/f virus IMC 
backbones for each of the two women.  Both mutations were located within the Nef acidic 
domain which overlaps with the EV11 epitope and consists of four Glutamic Acid residues 
(62EEEE65).  This domain was reported to be required for MHC Class I downregulation 
(Piguet et al., 2000), but was able to accommodate replacement of any two of the Glutamic 
acids at one time without a reduction in this viral function (Baugh et al., 2008).  The E65D 
mutation conferred a modestly enhanced replication capacity to the t/f virus from participant 
CAP63, whereas in the case of participant CAP45 expansion of the t/f and mutant virus 
(containing the Nef E64G mutation as well as a Rev I60F mutation) was similar.  It may be 
speculated that the type of amino acid transition influenced the impact on fitness.  In the 
case of the E65D mutation in CAP63, the negatively charged Glutamic Acid was replaced 
with a similar residue, negatively charged Aspartic Acid, and in the case of the E64G 
mutation, the Glutamic Acid was replaced with a dissimilar residue, unique amino acid 
Glycine.  The presence of the Aspartic Acid may be advantageous to viral functions involving 
the acidic domain.  Interestingly, in both participants CAP45 and CAP63, the virus toggles 
between Glycine and Aspartic Acid at position 65, and in the case of CAP45 reverts to 
consensus, but in the case of CAP63, selects the Aspartic Acid (see Table 9). 
While this study demonstrates the advantage of evaluating escape in cognate backbones, 
the generation of IMCs takes significant effort and resources, making this a difficult approach 
for evaluation of larger numbers of samples.  The method of IMC construction (modified from 
that described by Salazar-Gonzalez et al. (2009) and Ochsenbauer et al. (2012)) described 
here (Appendix 5) holds advantages since it made only limited use of PCR and thereby 
reduced the risk of introduction of polymerase-induced error into DNA sequences.  
Furthermore, the use of cloning by means of overlapping fragments between the insert and 
vector, as used in the case of In-Fusion technology, allowed for more stable integration of 
genome inserts compared to sticky-end ligation of restriction enzyme digested insert and 
vector. One potential drawback of the method of IMC construction described is the high cost 
of synthesis of DNA fragments.   
In conclusion, the significant impact of early escape resulting from Class I HLA-mediated 
targeting of CTL epitopes in Gag on viral replication capacity was illustrated in full-length 
cognate t/f viruses.  The utility of cognate t/f backbones was made apparent by the 




Chapter 5: General Discussion and Conclusion 
5.1 Discussion 
This thesis represents a detailed study of full-length subtype C HIV-1 genomes of the viruses 
establishing clinical infection in five South African women, their subsequent early evolution 
and the impact of early immune selection on viral replicative fitness.  The study contributes 
to our understanding of the globally dominant subtype C strain and is one of the first to 
demonstrate the impact of early immune selection on subtype C viral phenotype in the 
context of both cognate transmitted/founder (t/f) virus backbones and of differential disease 
progression.   
In the last six years, HIV-1 transmission studies have been accelerated with the finding that 
the majority of infections are established by a single viral variant (Keele et al., 2008) and that 
the sequence of that t/f variant can be derived and used as a basis for the mapping of early 
viral evolution (Salazar-Gonzalez et al., 2009).  Characterization of the transmission 
bottleneck in subtype C infection (Abrahams et al., 2009) formed the foundation for selection 
of the women investigated in this thesis, and the complete viral genome analysis performed 
confirmed single/low-diversity transmission originally determined by env-only analyses.  
The subsequent mapping of early selection on the genomes of these five women, revealed 
findings in agreement with those reported for similar near full-length genome subtype B 
studies (Goonetilleke et al., 2009; Herbeck et al., 2011).   As with the previous studies, early 
selection was dominated by immune pressure mediated by CD8+ cytotoxic T-lymphocytes 
(CTLs) but was also contributed to by early antibody pressure and reversion, and immune 
selection and viral evolution was most extensive in nef.  The high level of amino acid 
shuffling and toggling in HLA-targeted evolving epitopes identified in this study implies that 
early targets of CTL pressure are unstable and highly variable. 
Long-term disease outcome may largely be dictated by the type of host immune responses 
mounted and the mutations selected which may alter the virus’s replicative ability.  The field 
is moving towards the use of cognate viruses as more relevant research tools for evaluating 
viral phenotype with two subtype B studies characterizing the effect of immune escape and 
compensatory mutations in cognate viral backbones published to date (Song et al., 2012; 
Song et al., 2014).  The unique advantage of the use of cognate viruses for evaluating viral 
replicative capacity and the effect of CTL-escape mutations accrued very early in infection is 
demonstrated in this thesis.  Most notably, in one individual, enhancement of viral replication 
to a level exceeding that of the t/f virus through a combination of immune escape and 
transmitted compensatory polymorphisms was demonstrated, representing a novel finding in 
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the field.  The individual harboured the protective HLA-B*58:01 allele, but was not controlling 
disease.   
One objective of this thesis was to compare the evolution and phenotype of viruses 
transmitted to individuals who go on to control disease compared to those with rapid 
progression.  The numbers in this study were too limited to make any general statements 
regarding t/f viral evolution and disease progression, however one rapid progressor in this 
study was found to be unique as her virus displayed significantly higher viral diversification 
and evolution as well as a significantly higher replication capacity compared to the other 
women investigated.  The only CTL-escape mutation identified in an HLA-B-restricted 
epitope in this individual did not have a significant impact on viral replication capacity. 
A novel escape mutation, A146T, associated with B*15:10-restriction of the Gag VL10 
epitope was identified and potentially associated with a reduction of viral replication capacity 
(in this instance in combination with a V85A escape mutation in Vif). This epitope and an 
overlapping epitope, ISW9, are targeted by a number of different HLA alleles including the 
protective HLA-B*57 and B*13 alleles but also by non-protective HLA-A*25 alleles.  The 
individual in whom this mutation was identified was a rapid progressor and thus the 
attenuating mutation was not associated with a clinical benefit.  This may be due to the fact 
that the restricting B*15:10 allele is non-protective, and this outweighed the benefit of 
attenuation of viral replication.   
 
5.2 Conclusion 
Early immune selection in t/f subtype C viruses is dominated by CD8+ T-lymphocyte 
responses and characterized by rapid escape and complex mutational pathways.  Early 
escape from these responses can significantly alter viral replication fitness when introduced 
into cognate t/f viral backbones.  The importance of evaluating immune escape mutations in 
the context of the cognate virus is emphasized through the demonstration of the fitness 
enhancing effects of compensatory mutations.  Although we show that viral attenuation 
through immune escape is not restricted to protective HLA alleles, this attenuation was not 
sufficient to provide overall clinical benefit reaffirming that host genetics plays a dominant 
role in determining disease outcome.  However, the impact of escape in Gag on replicative 
fitness supports a role for Gag epitopes in vaccine immunogen selection since, in the 
absence of vaccine protection, immune escape mutations in Gag could provide clinical 
benefit.  Overall this thesis supports the need for eliciting CTL responses by a vaccine due to 
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their dominant role in early infection; however the extensive variability in early evolving 
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Identifying the specific genetic characteristics of successfully transmitted variants may prove central to the
development of effective vaccine and microbicide interventions. Although human immunodeficiency virus
transmission is associated with a population bottleneck, the extent to which different factors influence the
diversity of transmitted viruses is unclear. We estimate here the number of transmitted variants in 69
heterosexual men and women with primary subtype C infections. From 1,505 env sequences obtained using a
single genome amplification approach we show that 78% of infections involved single variant transmission and
22% involved multiple variant transmissions (median of 3). We found evidence for mutations selected for
cytotoxic-T-lymphocyte or antibody escape and a high prevalence of recombination in individuals infected with
multiple variants representing another potential escape pathway in these individuals. In a combined analysis
of 171 subtype B and C transmission events, we found that infection with more than one variant does not follow
a Poisson distribution, indicating that transmission of individual virions cannot be seen as independent events,
each occurring with low probability. While most transmissions resulted from a single infectious unit, multiple
variant transmissions represent a significant fraction of transmission events, suggesting that there may be
important mechanistic differences between these groups that are not yet understood.
The development of a human immunodeficiency virus
(HIV) vaccine remains a global priority. Since vaccines need to
target viruses at, or close to, the time of infection, there is great
interest in understanding both the genetic characteristics of
viruses that are successfully transmitted and the genetic diver-
sification that ensues during the earliest stages of infection.
There is evidence from cross-sectional studies of individuals
with acute and early HIV infections that transmission is asso-
ciated with a population bottleneck (4, 9, 16, 35, 36, 39, 46–48).
The best evidence of transmission bottlenecks is obtained from
studies of HIV discordant couples, where infection is associ-
ated with transmission of one or a few genetic variants despite
high degrees of viral diversity in the transmitting donors (13).
A recent study was able to quantify this bottleneck by using
methodologies that could identify precisely the transmitted,
founder virus population (16). That study found that as many
as 76% of transmission events involved productive clinical in-
fection by only a single genetic variant in HIV-1 subtype B
transmission by either heterosexual or homosexual routes.
These findings are encouraging since in the majority of infec-
tions a vaccine-mediated response may have to protect against
only a low-multiplicity infection event that is associated with
low viral diversity in the initial days and weeks of infection.
However, it is also apparent that the transmission bottleneck
can be overcome, as evidenced by the transmission of multiple
viral variants (9, 10, 12, 16, 35, 36). The clinical implications of
multiple variant transmission are potentially serious because
coinfection with genetically divergent viral lineages has been
associated with more severe disease progression (10, 12, 37).
Current estimates of the frequency of multiple variant trans-
missions vary widely with between 0 and 50% of successful
sexual transmissions estimated to involve the transfer of mul-
tiple genetic variants (9, 16, 35).
It is still an open question as to whether there are distinctive
features of viruses that enhance their transmissibility and
whether different risk behaviors are associated with different
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numbers of transmitted viruses. For example, intravenous in-
fection has been associated with more heterogeneous infec-
tions than intravaginal infection in a rhesus macaque model
(11). Besides the potential identification of previously unrec-
ognized transmission risk factors, attempts to discover the vari-
ables influencing multivariant transmission event frequencies
should also provide insights into natural barriers to HIV in-
fection. Unfortunately, because of methodological variations
between studies it has not been possible to directly compare
results and to assess the impacts of biological factors such as
gender, routes of transmission, the presence of sexually trans-
mitted diseases and viral subtype on multiple variant transmis-
sion frequencies (39). Complex cofactors in a given risk cate-
gory may impact rates of transmission of multiple variants just
as they impact overall transmission rates (32).
In the present study, we investigated the genetic character-
istics of subtype C variants transmitted via a heterosexual route
in order to understand mechanisms involved in HIV transmis-
sion at genital sites. We used here the approach described by
Keele et al. (16), which allowed us to directly compare multiple
transmission frequencies between subtype B and C viruses.
Our results indicate that similar proportions of subtype B and
subtype C infections involve the transmission of multiple vari-
ants. Analysis of a total of 171 transmission events in both the
subtype B and C studies showed that infection with multiple
variants does not follow a Poisson distribution, suggesting that
transmissions of multiple variants are not independent events
in a setting of a low probability of infection. The question of
the biological basis of the mucosal viral transmission bottle-
neck and factors associated with its breach, however, remains
unanswered.
MATERIALS AND METHODS
Cohort description. Plasma was obtained from 69 individuals experiencing
early HIV-1 subtype C infection. Twenty-six were identified through prospective
monthly monitoring of HIV-negative women using rapid HIV tests and RNA
PCR (44) (CAPRISA 002 cohort, Durban, South Africa); 22 were identified (i)
with negative rapid HIV or enzyme immunoassay assay (EIA) antibody test
results but positive HIV RNA and/or p24 antigen test results or (ii) who were
antibody positive but antibody negative or Western blot indeterminate within the
previous 45 days (CHAVI 001 cohorts, South Africa and Kamazu Central Hos-
pital Sexually Transmitted Disease Clinic, Malawi). An additional 21 individuals
enrolled from the Sexually Transmitted Disease Clinic in Malawi were identified
as HIV PCR positive with a rapid HIV or EIA antibody-negative test or who had
indeterminate HIV Western blot results (30).
This study was approved by institutional review boards, and all participants
provided written informed consent.
Staging of HIV infection. The durations of HIV-1 infection were categorized
into six stages based on evolving HIV-1 RNA or antibody profiles developed by
Fiebig et al. (8). Plasma was tested for HIV RNA by using Roche Amplicor
vRNA assays (Rotkreuz, Switzerland) and for antibodies by EIA (BEP 2000
[Dade Behring, Marburg, Germany] or Determine AntiHIV-1/2 3rd Generation
EIA [Abbott, Illinois] and Uni-Gold Recombigen [Trinity Biotech, Ireland]) and
a GS HIV-1 Western blot analysis kit (Bio-Rad, Washington). Individuals clas-
sified as being in stage I were viral RNA positive and p24 antigen and EIA
antibody negative, those in stage II were RNA and p24 antigen positive but EIA
antibody negative, those in stage III were EIA antibody positive but Western blot
negative, those in stage IV had an indeterminate Western blot result, those in
stage V were Western blot positive but without reactivity to the p31 integrase
band, and those in stage VI were Western blot positive with a p31 band present.
PCR amplification and sequencing. HIV-1 RNA was extracted from 140 to
200 l of ACD or EDTA plasma and eluted in a 50-l final volume. The full
volume of RNA was reverse transcribed to cDNA (100-l reaction volume) by
using a Superscript III reverse transcriptase (RT) system (Invitrogen, California)
with an OFM-19 primer as described previously (16) or with oligo(dT). The
cDNA was then serially diluted to obtain no more than 30% positive amplifica-
tion reactions so that each amplicon would theoretically be amplified from a
single template more than 80% of the time (39). This limiting dilution approach
of env gene amplification was initially described by Simmonds et al. (41) and
Edmonson and Mullins (7) and was thereafter modified by Palmer et al. (29) by
sequencing of the amplicon directly and finally modified by Salazar-Gonzalez et
al. (39), who showed that single genome amplification of the env gene with direct
sequencing precludes recombination and Taq-induced error, and provides pro-
portional representation of each viral sequence. PCR products were directly
sequenced by using an ABI 3000 genetic analyzer (Applied Biosystems, Foster
City, CA) and BigDye terminator reagents. To ensure that sequences reflected
single templates from the viral populations in vivo, amplicons with sequence
chromatograms with “double peaks,” indicative of coamplification of more than
one template, were excluded. Sequences with deletions larger than 100 nucleo-
tides compared to the intraparticipant consensus were excluded.
Sequence analysis. Differences in sequences were visualized by using neigh-
bor-joining trees (MEGA 3.1) (43) and Highlighter nucleotide transition and
transversion plots (www.hiv.lanl.gov). Pairwise DNA distances were computed by
using MEGA 3.1.
Conformance of intraparticipant sequence diversity to a mathematical model
of random evolution was evaluated as described by Keele et al. (16) and Lee et
al. (H. Y. Lee, E. E. Giorgi, B. F. Keele, B. Gaschen, G. S. Athreya, J. F.
Salazar-Gonzalez, K. T. Pham, P. A. Geopfert, J. M. Kilby, M. S. Saag, E. L.
Delwart, M. P. Busch, B. H. Hahn, G. M. Shaw, B. T. Korber, T. Bhattacharya,
and A. S. Perelson, submitted for publication) whereby exponential viral repli-
cation from a single lineage is assumed to fix mutations at a constant rate, in the
absence of positive selection, using the following parameters: an HIV-1 gener-
ation time of 2 days (24), a reproductive ratio of 6 (i.e., assuming that the virus
replicates exponentially, for each currently infected cell six new cells will be
infected in the next generation) (42), and a replication error rate of 2.16  105
substitutions per site per replication cycle (23).
Time of divergence from the most recent common ancestor (MRCA) was
estimated by using BEAST (i.e., Bayesian Evolutionary Analysis Sampling Trees,
v1.4.7) (5, 6) with a relaxed (uncorrelated exponential) molecular clock and
general time-reversible substitution model, with relative substitution rate param-
eters estimated by using HyPhy (31), as described previously (16). We used a
gamma distribution with four categories and a proportion of invariant sites to
model rate heterogeneity across sites. Substitution rates were unlinked across
codon positions with a mean fixed at 2.16  105 substitutions per site per
generation (23).
Sequences were analyzed for evidence of APOBEC3G-induced hypermutation
by using the Hypermut 2.0 tool (www.hiv.lanl.gov). Sequences with a P value of
0.1 were considered enriched for mutations consistent with APOBEC3G sig-
natures. In sequence sets showing evidence of enrichment for APOBEC3G-
driven G-to-A transitions but with no single significantly hypermutated sequence,
hypermutation was tested for after superimposition of all mutations within that
sequence set onto a single representative sequence.
We used randomization to test whether there was evidence of clustering of
mutations within 10-amino-acid stretches putatively associated with cytotoxic-T-
lymphocyte (CTL) immune responses (14). Sites were classified as mutated in a
given patient if there was at least one sequence from the patient differing from
the patient consensus at that site. For each mutated site, we calculated its
nearest-neighbor distance as the distance between the site and the closest mu-
tated site to the left or right of it on the intrapatient sequence alignment. We
then compared the number of mutations with a nearest neighbor within 10 amino
acids to the number expected by chance by randomizing the locations of the
mutated sites 1,000 times. A P value was calculated as the fraction of randomized
datasets for which the proportion of mutated sites within 10 amino acids of
another mutated site was equal to or greater than the observed proportion. The
null hypothesis here is random distribution of mutated sites, which is consistent
with the model of neutral drift of the infecting virus in acute infection, proposed
by Keele et al. (16). Rejection of the null hypothesis suggests clustering of the
mutations on a scale consistent with escape from CTL responses.
Multivariant transmission was considered if (i) within-patient env diversity was
heterogeneous, with multimodal distribution of pairwise Hamming distances
(HDs; that is, the number of differing sites between sequences) and structure
within the phylogenetic trees, and (ii) if these deviations from the model of
random evolution from a single founder virus could not be accounted for by
APOBEC3G mutations, immune pressure, or stochastic events. For individuals
infected with more than one variant, our expectation was that when multiple
variants were transmitted, the sequences in the recipient should coalesce at a
time predating the estimated time of infection. The number of infecting variants
was enumerated, after accounting for recombination, by identification of distinct
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lineages on phylogenetic trees, together with examination of Highlighter transi-
tion and transversion plots (www.hiv.lanl.gov).
N-linked glycosylation sites were identified by using the N-glycosite program
(www.hiv.lanl.gov). HXB2 env protein amino acid locations for putative epitopes
were obtained by using the HIV sequence locator tool (www.hiv.lanl.gov). Motif
Scan (www.hiv.lanl.gov) was used to detect HLA anchor residue motifs within
putative epitopes and to search for matching potential epitopes.
Recombination analysis. The GARD (www.datamonkey.org/GARD/) (17,
18), RAP Beta version (www.hiv.lanl.gov), and RDP version 3.27 (http://darwin
.uvigo.es/rdp/rdp.html) (25) tools were used to detect recombination in intrapar-
ticipant sequence sets.
Modeling the probability of multivariant infection. We have assumed that
established infection with a single genotypic variant signifies that a single virus
particle was involved in the transmission event and that, in the setting of low
probability of transmission, this represents the minimal infectious dose. The
Poisson distribution was used to model the frequency of transmission of one, two,
or more variants under the assumption that the transmission of each variant
occurs with the same probability, i.e., as independent events. A left truncated
Poisson model was used (since the zero events, i.e., no transmission, are not
observed), and the model fitted to all of the data with a maximum-likelihood
method; this then allowed the frequency of zero events to be estimated given the
distribution of one, two, etc., variants being detected. A corresponding transmis-
sion probability was estimated as the sum of all probabilities for observing one or
more variants.
Statistical testing. Categorical variables were compared by using Fisher exact
tests (two-tailed). P values of 0.05 were considered significant.
GenBank accession numbers. The GenBank accession numbers for the 1,505
env sequences are FJ443128 to FJ444362.
RESULTS
Cohort description and timing of infection. Blood plasma
samples were obtained from 69 study participants (30 men and
39 women) from South Africa and Malawi who had recently
acquired HIV-1 infection through heterosexual contact (Table
1). A total of 42 of the participants were in the very early stages
of infection: 22 were in stage I/II (viral RNA positive, p24
antigen and EIA antibody negative, or RNA and p24 antigen
positive but EIA antibody negative), 6 were in stage III (EIA
antibody positive but negative by Western blotting), and 14
were in stage IV (EIA antibody positive with an indeterminate
Western blot result). Individuals in these stages had high viral
loads (mean of 6 million copies/ml) typical of acute infection
(Fig. 1). Twenty-seven participants were in the later stages of
primary infection, eighteen in stage V (Western blot positive
but without reactivity to the p31 integrase band) and eight in
stage VI (Western blot positive with a p31 band present), with
lower viral loads (medians of 84,572 and 21,176 copies/ml,
respectively); one individual was classified as being in stage V
or VI, with reactivity to p31 integrase not yet determined.
Characterization of env gene diversity. A total of 1,505 env
gene sequences encoding gp160 (with an average of 22 se-




A single variant More than one variant
Cohort
Total no. of subjects 54 15
No. of female subjects 32 7
No. of male subjects 22 8




Mean age in yr (female)  SD 29  10 25  7
Infecting virus
Maximum % DNA distance range 0.08–0.64 0.32–8.49
Median no. of infecting variants (range) 1 3 (2–5)
Viral load at 12 mo postinfectiona 39,300  106,072 (400–376,000) 70,100  532,413 (400–1,230,000)
CD4 counts at 12 mo postinfectionb 468  193 (303–1,030) 274  251 (188–695)
a Expressed as median copies/ml  the standard deviation (n  24).
b Expressed as median cells/l  the standard deviation (n  24).
FIG. 1. Log viral loads of 68 participants categorized into stage I/II
(viral RNA positive, p24 antigen and EIA antibody negative, or RNA
and p24 antigen positive but EIA antibody negative), stage III (EIA
antibody positive but negative by Western blot), stage IV (EIA anti-
body positive with an indeterminate Western blot result), stage V
(Western blot positive but without reactivity to the p31 integrase
band), and stage VI (Western blot positive with a p31 band present)
(8). Boxes represent the 70th percentile; horizontal bars represent the
median, and whisker bars correspond to minimum and maximum val-
ues. p24 antigen tests, which differentiate stages I and II of infection,
were not carried out for all participants; therefore, HIV RNA-positive,
enzyme-linked immunosorbent assay-negative individuals were classi-
fied as stage I/II. One participant was classified as being in stage V or
VI of infection and is thus not included in this figure. The mean
number of days postinfection was determined by Fiebig et al. (8) and
modified by Keele et al. (16).
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quences per participant; range, 15 to 42) were generated from
the 69 participants using single genome amplification and di-
rect sequencing of amplicons. All sequences were classified as
HIV-1 subtype C (Fig. 2). Fourteen participants clearly har-
bored highly heterogeneous viral populations (maximum in-
trapatient DNA distances of 0.73 to 8.49%) forming more than
one phylogenetic lineage. These individuals were postulated to
be infected with multiple variants and were further character-
ized to quantify the number of infecting variants. The remain-
ing 55 participants harbored virus populations with lower di-
versity (maximum intrapatient DNA distances ranging from
0.08 to 0.64%) with sequences clustering as single lineages with
no, or very little, structure within phylogenetic trees (see Ta-
bles S1A to S1C in the supplemental material). On further
analysis, one of the 55 individuals with a low diversity env
population, participant 1176, was subsequently found to be
infected with three closely related viruses.
All sequences were initially analyzed for evidence of
APOBEC3G-induced G-to-A hypermutation and, after re-
moval of these mutations from the relevant sequence sets, all
sequences were compared to a model of random evolution in
which infection with a single founder virus is followed by neu-
tral expansion characterized by exponential population growth
(16). This is expected to result in a star-like phylogeny and a
Poisson distribution for the intrapatient HD. Sequence sets
that did not conform to the model after the removal of the
G-to-A hypermutation were analyzed for evidence of immune
pressure, selection, or evidence of scattered APOBEC3G-re-
lated hypermutation, although not detected as significant (P 
0.1), to determine possible reasons for the deviation from the
model. Finally, the time of infection estimated from laboratory
staging was compared to the estimated time to the MRCA of
the sequences.
Two study participants were identified as being a donor-
recipient pair based on their sexual history and the close phy-
logenetic linkage of their viruses (Fig. 2). Participant
703010131 was assumed to be the donor since he was classified
as being in stage III infection, while the assumed recipient,
participant 703010159, was found to be in stage I/II.
Low env diversity after transmission. Of the 55 individuals
harboring viruses with low diversity, sequences from 30 indi-
viduals displayed Poisson distributed HDs and a star-like phy-
logeny consistent with infection with a single founder virus and
with the subsequent incorporation of randomly distributed mu-
tations (Fig. 3A and see Table S1A in the supplemental ma-
terial). Sequences from a further five individuals conformed to
the model following the removal of G-to-A substitutions em-
bedded in APOBEC3G signature patterns after showing sig-
FIG. 2. Neighbor-joining tree of env sequences from each of the 69
study participants from South Africa and Malawi. To limit the size of
the tree, only 626 sequences of the 1,505 sequences generated were
analyzed: where individuals harbored viruses with multiple identical
env sequences, only the unique sequences were included. Red
branches represent sequences from participants infected with more
than one variant. Diamonds represent sequences with 6% divergence
from the participant sequence population. The sequences for partici-
pants 703010131 and 703010159, a donor-recipient pair, cluster to-
gether, as indicated.
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nificant enrichment of these substitutions within a single se-
quence and/or within the overall participant sequence set with
no single overtly hypermutated sequence (P  0.1) (see Table
S1B in the supplemental material). In a sixth individual with
significant APOBEC3G-driven hypermutation (P  0.0067),
participant CAP85, sequences did not conform to a star-like
phylogeny even after removal of APOBEC-driven substitu-
tions (data not shown). This was not investigated further. Se-
quence sets for an additional two individuals (CAP225 and
704810053) conformed to the model following removal of scat-
tered G-to-A mutations, despite the fact that this hypermuta-
tion was not significant (P  0.1) (see Table S1B in the sup-
plemental material).
Thus, in seven of eight individuals, the model violation prior
to the removal of G-to-A substitutions would likely be due to
an increased relative mutation rate in these sites. This result is
similar to that reported for a small set of individuals identified
in the acute subtype B-infected cohort of Keele et al. (16),
where an overall enrichment of G-to-A substitutions in APO-
BEC motifs was scattered throughout the available sequences
in 7 of 81 homogeneous infections, with an additional six sub-
jects carrying one or more overtly hypermutated sequence. The
FIG. 3. env sequence diversity was visually determined by the structure of the phylogenetic tree (left), and the pattern of nucleotide base
mutations within sequences was observed on a Highlighter plot (right). The Highlighter plots compare sequences from each participant’s sequence
set to an intraparticipant consensus (uppermost sequence) and illustrate the positions of nucleotide base transitions and transversions using short,
color-coded bars. (A) Participant 1172 with a highly homogeneous env sequence population displaying limited structure on a tree and a few
nucleotide changes from the intraparticipant consensus. (B) Participant 1176 infected with three closely related env populations (indicated in black,
blue, and red, respectively) based on the clustering of sequences into individual clades on a tree and the shared patterns of mutations observed
on a Highlighter plot. Both participants were viral RNA positive but ELISA negative (stage I/II of infection).
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balance between HIV-1 Vif and APOBEC3G (22) may be
altered in such cases. In addition, a recent study suggests that
this type of pattern may be associated with improved clinical
outcome (19).
The remaining 17 of the 55 individuals with low-diversity env
populations had no evidence of enrichment for G-to-A hyper-
mutation but harbored virus populations that did not conform
to the model due to their having either non-Poisson-distrib-
uted HDs and/or non-star-like phylogenies. Six of these indi-
viduals were classified as infected with a single founder virus
based on divergence within a single lineage (n  2) and/or on
patterns of shared mutations between sequences (n  4) (i.e.,
internal branching in the intrapatient tree inconsistent with the
expected star-like phylogeny). These shared mutations were
possibly due to stochastic accumulation of neutral mutant al-
leles, either as neutral mutations that occurred very early in the
infection and could thus be established and retained in a high
enough frequency to be sampled or due to very early CTL
escape mutations.
A further 7 of these 17 individuals had evidence of early
antibody pressure with sequences showing loss or gain of N-
linked glycosylation sites or changes in envelope loop length;
all 7 were recruited in stages IV to VI of infection (Fig. 4). In
four of the seven participants, these changes occurred in the
V1/V2 loop region, which may indicate that this area is an early
target for immune pressure during primary infection.
Three of the seventeen individuals had evidence of cellular
immune pressure. In one individual there was a mutation as-
sociated with a known epitope (CAP8, HLA-B*0801). In the
other two individuals there was clustering of mutations within
10-mers (participants 70310054 and 705010015) (Fig. 4), a phe-
nomenon previously found to be associated with CTL escape
(14). The clustered mutations within these two participants’
10-mers fell within sequences found to contain HLA anchor
residue motifs for a range of HLA genotypes and which were
also matched to potential epitopes by Motif Scan (www.hiv.lanl
.gov). However, since the HLA types for these two individuals
are not known, the inference of putative CTL escape remains
speculative, and the relevance of these mutations unknown.
Finally, the last individual harboring low diversity virus, sub-
ject 1176, had sequences that exhibited shared mutations be-
tween sequence subsets and an estimated time to MRCA of 88
days, which exceeded the estimated time of infection since this
individual was in stage I/II infection; thus, we infer that this
subject was infected with three closely related viruses (average
DNA distance, 0.1%) (Fig. 3B).
In summary, of the 55 individuals with low diversity after
transmission, 54 were classified as likely to be infected with a
single variant, and 1 was classified as likely to be infected with
three closely related variants. For participants identified as
infected with a single infectious unit, the estimated time to the
MRCA was consistent with the expected time of infection with
one exception, participant CAP217, whose infecting virus dis-
played lower genetic diversity (mean, 0.02%) than expected,
given this participant was in Fiebig stage IV of infection (see
Table S1A in the supplemental material).
Infection with multiple unique infectious units. After cor-
recting for recombination and hypermutation, phylogenetic
analyses of the high diversity sequence sets indicated that all 14
were infected with more than one viral variant (see Table S1D
in the supplemental material). Including participant 1176 in-
fected with three closely related viruses brings the total num-
ber of individuals with multivariant infections to 15. Interlin-
eage recombination between transmitted variants was observed in
10 of the 14 individuals, using the Recombination Analysis
Program (www.hiv.lanl.gov) (Fig. 5). In 9 of these 10 cases,
recombination was also detected by GARD or RDP3.27 (18,
19, 26) or both. However, since donor samples were not avail-
able for these individuals, the transmission of recombinants
cannot conclusively be ruled out. In all 14 sequence sets, the
estimated number of days since the MRCA significantly ex-
ceeded the period for which the associated individual could
realistically have been infected (MRCA range, 605 to 5,998
days).
Therefore, including the individual infected with three
closely related variants, a total of 15 individuals were inferred
to be infected with multiple viruses. The median number of
readily distinguishable infectious units per individual was three
(range, two to five), with each viral lineage having a unique
pattern of nucleotide variation (Fig. 5). This represents the
minimum number of transmitted viruses in these individuals,
given the limitations in sampling. While we cannot exclude the
possibility that multiple variants were transmitted and a single
variant grew out at the time of detection, there is no bias for
the detection of multiple variants at earlier Fiebig stages
(Table 1).
Two of the fourteen participants, CAP37 and 1335, were
both infected with viruses with env sequences differing from
one another by more than 6% nucleotide sequence identity
(Fig. 2). Although the complete env sequences from these
individuals clustered as an outlier to the participant sequences,
the region encoding gp41 separated into distinct phylogenetic
branches separated by epidemiologically unlinked sequences.
This suggests that these two subjects had dual infections, al-
though it is not possible to determine whether these individuals
were infected by two independent transmission events from
different donors or if variants were cotransmitted from a donor
who had a dual infection.
Recombinant genomes result from the dual infection of
cells, followed by recombination in a subsequent round of
infection and thereafter outgrowth, allowing detection. We
sought to determine whether the detection of recombination
was related to the Fiebig stage. To have a large enough data
set, we pooled data from Fiebig stage I to III to compare them
to Fiebig stage IV to VI and also included the data reported by
Keele et al. (16). We detected the presence of recombinant
viruses at a significantly higher rate in the later Fiebig samples
(P  0.0015). In most individuals, we detected each recombi-
nant genome once. While we can conclude from these results
that the detection of recombinants becomes more likely with
later stages of infection, without corresponding donor samples
the possibility that detected recombinants were transmitted
cannot be ruled out. In particular, this could be the case with
participant CAP69 (stage I/II of infection) in whom we saw the
outgrowth of some recombinants (Fig. 5B).
Clustering of mutations. We screened all sequences for ev-
idence of the clustering of mutations. We identified tight clus-
ters of mutations by visual inspection, as well as by means of a
test based on randomizing the locations of mutated sites within
each patient in order to determine whether these mutations
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were significantly more clustered than would be expected by
chance. We focused specifically on clustering on a length scale
of 10 amino acids (roughly the size of a CTL epitope), since the
presence of clusters of mutations within a region of approxi-
mately this size is consistent with selective pressure resulting in
evasion of early cellular immune responses such as CTL re-
sponses (14). We determined the number of mutations with a
nearest neighbor within 10 amino acids and compared this to
the number expected by chance, estimated by randomizing the
locations of the mutated sites 1,000 times. Under a model of
neutral divergence (16), we expect mutated sites to be distrib-
uted randomly throughout the sequence. In addition, tight
clustering of mutations is unlikely even if purifying selection
were to affect a proportion of mutations. This would thus
suggest that mutations within these clusters would be favored
by selection.
Significant clustering was identified in 16 individuals (Fig. 4).
Nine of these individuals with clustered mutations had single
variant infections; six of these subjects (CAP129, CAP217,
0626, 703010193, 703010217, and 706010164) harbored se-
quences consistent with the model of neutral evolution from a
single founder virus (see Table S1A in the supplemental ma-
terial), suggesting that the virus populations from these indi-
viduals were under early selection despite the failure to reject
the model of neutral evolution. Clustered mutations were de-
tected in seven individuals with multivariant transmission.
As expected, most participants harboring sequences with
evidence of clustered mutations were in later stages of primary
infection (stages IV to VI) although, interestingly, three indi-
viduals with very early infection (stages I to III) harbored
sequences with clustered mutations, providing evidence for
very early selective pressure. In the absence of sequence data
from donor individuals, however, it is unknown whether any of
these mutations were transmitted.
Multiple variants are not transmitted as independent events
with low probability. Transmission of HIV-1 is infrequent (32),
and the homogeneity of sequences in acute infection suggests
that most transmission events represent the minimal infectious
dose. For both the subtype B (16) and the subtype C datasets
we found that ca. 80% of transmissions result in infection by a
single genotypic variant or a single virus particle. To determine
whether transmission of multiple variants represents indepen-
dent but concurrent infectious events where transmission of
the first variant had no effect on the probability of transmission
of the second (or third) variant, we modeled the number of
transmitted variants using the Poisson distribution and esti-
mated a putative transmission probability as the likelihood that
one or more variants are transmitted (equal to 1  the prob-
ability that no variants are transmitted). In Fig. 6 we show the
expected number of infections with one, two, or more than two
variants for when the probability of transmission in a single
exposure is 0.1, 0.25, and 0.4. Transmission probabilities in this
range are needed to observe the transmission of multiple vari-
ants at significant levels. In contrast, a more realistic transmis-
sion rate of 0.01, for example, would result in the transmission
of two variants once in 10,000 transmission events.
In Fig. 6 we also show the observed number of individuals
infected with one, two, or more than two variants in the sub-
type B and subtype C primary infection cohorts. When these
data are fitted to the Poisson model we estimate a transmission
rate of 0.48 for the subtype C data set (Poisson mean of 0.65
with a standard error of 0.12) and a transmission rate of 0.55
for the subtype B data set (Poisson mean of 0.80 with a stan-
dard error of 0.05). These rates of transmission are unreason-
ably high compared to reported sexual transmission rates,
which have a lower bound of 	0.001 (reviewed in Powers et al.
[32]). We therefore conclude that the transmission of multiple
variants does not represent low probability independent events
but rather results from either transiently high transmission
rates or linked transmission of multiple virions.
Multiple variant infection and disease progression. Of the
24 individuals monitored for 1 year postinfection, we found no
significant difference between viral RNA load set point or
CD4 T-cell counts in participants who were infected with a
single variant (19 of 24) compared to those infected with mul-
tiple variants (5 of 24) (P  0.3198 and P  0.2232, respec-
tively) (Table 1). However, 4 of 6 (67%) individuals with mul-
tiple variant infections had CD4 T-cell counts consistently
below 350 cells/l and were classified as rapid progressors,
whereas only 4 of 20 (20%) individuals that were infected with
single variants fell into this category. This association between
rapid disease progression and multiple variant transmission
(P  0.051) supports previous studies that have shown that
high diversity after infection is associated with increased rates
of disease progression (10, 12, 37).
DISCUSSION
This study is the first to provide a comprehensive assessment
of the multiplicity of HIV-1 subtype C infection in the context
of heterosexual transmission in men and women. Our findings
mirror observations of subtype B transmissions via heterosex-
ual or homosexual routes using the same methodology (16).
Together with the subtype B study, these data demonstrate
that in 171 individuals a single virus is responsible for infection
of 77% of individuals, with 23% of individuals infected with
FIG. 4. (A and B) Clustering of mutations within stretches of 10 amino acid residues associated with putative CTL pressure illustrated in
participant 703010054 (stage V of infection) (A) and participant 705010015 (stage V of infection) (B). (C and D) Changes in the V1/V2 loop in
env associated with putative antibody pressure illustrated in participant 704010017 (stage VI of infection) displaying clustered mutations within the
V2 loop resulting in the gain of three N-linked glycosylation sites (C) and participant CAP269 displaying multiple amino acid insertions within the
V1 loop resulting in the gain of one to four N-linked glycosylation sites (D). Highlighter plots (left) compare sequences from each participant’s
sequence set to an intraparticipant consensus (uppermost sequence) and illustrate the positions of nucleotide base transitions and transversions
using short, color-coded bars. Amino acid identity alignments (right) illustrate regions of clustering of mutations in sequences aligned with an
intraparticipant subtype C consensus sequence with corresponding HXB2 env protein locations indicated above. The number of sequences
harboring a particular mutation is displayed alongside each sequence. N-linked glycosylation sites are indicated as red amino acid residues. Where
significant mutational clustering was detected by a randomization test, P values are provided in parentheses.
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multiple variants. Based on the frequency of the transmission
of multiple variants, we find that infection with more than one
variant does not occur as independent events at low probabil-
ity. This implies that transmission of the second variant is
linked to transmission of the first variant. Understanding the
frequency and cause of multivariant transmission is relevant
since individuals infected with multiple variants would require
a vaccine that protects against greater initial viral diversity
instead of a single homogeneous virus population. In addition,
it is clinically important since high diversity following transmis-
sion has been associated with faster disease progression (10,
12, 37). In keeping with this observation, the present study
found an association between multivariant transmission and
disease progression.
Discrepant results due to differences in methodological ap-
proaches have hindered a clear understanding of multivariant
transmission. A key advantage of our study is that we used the
same methodological and analytical approaches to define the
founder virus population that was used recently to study sub-
type B acute infection (16), thus enabling us to clearly enu-
merate the infecting viruses and also directly compare results.
Despite different infecting subtypes and routes of transmission,
the frequencies of multivariant transmission were strikingly
similar: we report 22% in subtype C heterosexually infected
men and women compared to the 24% of participants infected
with subtype B via homosexual and heterosexual transmission
reported by Keele et al. (16). Phylogenetic analysis indicated
that the multiple variants came from a single donor in 87% of
the cases (13 of 15 subjects), and the time to the MRCA
demonstrates that the variants diverged at times significantly
before the transmission event.
This estimated frequency of multivariant transmissions
should, however, be considered a minimum. Many infections in
highly epidemic regions have been attributed to transmissions
during the acute stage of infection (30). Since this stage is
generally associated with a highly homogeneous viral popula-
tion, multiple variant transmissions in these instances could be
missed. In addition, we may miss variants present at a low
frequency (with a sample size of 20 sequenced amplicons, there
is 95% confidence of detecting sequences present at frequen-
cies greater than 15%) (16).
Although we used a model which assumes neutral evolution
(16), deleterious mutations will be lost through purifying se-
lection, and early innate and adaptive host responses are likely
to impact the apparent mutation rate, especially in participants
sampled after peak viremia. We did in fact identify putative
immune pressure in acute infection, with a third of the se-
quence sets containing evidence of putative CTL pressure
(based on clustered mutations) or antibody pressure (based on
changes in N-glycosylation sites or variable loop length). The
rates of mutation were also influenced by APOBEC3G-medi-
ated hypermutation observed in eight individuals with single
variant infections. In addition, sequences were under purifying
selection with a higher rate of synonymous (dS) compared to
nonsynonymous (dN) substitutions (mean dN/dS ratio of 0.79;
variance, 0.44). A mean dN/dS ratio of 1 suggests that the
rate of diversification of the sequences could be slightly less
than the rate estimated under a strict assumption of neutrality.
However, the impact of a relatively small departure from neu-
trality on the estimated times to the last common ancestors of
intrapatient sequence sets is likely to be minor.
The rate of HIV transmission is in the range of one trans-
mission event per 1,000 exposures (34; reviewed in Powers et
al. [32]), although two studies reported rates of 31 per 1,000
exposures (26), (40) and 97 per 1,000 exposures(3). However,
even rates as high as 0.03 to 0.1 cannot account for a frequency
of multivariant transmission of 22 to 24%, if multiple variants
are transmitted independently. This suggests that transmission
of each variant is not an independent event in the context of a
low transmission probability. One explanation of the frequency
of multiple variant transmissions is that different cofactors
transiently change the rate of multivariant transmission. The
distribution of frequency of one, two, and more than two vari-
ants can be explained if two rates are incorporated: one rate
would account for 70 to 75% of transmission events and have
a low probability of transmission with only rare occurrences of
the transmission of multiple variants; the second rate would
account for 25 to 30% of transmission events. However, a
probability of transmission of 	0.8 would be required to result
in equal numbers of transmission events of two variants and
more than two variants, which would approximate the ob-
served data. It is likely that increased transmission occurs as a
result of sexually transmitted infections (38) or traumatic
breaks in the epithelium. However, it is also possible that the
transmission of multiple variants represents a linked event, i.e.,
infection by one particle (or genome) is in some way linked to
an increased probability of infection with a second particle (or
genome). If the infectious unit were an infected CD4 T cell,
which can be infected with multiple viruses (15), this could
account for at least some of the multivariant transmission
events. A recent report has shown the potential for infected
cells to penetrate a disturbed epithelium (45), and the appar-
ent need for infection via infected cells in the case of HTLV-1
provides further support for a cell-mediated mechanism of
transmission (33). Alternatively, virus particles could be aggre-
gated by biological molecules such as SEVI (for semen-derived
enhancer of virus infection) (27) or tetherin during budding
(28), potentiating infection with two particles in a single, rare
transmission event.
A previous study from Kenya showed women were generally
FIG. 5. Highly heterogeneous, multiple variant env sequence populations are visually represented by phylogenetic trees with extensive branch
structure and discernible clades (left) and Highlighter plots with diverse patterns of nucleotide base mutations compared to the intraparticipant
consensus (right). env variants resulting from recombination between clades are displayed below with RAP (for recombination analysis program)
plots. Parental strains for each recombinant are color coded on the trees, with regions within each recombinant likewise color coded to correspond
to respective parental strains. Recombination breakpoints are illustrated by empty boxes on RAP plots. (A) Participant CAP37 was infected with
three distinct variants. Sequence 5998 differs by up to 6% from the remaining sequences from this participant and is a suspected dual infection.
(B) Participant CAP69 was infected with at least five distinct viruses with extensive recombination between clades. Six recombinant strains are
illustrated here.
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infected with more heterogeneous virus populations compared
to men (21). Although in our study, we did not find that
females were infected with higher-diversity viral populations
compared to men (data not shown), there were differences in
frequency of sexually transmitted infections, with genital ulcer-
ative disease being much more common in men from our study
than in women (82% versus 13%). Thus, since genital ulcer-
ative disease has an impact on transmission, this could con-
found our analysis. In addition, uncircumcised men are more
susceptible to infection (1, 2); thus, this difference in results
between studies may be due to the fact that most of the men in
our study were from Malawi where there is a very low fre-
quency of circumcision, whereas the Kenyan study recruited
from a cohort of individuals where 87% were circumcised (34).
In conclusion, infection with a single virus in the majority of
individuals demonstrates the severity of the genetic bottleneck
at transmission. These data in conjunction with the subtype B
analysis suggests a universal observation that mucosal HIV-1
infection most frequently originates from a single infectious
unit. Less frequently, multiple viral variants are transmitted,
which not only increases the genetic diversity, but this in-
creased diversity also provides the virus with greater opportu-
nity to escape early selective pressure through recombination.
Although the biological basis for the transmission of multiple
variants remains unknown, possible explanations include tran-
siently high rates of transmission due to cofactors, transmission
via a multiply infected cell, or transmission of viral aggregates.
Since one in five individuals will become infected with multiple
infectious variants, it is important to translate how this infor-
mation impacts on the breadth and targeting needed for pro-
tective vaccination.
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Rapid, complex adaptation of transmitted HIV-1
full-length genomes in subtype C-infected
individuals with differing disease progression
Melissa-Rose Abrahamsa, Florette K. Treurnichta,
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Objective(s): There is limited information on full-length genome sequences and the
early evolution of transmitted HIV-1 subtype C viruses, which constitute the majority of
viruses spread in Africa. The purpose of this study was to characterize the earliest
changes across the genome of subtype C viruses following transmission, to better
understand early control of viremia.
Design: We derived the near full-length genome sequence responsible for clinical
infection from five HIV subtype C-infected individuals with different disease pro-
gression profiles and tracked adaptation to immune responses in the first 6 months
of infection.
Methods: Near full-length genomes were generated by single genome amplification
and direct sequencing. Sequences were analyzed for amino acid mutations associated
with cytotoxic T lymphocyte (CTL) or antibody-mediated immune pressure, and for
reversion.
Results: Fifty-five sequence changes associated with adaptation to the new host were
identified, with 38% attributed to CTL pressure, 35% to antibody pressure, 16% to
reversions and the remainder were unclassified. Mutations in CTL epitopes were most
frequent in the first 5 weeks of infection, with the frequency declining over timewith the
decline in viral load. CTL escape predominantly occurred in nef, followed by pol and
env. Shuffling/toggling of mutations was identified in 81% of CTL epitopes, with only
7% reaching fixation within the 6-month period.
Conclusion: There was rapid virus adaptation following transmission, predominantly
driven by CTL pressure, with most changes occurring during high viremia. Rapid escape
and complex escape pathways provide further challenges for vaccine protection.
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Introduction
Early host selective pressures drive genetic diversification
of the transmitted HIV and potentially influence the
course of disease. In heterosexual infection, it is estimated
that approximately 80% of individuals are infected with a
single virus or virus-infected cell [1,2]. Vaccines that do
not block the establishment of this initial infecting virus
will need to target the early diversifying virus and thus an
understanding of early viral evolution is important. The
frequency and speed at which the transmitted virus
changes in response to host immune pressures are of key
interest to vaccine immunogen design as these provide
insights into its strengths and vulnerabilities.
Recent methodologies using single genome amplification
(SGA) applied to individuals with acute HIV-1 infection
have enabled identification of the sequence of trans-
mitted/founder (t/f) full-length viral genomes [1,3,4].
This approach uses mathematical modeling to derive the
sequence of the virus(es) responsible for productive
clinical infection, and was proven in the simian
immunodeficiency virus (SIV) model wherein the
derived t/f was identical, or differed by a few nucleotides,
to the virus in the inocula [5].
Using this approach, early evolutionary changes following
transmission in three subtype B infections from the USA
have been mapped [3]. No longitudinal studies elucidat-
ing early evolution in full-length subtype C genomes have
been reported despite subtype C being the dominant
subtype both globally and in southern Africa where large
vaccine and microbicide trials take place [6,7]. Studies in
different population settings are essential given that
differences in host genetics influence viral evolution [8].
The transmitted virus encounters immune selective
pressures almost immediately following infection. Cyto-
toxic T lymphocyte (CTL) and neutralizing antibody
pressure are the proven driving forces for viral
diversification [9–16]. Evidence of CTL pressure on
the viral genome has been identified in the very first
weeks of subtype B and C infection [1–3,17–23], and
CTL activity has been associated with control of viremia
early in infection [24–26]. Most recently, a subtype B
full-length genome study using mathematical modeling
to determine the killing rate of CTL during acute viremia
suggested that these cells have a role in controlling peak
viremia [21].
In this study, we investigated changes observed across the
genomes of t/f subtype C viruses from five heterosexually
infected women with differing disease progression
profiles. We extrapolated the near full-length genome
sequence of the t/f viruses and quantified genetic
mutations associated with positive selection from humoral




Samples were obtained from the Centre for the AIDS
Program of Research in South Africa (CAPRISA) 002
Acute Infection cohort (Durban, South Africa) [27]. Date
of infection was estimated as the midpoint between last
negative and first positive HIVantibody test and as 14 days
prior for individuals who were RNA positive/antibody
negative. Human leukocyte antigen (HLA) A, B and C
types were determined using four-digit high-resolution
HLA typing as described [28]. The study was approved
by the Universities of Cape Town, Witwatersrand and
KwaZulu Natal.
PCR amplification and sequencing
RNA was extracted from 200–400ml plasma using the
Qiagen Viral RNA Mini Kit (Qiagen, Valencia,
California, USA) and reverse transcribed to cDNA using
superscript III reverse transcriptase and Oligo(dT)20
(Invitrogen, GmbH, Karlsruhe, Germany). SGA [4] and
sequencing of near full-length genome amplicons was
done using Expand Long Template Taq (Roche
Diagnostics, Rotkreuz, Switzerland) as reported [4] with
primers described by Rousseau et al. [29] optimized for
subtype C. Sequences less than 6000 bp were excluded.
Salazar-Gonzalez et al. [3] attributed one to five
ambiguities within a genome obtained at less than 20%
PCR positivity predominantly to PCR Taq error. We
accepted amplicons obtained at less than 66% positivity
with up to six ambiguities. Targeted epitope sequencing
was done following gene-specific limiting dilution PCR.
Gag and nef clones were generated using limiting dilution
PCR and the pGEM-T Easy system as described [30].
Env SGAwas described previously [4]. All products were
directly sequenced using the ABI 3000 genetic analyzer
(Applied Biosystems, Foster City, California, USA) and
BigDye terminator reagents.
Sequence analysis
Analyses performed were sequence alignments, amino
acid identity and frequency plots and consensus sequence
derivation (BioEdit version 7.0.8.0 [31]); subtyping
(REGA HIV Subtyping Tool; http://dbpartners.stanfor-
d.edu/RegaSubtyping/); phylogenetic and pairwise
DNA distance analyses (Mega 4 [32]); Highlighter plots
(http://www.hiv.lanl.gov/content/sequence/HIGHLIG
HT/highlighter); CTL epitope prediction (Epitope
Location Finder (ELF) (http://www.hiv.lanl.gov/con-
tent/sequence/ELF/epitope_analyzer) andNetMHCpan
2.2 (http://www.cbs.dtu.dk/services/NetMHCpan)[33]);
Hypermut detection of APOBEC hypermutation
(http://www.hiv.lanl.gov/content/sequence/HYPER
MUT/hypermnut.html); Shannon entropies (Entropy
One; http://www.hiv.lanl.gov/content/sequence/ENT
ROPY/entropy_one) and mapping of functionally/
structurally relevant genome regions (http://www.
hiv.lanl.gov/content/sequence/HIV/MAP/landmark). A
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high average Shannon entropy score was taken as more
than 0.25 as described by Bansal et al. [34] for variable HIV
proteins. Where an optimal epitope (9–11-mer) has not
yet been described, the entropy of an 18-mer peptide
encompassing the mutating region was used.
Time to most recent common ancestor (MRCA) was
determined using Bayesian Evolutionary Analysis
Sampling Trees (BEAST) v1.4.7 [35,36] as described
previously [1,2]. A relaxed (uncorrelated exponential)
molecular clock with general time-reversible substitution
model, mean of 2.16 105 substitutions per site per
generation with rates unlinked across codon sites [37] and
gamma distribution with four categories and a proportion
of invariant sites was used.
Known HLA class I restricted epitopes or class I HLA-
associated polymorphisms were identified using the Los
Alamos HIV Molecular Immunology 2008 Compen-
dium (http://www.hiv.lanl.gov/content/immunology/
compendium.html) and Matthews et al. [38]. Subtype
C database alignments were obtained from the Los
Alamos HIV database (http://www.hiv.lanl.gov/com
ponents/sequence/HIV/).
Positive selection and statistical analysis
Nonsynonymous to synonymous substitution (dN/dS)
rate ratios per codon site were estimated using the
MG94xHKY85 codon model [39]. We allowed dS to
vary across codon sites and employed the Dual model
which takes into account that dS may vary independently
of dN [40]. Models were implemented within HyPhy
[41] and ensured that correct phylogenetic relationships
were used for regions separated by recombination
breakpoints [42].
Categorical statistical tests were carried out using the
Fisher’s exact two-tailed test (http://www.graphpad.
com/quickcalcs).
Results
This study characterized virus evolution in five subtype
C-infected women recruited 2–5 weeks following
transmission. These women were selected based on
infection with a single transmitted/founder virus [2] and
clinical disease progression profile (Table 1). One woman
was classified as a viremic controller (CAP45; viral loads
consistently <2000 copies/ml and CD4 cell counts
>350 cells/ml in the absence of antiretroviral therapy)
[43], two as rapid progressors (CAP63 and CAP210; viral
loads >100 000 copies/ml and CD4 cell counts
<350 cells/ml on consecutive visits within the first year
of infection) [23,44], and two as intermediate progressors
(CAP85 and CAP239; not fitting either controller or
rapid status) (Fig. 1). A total of 112 near full-length
genomes were generated, with an average of nine at
screening per enrolment (2–5 weeks after infection), six
at 3 months (11–13 weeks after infection) and nine at
6 months (22–29 weeks after infection). No sequences
could be generated at 6 months for viremic controller
CAP45 due to low viral loads. Additional sequences (half-
genome, SGA and clonal) were generated from various
time points ranging from 2 to 117 weeks after infection
(Table 1).
Derivation of transmitted/founder virus
sequences
All sequences were classified as subtype C along the entire
length of the genome. Mean intraparticipant DNA
distances ranged from 0.008 to 0.25% (median 0.03%) at
the first time point and mean number of days since
MRCA ranged from 18 to 53 days (Table 1), indicating
limited sequence diversification since transmission
(see Fig. S1, Supplemental Digital Content 1, http://
links.lww.com/QAD/A282, illustrating intraparticipant
sequence diversity in a Neighbour-Joining tree). The t/f
sequences were defined as the consensus of sequences from
the earliest time point where all genes had an intact open
reading frame and no ambiguities [3]. Although CAP63
and CAP85 were classified as infected with a single t/f
variant based on env [2], we identified aminor early variant
in each (not detected at later time points) which, in both
cases, differed from the derived t/f at five nucleotide
positions, suggesting that these individuals may each have
been infected with two very closely related variants.
The majority of early genetic changes are due to
cytotoxic T lymphocyte pressure or reversion
Using longitudinal near full-length genome and env
screening/enrolment SGA sequences, viral evolution
from the t/f was analyzed for evidence of immune escape
or reversion. Substitutions from high-frequency/con-
sensus to lower frequency/nonconsensus amino acids
within or adjacent to known class I HLA-restricted
epitopes, or corresponding to known HLA-associated
polymorphisms, were classified as CTL pressure [16,19,
45,46]. Mutations within the hypervariable loops and
potential N-linked glycosylation sites (PNGSs) in env
were classified as antibody pressure [9]. Mutations from
low/nonconsensus to higher frequency/consensus subtype
C amino acids within CTL epitopes not restricted by the
participants HLAwere classified as reversion of transmitted
CTL escape mutations [16,45,46]. In addition, clustered
mutations within amino acid 9-mers, previously reported
to be associated with immune selection [18], or single
amino acid mutations persisting to fixation and corre-
sponding to sites under positive selectionwere identified as
putative immune escape.
In viruses from the five women, immune pressure was
identified in 55 genome regions (see Figs S2–S6,
Supplemental Digital Content 2, http://links.lww.
com/QAD/A282, which illustrate genome regions
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Fig. 1. Clinical and immune selection profiles for each of the five women illustrated with viral load and CD4 cell count graphs.
The number of epitopes/genome regions identified as under putative cytotoxic T-lymphocyte pressure (black squares) and
antibody pressure (black triangles) are illustrated for approximate periods after infection of 0–5 weeks (pale blue shaded region),
5–12 weeks (darker blue shaded region) and 12–29 weeks (gray shaded region). The dashed gray box is used for participant
CAP45 as the black square represents an epitope which may have mutated anywhere between 12 and 65 weeks after infection.
Time of first detection of autologous neutralizing antibodies is indicated by dashed red lines.
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under immune pressure): 21 were classified as under CTL
pressure (Table 2), 19 under antibody pressure (Table 3),
nine as reversion (see Table S1, Supplemental Digital
Content 3, http://links.lww.com/QAD/A282, which
tabulates genome regions undergoing reversion) and
further six regions contained mutations (clustered within
amino acid 9-mers or single persisting to fixation in sites
under positive selection) which did not conform to
criteria described for CTL or antibody pressure or
reversion (Table 3). Identification of regions under
immune pressure was supported by selection analysis (for
which gag, env and nef supplemental sequences were
included), which found a total of 55 sites under positive
selection (dN/dS >1) of which 84% (46/55) were
situated within genome regions identified as under
immune pressure (see Tables 2 and 3; Table S1, Supple-
mental Digital Content 3 and Figs S2–S6, Supplemental
Digital Content 2, http://links.lww.com/QAD/A282,
which illustrate positive selection sites corresponding to
genome regions under immune pressure). The majority
of positively selected sites were identified in env (n¼ 30),
followed by gag (n¼ 9), pol (n¼ 7), nef (n¼ 5), rev (n¼ 3)
and tat (n¼ 1). APOBEC-mediated G to A hypermuta-
tion was identified in 24% (13/55) of regions under
immune selection.
Of the mutating genome regions associated with CTL
pressure, 19 spanned known CTL epitopes, and two
spanned predicted epitopes (Table 2). The highest
frequency of CTL-driven mutations was located in nef
(even when normalizing for amino acid length) (n¼ 6),
followed by pol and env (n¼ 4), gag and vif (n¼ 2) and
finally rev, tat and vpr (n¼ 1) (Fig. 2a). Reversion was
identified most frequently in vpu (n¼ 3) followed by gag,
env and nef (n¼ 2) (see Table S1, Supplemental Digital
Content 3, http://links.lww.com/QAD/A282).
Cytotoxic T lymphocyte escape is most frequent
in acute infection
We supplemented near full-length genomes with sub-
genomic (gag, env, nef and targeted epitope) sequence data
to better elucidate timing of mutations associated with
CTL pressure and escape. The majority of mutating
epitopes was identified within the first 5 weeks of
infection in structural genes gag, pol, env and nef (Figs 1
and 2b). The earliest of these was identified at 2 weeks
postinfection in the gag HLA B58 : 01 restricted TW10
epitope; and the nef HLA B45 : 01 restricted EV11
epitope. The frequency of mutation associated with
escape slowed over time with an initial 1.6 total escapes
per week for the first 5 weeks of infection, to 0.9 escapes
per week between 5 and 12 weeks postinfection, and 0.4
escapes per week between 12 and 29 weeks postinfection
(Fig. 2b).
Of the 19 regions of env with changes in hypervariable
loops and PNGSs, mutations in seven (37%) arose in the
first 5 weeks of infection (Fig. 1 and Table 3). Since first
detection of autologous neutralizing antibodies (nAb) for
the women in this study ranged from 9 to 46 weeks
[44,47] (Fig. 1), these early changes are unlikely to be the
result of nAb pressure. However, in one instance, early
mutating sites in V5 of participant CAP45 corresponded
to sites where neutralization escape mutations (K460D
and D462G) were identified later in infection (see
Table 3) [44].
Finally, of the nine reversions identified, four occurred in
the first 5 weeks of infection and the remaining between
13 and 29 weeks postinfection (data not shown).
Shuffling and toggling of amino acid mutations
Shifting of mutations between different positions within
an epitope (shuffling) or between different amino acids at
the same position (toggling) was observed in 81% (17/21)
of mutating CTL epitopes (see Table 2 and Table S2,
Supplemental Digital Content 4, http://links.lww.com/
QAD/A282, illustrating shuffling and toggling in a Nef
epitope). For four of the five participants, the number of
mutant variants per CTL epitope increased over the
6 months of infection after which a plateau or decrease
was seen owing in part to eventual fixation of escape
mutants (Fig. 2c).
Twelve of the 17 CTL epitopes with shuffling/toggling
mutations corresponded to subtype C database epitopes
with high Shannon entropy (scores >0.25 [34]).
Shuffling/toggling was however not more frequent in
epitopes corresponding to high-entropy regions than in
more conserved regions (P¼ 0.25). We investigated
whether mutational shuffling/toggling was due to
mutations arising in structurally or functionally essential
sites, which when altered may abrogate efficient RNA
folding or alter protein structure and function. We
therefore compared the proportion of epitopes with
shuffling/toggling in functionally or structurally relevant
sites with the proportion in sites with no currently known
functional or structural significance. We found no signi-
ficant difference between the two categories (P¼ 0.53),
even when including the six genome regions under
unclassified immune pressure (P¼ 0.28).
Immune pressure, sequence diversification and
disease progression
To determine whether rate of genetic diversification from
t/f sequences differed with different disease progression
profiles, we compared gene-specific tree lengths using
sequences from the first 3 months of infection. No
significant differences between rates of diversification
were found (data not shown). Furthermore, no significant
association between number of genome regions under
immune pressure and viral load over time was identified
(data not shown); possibly owing to low participant
numbers.
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Discussion
Design of a globally relevant HIV-1 vaccine requires an
understanding of transmitted viruses and their early
immune adaptation in different populations. Here, we
report the first study to comprehensively identify and
classify the earliest changes to subtype C transmitted/
founder full-length genome viruses. We provide a
detailed analysis of the timing, frequency and patterns
of these changes in five women with differing clinical
disease progression. The predominant and earliest host
selective pressure was from cytotoxic T lymphocytes.
Despite increasing breadth of CTL responses over time
[23], the frequency of mutations associated with CTL
escape declined as viral load declined. We show that
complex mutational pathways are used to escape in the
majority of epitopes.
We predicted that CTL pressure, or reversion of
transmitted escape, accounted for the majority (54%)
of changes across the genome, reaffirming the importance
of this response in early infection. Supporting our
predictions, autologous peptide screening using IFN-g
ELISPOT in three of the five participants confirmed all
nine epitopes predicted for these individuals (Liu et al., in
press). A further four of the 21 epitopes were likewise
confirmed to be responsive (Liu et al., unpublished data).
The remaining eight were not confirmed either due to
poor cell quality or screening after escape had already
occurred. Mutations associated with CTL escape
occurred earliest in gag and most frequently in nef,
although this was likely influenced by the fact that three of
the five individuals were HLA B45 : 01 positive and
targeted the same nef epitope. A further 35% of changes
were associated with antibody pressure. We could not
classify 11% of changes which may be associated with
novel CTL epitopes (possibly in alternate reading frames
[48,49]), compensation of escape, changes in antigen
processing, CD4þ T-cell pressure, natural killer (NK) cell
pressure [50], nonneutralizing binding antibody activity,
antibody-dependent cellular cytotoxicity (ADCC), viral
fitness or evolutionary drift/hitchhiking. One unclassi-
fied mutating region in pol of participant CAP210 was
subsequently found to be responsive by IFN-g ELISPOT
and may represent a novel CTL epitope (Liu et al., in
press). Another mutating region in nef of CAP210
corresponded to a known HLA-DR CD4þ T-cell
epitope; however, it was not restricted by the participants’
HLA-DR (data not shown).
Three findings from this study illustrate the immense
pressure the virus is under following infection. First, in
these five women, escape was rapid and occurred at high
frequency in acute infection (<5 weeks postinfection),
with a four-fold reduction in the number of escapes per
week over the 6-month period. Seventy percent of early
514 AIDS 2013, Vol 27 No 4









Time of first mutation in
hypervariable loop or PNGS
(range) (weeks)
CAP45 Gp120 LTRDGGKTDRNDTEIFRP 454–470 Antibody 0–2
CAP63 Gp120 QEIVLENVIENFNMWKND 82–99 Antibody 5–11
Gp120 LTPLCVTLNCANANITKN 122–139 Antibody 11–29
Gp120 MIGEIKNCSFNATTELRD 147–167 Antibody 2–5
Gp120 LNNNRSNENSYILINCNS 184–198 Antibody 0–2
Gp120 IVHFNQSVKIVCARPHNN 285–302 Antibody 11–29
Gp120 IRQAHCNISKTQWNTTLE 326–343 Antibody 11–29
Gp120 FNSTYMPNGIHIPNGASEVIT 396–415 Antibody 2–5
Gp41 LWSWFNISHWLWYIRIFI 158–147 Antibody 11–29
Gp41 IEEEGGEQDNSRSIRLVS 222–239 Antibody 5–11
CAP85 Gp120 DIVPLNNDIGNYSEYRLI 180–194 Antibody 5–13
Gp120 IVHLNHSVKIVCTRPGNN 285–302 Antibody 0–5
Gp120 IRQAHCNISKAEWNNTLE 326–343 Antibody 13–29
Gp120 GSSTTTNGSSPITLPCRI 404–420 Antibody 0–5
Gp120 RPGGGDMKDNWRSELYKY 469–486 Unclassified 0–5
Nef GVGAASQDLGKYGALTSS 29–46 Unclassified 0–5
CAP210 Pol FFRENLAFPEGEARELPS 1–18 Unclassified 12–16
Gp120 ICSFNATTELRDKKKKEY 156–173 Antibody 5–12
Gp120 FNSTHNSTDSTVNSTDST 391–409 Antibody 5–12
Gp120 ITCISNITGLLLTRDGGE 443–460 Antibody 22–26
Nef SLHGMEDTEREVLQWKFD 169–186 Unclassified 5–12
CAP239 Gag SNPSGPKRPIKCFNCGRE 382–399 Unclassified 2–5
Rev GRPAEPVPFQLPPIERLH 65–82 Unclassified 2–5
Gp120 DIIIRSQNILDNTKTIIV 269–286 Antibody 2–5
Gp120 GLLLTWDGGDSKENKTRH 451–467 Antibody 11–22
PNGS, potential N-linked glycosylation site.
aBold amino acids indicate sites undergoing mutation; underlined amino acids indicate sites evolving under positive selection; highlighted amino
acids indicate sites mutating to result in a change within, or gain/loss of a potential N-linked glycosylation site gain/loss (NXS/Tx, where x is not
Proline).
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escape (<12 weeks postinfection) occurred in high-
entropy locations comparedwith only 33% after 12weeks.
These observations, although not statistically significant
due to low sample size, consolidate reports that strong
CTL pressure and rapid escape prevail early in infection
[21,51] and that epitopes with higher entropy escape
faster than more conserved epitopes [52]. Thus, the
observed reduction in mutations associated with CTL
escape later in infection seen in these women may be
associated with targeting of epitopes that escape slowly.
Second, the pathway to CTL escape is complex, with this
study showing an unprecedented level (81%) of genome
regions under CTL pressure with mutations shifting
between different amino acid sites or between different
amino acids at the same site resulting in late or no fixation
over the period investigated. A recent study proposed that
initial mutations are replaced by secondary mutations
which are less costly to the virus with respect to its
survival [53]; however, we found no statistical support for
more frequent shuffling/toggling in virus regions of
structural or functional importance. It may be that this
pattern of variation is seen simply because these regions of
the genome are able to tolerate multiple changes
(supported by the fact that 71% of the epitopes with
shuffling/toggling corresponded to high-entropy data-
base epitopes). Alternatively, fixation may only occur
once mutations are introduced into sites facilitating
complete escape as postulated in a detailed study of one
participant by Henn et al. [54].
Third, and perhaps surprisingly since neutralizing
antibody pressure typically emerges some weeks or
months after infection [9,55,56], we identified escape
patterns typically associated with antibody pressure as
early as 2 weeks postinfection. Autologous nAb response
data for these five participants indicate the earliest
response to have arisen at 9 weeks postinfection [44].
These early changes could possibly be attributed to
reversion of antibody escape mutations in the donor, early
stochastic changes, nonneutralizing binding antibody
activity, ADCC, env fitness or as very recently reported in
a subtype B study by Bar et al. [57], may in fact be a result
of early low level neutralizing antibody responses from
which the virus escapes.We saw evidence for this in V5 of
CAP45 wherein early changes corresponded to sites
where nAb escape later in infection was confirmed in this
participant [44].
When examining participant sequence data in the context
of disease progression, we found no significant differences
in early virus sequence diversification between individ-
uals in our study. However, larger studies would be
needed to evaluate the role of CTL escape in disease




























































































































Fig. 2. Frequency, timing and complexity of putative cytotoxic T lymphocyte escape in the first 6 months of infection. (a) Total
number of putative escapes per gene and per 100 amino acids (AAs). (b) Total number of putative escapes per week. (c) Total
number of variants per CTL epitope over time for each of the five women. CTL, cytotoxic T lymphocyte.
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progression. Recent studies revealed that clinical disease
profiles are heritable in donor–recipient pairs [58,59] and
that viral genotype can be a determinant of viral load
set point [60]. Furthermore, transmission of a virus
harboring a mutation with a fitness cost can also
contribute to viral control [28,61]. We observed that
viremic controller CAP45 was infected with a virus
harboring mutations flanking the B57/58 Gag TW10
and ISW9 epitopes previously reported to be associated
with disease control [28]. It is worth mentioning that the
two rapid progressors in this study were HLA-B (CAP63)
and HLA-A, HLA-B and HLA-C (CAP210) homo-
zygous. HLA homozygosity has previously been associ-
ated with poor clinical outcome [62].
Numerous CTL studies propose stable CTL epitopes that
escape slowly or late in infection due to high fitness costs
to be good vaccine targets [21,38,51]. This study suggests
that the process of immune escape holds greater
complexities which vaccine design strategies will need
to take into account. Frequent and persistent shuffling
and toggling of mutations within targeted epitopes may
indicate high levels of epitope instability early in
infection. Early APOBEC-mediated hypermutation,
identified in more than a quarter of genome regions
under putative immune pressure in this study, represents
an efficient mechanism of CTL escape [22]. Not to be
discounted is the unclassified 11% of genome changes
which demonstrate that much more is at play very early in
infection, possibly such as pressure from NK cells which
has recently been emphasized [50]. These additional
forces likely play a significant role in shaping the
early virus.
Our findings provide novel data on the dynamic interplay
between virus and host very early in infection and the
complex pathways of escape in response to the earliest
immune pressures acting on transmitted/founder subtype
C viruses. These processes of immune adaptation are
likely to pose further challenges that vaccines will need to
overcome. Furthermore, this study demonstrates the
highly sensitive nature of viral sequencing as a tool for the
identification and characterization of early immune
selective pressures that mould early HIV-1 evolution.
Examining early host–virus interactions in the context of
disease progression will enable us to identify those
changes to the virus which are associated with better
disease outcome and may therefore be incorporated into
vaccine design.
Acknowledgements
This work is funded by the National Institute of Allergy
and Infectious Disease (NIAID), National Institutes of
Health (NIH) and the US Department of Health and
Human Services (DHHS) (#AI51794, CAPRISA; #DK
49381 (MSC), CHAVI), as well as by the National
Research Foundation (#67385), SA; the South African
AIDS Vaccine Initiative; and amfAR grant 106997-43.
We thank the clinical staff and participants from the
CAPRISA 002 Acute Infection Study. We would like to
thank Denis Chopera, Gama Bandawe and Roman Ntale
for subgenomic sequence data and Ziyaad Valley-Omar
for assistance with data analysis.
Author contributions: M.-R.A.: first author, manuscript
writing, full-length genome and focused epitope DNA
amplification and sequencing, data collation, sequence
analyses, statistical analyses; F.K.T.: study design and
coordination, full-length genome DNA amplification
and sequencing, sequence analysis; N.K.N.: positive
selection analyses and selection methods writing; S.A.G.:
full-length genome and focused epitope DNA amplifica-
tion and sequencing, statistical and sequence analyses;
J.C.M.: full-length genome sequencing, focused epitope
amplification and sequencing, sequence analysis; H.B.:
half-genome DNA amplification and sequencing,
sequence analysis; R.T.: full-length genome amplification
and sequencing; D.d.A.R.: HLA typing of CAPRISA
participants; K.M.: clinical site project director; C.S.:
advising and guidance of clustered mutation and selection
analyses; S.A.K.: CAPRISA study design; C.M.G.:
immunology consultant and assistance with manuscript
writing; and C.W.: principal investigator, corresponding
author, manuscript writing.
Conflicts of interest
There are no conflicts of interest.
References
1. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT,
Salazar MG, et al. Identification and characterization of trans-
mitted and early founder virus envelopes in primary HIV-1
infection. Proc Natl Acad Sci U S A 2008; 105:7552–7557.
2. Abrahams M-R, Anderson JA, Giorgi EE, Seoighe C, Mlisana K,
Ping L-H, et al. Quantitating the multiplicity of infection with
human immunodeficiency virus type 1 subtype C reveals a
nonpoisson distribution of transmitted variants. J Virol 2009;
83:3556–3567.
3. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi
EE, Li H, et al. Genetic identity, biological phenotype, and
evolutionary pathways of transmitted/founder viruses in acute
and early HIV-1 infection. J Exp Med 2009; 206:1273–1289.
4. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey
MB, Keele BF, et al. Deciphering human immunodeficiency
virus type 1 transmission and early envelope diversification by
single-genome amplification and sequencing. J Virol 2008;
82:3952–3970.
5. Keele BF, Li H, Learn GH, Hraber P, Giorgi EE, Grayson T, et al.
Low-dose rectal inoculation of rhesus macaques by SIVsmE660
or SIVmac251 recapitulates human mucosal infection by HIV-
1. J Exp Med 2009; 206:1117–1134.
6. Pantaleo G. HIV-1 T-cell vaccines: evaluating the next step.
Lancet Infect Dis 2008; 8:82–83.
7. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC,
Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir
gel, an antiretroviral microbicide, for the prevention of HIV
infection in women. Science 2010; 329:1168–1174.
516 AIDS 2013, Vol 27 No 4
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
8. Yu XG, Addo MM, Perkins BA, Wej F, Rathod A, Geer SC, et al.
Differences in the expressed HLA class I alleles effect the
differential clustering of HIV type 1-specific T cell responses
in infected Chinese and caucasians. AIDS Res Human Retro-
viruses 2004; 20:557–564.
9. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al.
Antibody neutralization and escape by HIV-1. Nature 2003;
422:307–312.
10. Treurnicht FK, Seoighe C, Martin DP, Wood N, Abrahams M-R,
Rosa DDA, et al. Adaptive changes in HIV-1 subtype C proteins
during early infection are driven by changes in HLA-associated
immune pressure. Virology 2010; 396:213–225.
11. Rybarczyk BJ, Montefiori D, Johnson PR, West A, Johnston RE,
Swanstrom R. Correlation between env V1/V2 region diversi-
fication and neutralizing antibodies during primary infection
by simian immunodeficiency virus sm in rhesus macaques.
J Virol 2004; 78:3561–3571.
12. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution
of the neutralizing antibody response to HIV type 1 infection.
Proc Natl Acad Sci U S A 2003; 100:4144–4149.
13. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal
SA. Evidence of HIV-1 adaptation to HLA-restricted immune
responses at a population level. Science 2002; 296:1439–
1443.
14. Frost SDW, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y,
Paxinos E, et al. Neutralizing antibody responses drive the
evolution of human immunodeficiency virus type 1 envelope
during recent HIV infection. Proc Natl Acad Sci U S A 2005;
102:18514–18519.
15. Carlson JM, Brumme ZL. HIV evolution in response to HLA-
restricted CTL selection pressures: a population-based perspec-
tive. Microbes Infect 2008; 10:455–461.
16. Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C, Sullivan
KMO, et al. Selective escape from CD8R T-cell responses
represents a major driving force of human immunodeficiency
virus type 1 (HIV-1) sequence diversity and reveals constraints
on HIV-1 evolution. J Virol 2005; 79:13239–13249.
17. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H,
et al. Antiviral pressure exerted by HIV-1-specific cytotoxic
T lymphocytes (CTLs) during primary infection demonstrated
by rapid selection of CTL escape virus. Nature 1997; 3:205–
211.
18. Jones NA. Determinants of human immunodeficiency virus
type 1 escape from the primary CD8R cytotoxic T lymphocyte
response. J Exp Med 2004; 200:1243–1256.
19. Liu Y, McNevin J, Cao J, Zhao H, Genowati I, Wong K, et al.
Selection on the human immunodeficiency virus type 1 pro-
teome following primary infection. J Virol 2006; 80:9519–
9529.
20. Gray CM, Mlotshwa M, Riou C, Mathebula T, de Assis Rosa D,
Mashishi T, et al. Human immunodeficiency virus-specific
gamma interferon enzyme-linked immunospot assay responses
targeting specific regions of the proteome during primary
subtype C infection are poor predictors of the course of viremia
and set point. J Virol 2009; 83:470–478.
21. Goonetilleke N, Liu MKP, Salazar-Gonzalez JF, Ferrari G,
Giorgi E, Ganusov VV, et al. The first T cell response
to transmitted/founder virus contributes to the control of
acute viremia in HIV-1 infection. J Exp Med 2009; 206:
1253–1272.
22. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, Gaschen B,
et al. HIV evolution in early infection: selection pressures,
patterns of insertion and deletion, and the impact of APOBEC.
PLoS Pathog 2009; 5:e1000414.
23. Mlotshwa M, Riou C, Chopera D, de Assis Rosa D, Ntale R,
Treunicht F, et al. Fluidity of HIV-1-specific T-cell responses
during acute and early subtype C HIV-1 infection and associa-
tions with early disease progression. J Virol 2010; 84:12018–
12029.
24. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky
W, et al. Temporal association of cellular immune responses
with the initial control of viremia in primary human immu-
nodeficiency virus type 1 syndrome. J Virol 1994; 68:4650–
4655.
25. Borrow P, Lewicki H, Hahn BH, ShawGM,OldstoneMB.Virus-
specific CD8R cytotoxic T-lymphocyte activity associated
with control of viremia in primary human immunodeficiency
virus type 1 infection. J Virol 1994; 68:6103–6110.
26. OggGS, Jin X, Bonhoeffer S, Dunbar PR, NowakMA,Monard S,
et al. Quantitation of HIV-1-specific cytotoxic T lympho-
cytes and plasma load of viral RNA. Science 1998; 279:
2103–2106.
27. van Loggerenberg F, Mlisana K, Williamson C, Auld SC, Morris
L, Gray CM, et al. Establishing a cohort at high risk of HIV
infection in South Africa: challenges and experiences of
the CAPRISA 002 acute infection study. PLoS One 2008;
3:e1954.
28. Chopera DR, Woodman Z, Mlisana K, MlotshwaM, Martin DP,
Seoighe C, et al. Transmission of HIV-1 CTL escape variants
provides HLA-mismatched recipients with a survival advan-
tage. PLoS Pathog 2008; 4:e1000033.
29. Rousseau CM, Birditt BA, McKay AR, Stoddard JN, Lee TC,
McLaughlin S, et al. Large-scale amplification, cloning and
sequencing of near full-length HIV-1 subtype C genomes.
J Virol Methods 2006; 136:118–125.
30. Chopera DR, Mlotshwa M, Woodman Z, Mlisana K, de Assis
RosaD,Martin DP, et al.Virological and immunological factors
associated with HIV-1 differential disease progression in HLA-
B 58:01-positive individuals. J Virol 2011; 85:7070–7080.
31. Hall TA. BioEdit: a user-friendly biological sequence alignment
editor and analysis program for Windows 95/98/NT. Nucleic
Acids Symp Ser 1999; 41:95–98.
32. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular
Evolutionary Genetics Analysis (MEGA) software version
4.0. Mol Biol Evol 2007; 24:1596–1599.
33. Nielsen M, Lundegaard C, Blicher T, Lamberth K, Harndahl M,
Justesen S, et al. NetMHCpan, a method for quantitative pre-
dictions of peptide binding to any HLA-A and -B locus protein
of known sequence. PLoS One 2007; 2:e796.
34. Bansal A, Gough E, Sabbaj S, Ritter D, Yusim K, Sfakianos G,
et al. CD8 T-cell responses in early HIV-1 infection are skewed
towards high entropy peptides. AIDS 2005; 19:241–250.
35. Drummond AJ, Ho SYW, Phillips MJ, Rambaut A. Relaxed
phylogenetics and dating with confidence. PLoS Biol 2006;
4:e88.
36. Drummond AJ, Rambaut A. BEAST: Bayesian evolutionary
analysis by sampling trees. BMC Evol Biol 2007; 7:214.
37. Mansky LM, Temin HM. Lower in vivo mutation rate of human
immunodeficiency virus type 1 than that predicted from the
fidelity of purified reverse transcriptase. J Virol 1995; 69:5087–
5094.
38. Matthews PC, Prendergast A, Leslie A, Crawford H, Payne R,
Rousseau C, et al. Central role of reverting mutations in HLA
associations with human immunodeficiency virus set point.
J Virol 2008; 82:8548–8559.
39. Kosakovsky Pond SL, Frost SDW. Not so different after all: a
comparison of methods for detecting amino acid sites under
selection. Mol Biol Evol 2005; 22:1208–1222.
40. Pond SK, Muse SV. Site-to-site variation of synonymous sub-
stitution rates. Mol Biol Evol 2005; 22:2375–2385.
41. Pond SLK, Frost SDW, Muse SV. HyPhy: hypothesis testing
using phylogenies. Bioinformatics 2005; 21:676–679.
42. Scheffler K, Martin DP, Seoighe C. Robust inference of positive
selection from recombining coding sequences. Bioinformatics
2006; 22:2493–2499.
43. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A,
et al. Genetic and immunologic heterogeneity among persons
who control HIV infection in the absence of therapy. Int J Infect
Dis 2008; 197:563–571.
44. Moore PL, Ranchobe N, Lambson BE, Gray ES, Cave E, Abra-
hams M-R, et al. Limited neutralizing antibody specificities
drive neutralization escape in early HIV-1 subtype C infection.
PLoS Pathog 2009; 5:e1000598.
45. Li B, Gladden AD, Altfeld M, Kaldor JM, Cooper DA, Kelleher
AD, et al. Rapid reversion of sequence polymorphisms dom-
inates early human immunodeficiency virus type 1 evolution.
J Virol 2007; 81:193–201.
46. Brumme ZL, Brumme CJ, Carlson J, Streeck H, John M,
Eichbaum Q, et al. Marked epitope- and allele-specific differ-
ences in rates of mutation in human immunodeficiency type 1
(HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in
acute/early HIV-1 infection. J Virol 2008; 82:9216–9227.
47. Moore PL, Gray ES, Choge IA, Ranchobe N, Mlisana K, Abdool
Karim SS, et al. The C3-V4 region is amajor target of autologous
neutralizing antibodies in human immunodeficiency virus
type 1 subtype C infection. J Virol 2008; 82:1860–1869.
Transmitted subtype C HIV-1 rapid adaptation Abrahams et al. 517
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
48. Bansal A, Carlson J, Yan J, Akinsiku OT, Schaefer M, Sabbaj S,
et al. CD8 T cell response and evolutionary pressure to HIV-1
cryptic epitopes derived from antisense transcription. J Exp
Med 2010; 207:51–59.
49. Berger CT, Carlson JM, Brumme CJ, Hartman KL, Brumme ZL,
Henry LM, et al. Viral adaptation to immune selection pressure
by HLA class I-restricted CTL responses targeting epitopes in
HIV frameshift sequences. J Exp Med 2010; 207:61–75.
50. Alter G, Heckerman D, Schneidewind A, Fadda L, Kadie CM,
Carlson JM, et al. HIV-1 adaptation to NK-cell-mediated
immune pressure. Nature 2011; 476:96–100.
51. Davenport MP, Loh L, Petravic J, Kent SJ. Rates of HIV immune
escape and reversion: implications for vaccination. Trends
Microbiol 2008; 16:561–566.
52. Ferrari G, Korber B, Goonetilleke N, Liu MKP, Turnbull EL,
Salazar-Gonzalez JF, et al. Relationship between functional
profile of HIV-1 specific CD8 T cells and epitope variability
with the selection of escape mutants in acute HIV-1 infection.
PLoS Pathog 2011; 7:e1001273.
53. Herbeck JT, Rolland M, Liu Y, McLaughlin S, McNevin J, Zhao
H, et al. Demographic processes affect HIV-1 evolution in
primary infection before the onset of selective processes.
J Virol 2011; 85:7523–7534.
54. Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA,
Macalalad AR, et al. Whole genome deep sequencing of HIV-1
reveals the impact of early minor variants upon immune
recognition during acute infection. PLoS Pathog 2012; 8:
e1002529.
55. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li
H, et al. Neutralizing antibody responses in acute human
immunodeficiency virus type 1 subtype C infection. J Virol
2007; 81:6187–6196.
56. YehWW, Rahman I, Hraber P, Coffey RT, Nevidomskyte D, Giri
A, et al. Autologous neutralizing antibodies to the transmitted/
founder viruses emerge late after simian immunodeficiency
virus SIVmac251 infection of rhesus monkeys. J Virol 2010;
84:6018–6032.
57. Bar KJ, Tsao C-Y, Iyer SS, Decker JM, Yang Y, Bonsignori M,
et al. Early low-titer neutralizing antibodies impede HIV-1
replication and select for virus escape. PLoS Pathog 2012;
8:e1002721.
58. Hecht FM,HartogensisW, Bragg L, Bacchetti P,Grant R, Barbour
J, et al.HIVRNA level in early infection is predicted by viral load
in the transmission source. AIDS 2010; 24:941–945.
59. Hollingsworth TD, Laeyendecker O, Shirreff G, Donnelly C a,
Serwadda D,Wawer MJ, et al.HIV-1 transmitting couples have
similar viral load set-points in Rakai, Uganda. PLoS Pathog
2010; 6:e1000876.
60. Alizon S, von Wyl V, Stadler T, Kouyos RD, Yerly S, Hirschel B,
et al. Phylogenetic approach reveals that virus genotype largely
determines HIV set-point viral load. PLoS Pathog 2010;
6:e1001123.
61. MiuraT,BrummeZL,BrockmanMa,RosatoP, Sela J,BrummeCJ,
et al. Impaired replication capacity of acute/early viruses in
persons who become HIV controllers. J Virol 2010; 84:7581–
7591.
62. Tang J, Costello C, Keet IP, Rivers C, Leblanc S, Karita E, et al.
HLA class I homozygosity accelerates disease progression in
human immunodeficiency virus type 1 infection. AIDS Res
Human Retroviruses 1999; 15:317–324.
63. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT,
Peddada L, et al. Dynamics of HIV viremia and antibody sero-
conversion in plasma donors: implications for diagnosis and
staging of primary HIV infection. AIDS 2003; 17:1871–1879.
518 AIDS 2013, Vol 27 No 4
147 
 
































CAP45 20-Apr-05 2 
 














7   
 
 
04-Jul-06 65 3    
 
    
   
 
CAP63 06-Jan-05 2 
 





26   
 
 
07-Sep-05 37 3    
 
    
   
 
CAP85 22-Jun-05 5 
 















 9  
 
 










 7  
 
    
   
 
CAP210 03-May-05 2 
 















  3 
 
    
   
 
CAP239 19-Jul-05 2 
 














 9  
 
 





 9  
 
 
04-Oct-07 117 3    
 
1
Time from mid-point date between first positive and last negative HIV EIA test to date of sampling, or time since 
first HIV RNA positive date plus 14 days in antibody negative individuals 
2
Whole genome sequence numbers include smaller genomes no less than 6 000 bp in size 
3
Sequences from 2-5 weeks are published in Abrahams et al., 2009; the remaining sequences were obtained 
from G. Bandawe 
4
Obtained from D. Chopera and R.Ntale 
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Appendix 4: Limiting dilution amplification of gag, vif and nef 
Viral RNA extraction and cDNA synthesis are described in Chapter 2 section 2.5.2.   For gag 
and nef, cDNA was serially diluted and nested PCR amplification was carried out using 
Expand High Fidelity Taq (Roche Diagnostics, Rotkreuz, Switzerland).  For vif, a hemi-
nested PCR amplification was carried using methods described in Chapter 2 section 2.5.3 
with the exception that primer VIF-1 was used in both the first and second round of 
amplification.  Amplicons obtained at <60% positivity were directly sequenced using the ABI 
3000 genetic analyzer (Applied Biosystems, Foster City, CA, USA) and BigDye terminator 
reagents.  In the case of gag and vif, only the region containing the epitope/s of interest was 
sequenced, and in the case of nef the whole gene was sequenced.  Primer details, reaction 
mixes and PCR cycling conditions for gag and nef amplification are provided below. 
 
Amplification of gag: 
1st round forward primer: Gag D forw 5'-TCT CTA GCA GTG GCG CCC G-3' 
1st round reverse primer: Gag D rev 5'-AAT TCC TCC TAT CAT TTT TGG-3' 
2nd round forward primer: Gag A forw 5'-CTC TCG ACG CAG GAC TCG GCT T-3' 
2nd round reverse primer: Gag A rev 5'-TCT TCT AAT ACT GTA TCA TCT GC-3' 
 











 95 2 min  
10 X Buffer 1 + MgCl2 (15mM) 2 
 95 15 sec 
10 dNTPs (10 mM) 0.4  52 30 sec 
Gag D forw (10µM) 0.4  72 1 min 
Gag D rev (10µM) 0.4  95 15 sec 
15 Expand High Fidelity (5U/µl) 0.3  55 30 sec 
cDNA 1 
 72 1.5 min 
Total 20 
 72 7 min  
  















 95 2 min  
10 X Buffer 1 + MgCl2 (15mM) 2 
 95 15 sec 
35 dNTPs (10 mM) 0.4  55 30 sec 
Gag A forw (10µM) 0.4  72 1.5 min 
Gag C rev (10µM) 0.4  72 7 min  
Expand High Fidelity (5U/µl) 0.3  4 Hold  
1st round product 1 
    
Total 20 
    
 
Amplification of nef: 
1st round forward primer: SQ15FC 5′-GAG AGC GGT GGA ACT TCT-γ′   
1st round reverse primer: Nef OR 5′-AGG CAA GCT TTA TTG AGG -γ′   
2nd round forward primer: Nef F 5′-CCT AGA AGA ATA AGA CAG GGC TT-γ′ 
2nd round reverse primer: Nef R 5′-CCT GGA ACG CCC CAG TGG-γ′ 
 











 95 2 min  
10 X Buffer 1 + MgCl2 (15mM) 2 
 95 15 sec 
10 dNTPs (10 mM) 0.4  52 45 sec 
SQ15FC (10µM) 0.4  72 1 min 
Nef OR (10µM) 0.4  95 15 sec 
15 Expand High Fidelity (5U/µl) 0.3  55 30 sec 
cDNA 1 
 72 1 min 
Total 20 
 72 7 min  
  
 4 Hold  
150 
 











 95 2 min  
10 X Buffer 1 + MgCl2 (15mM) 2 
 95 15 sec 
35 dNTPs (10 mM) 0.4  55 30 sec 
Nef F (10µM) 0.4  72 1 min 
Nef R (10µM) 0.4  72 7 min  
Expand High Fidelity (5U/µl) 0.3  4 Hold  
cDNA 1 
    
Total 20 


















Appendix 5: Construction of IMC pCAP200.t/f 
The t/f virus full-length genome (including cognate LTRs) of CAPRISA AI 002 cohort 
participant CAP200 was selected for cloning into the low-copy number plasmid pBR322 for 
use in characterization of transmitted/founder virus phenotype.  The method described is a 
modification of that described by Salazar-Gonzalez et al. (2009) and Ochsenbauer et al. 
(2012).  The sequence of the t/f virus was derived as the consensus of 11 SGA near full-
length genome sequences from the earliest time-point post-infection by S Goodier 
(approximately two weeks).  Derivation of the complete 5’ and γ’LTRs is outlined in Methods 
and Materials section 4.5.1.   
The IMC, named pCAP200.t/f was designed so as to sequentially clone the complete 
genome in three fragments into a low copy number vector pBR322 using restriction enzyme 
digestion and sticky-end ligation. Fragment synthesis eliminates error induced by 
polymerases during PCR amplification of genome fragments and thus eliminates the need 
for back-mutation of unwanted polymorphisms following cloning. Furthermore, the use of a 
low copy number vector enhances the stability of the large IMC construct (approximately 14 
kb) which is often unstable following transformation into bacterial cells. 
The design and construction of the IMC, named pCAP200.t/f, was as follows:  
(i) Genome partitioning 
The CAP200 full-length viral sequence was analysed for the presence of restriction 
enzyme sites which would partition the genome into three fragments.  Two single-cutter 
restriction enzyme sites (PflFI and BstBI), which cut the genome into three fragments of 
approximately 2 100 bp (fragment I, 5’LTR start to gag), 4 700 bp (fragment II, gag to 
env) and 2 700 bp (fragment III, env to γ’LTR end). Since env may prove toxic to 
bacterial cells resulting in complete or partial loss or shuffling of the gene within bacterial 
plasmid vectors, the second restriction enzyme site selected interrupted the env open 
reading frame to ensure that the complete gene would only be present once the final of 
the three fragments was inserted into pBR322. The selected restriction enzyme sites and 
their positioning within the CAP200 viral genome are indicated in Figure 36A.  
 
(i) Optimization of fragment design for 3-step cloning 
In order to insert the genome in three steps using restriction enzyme digestion and 
sticky-end ligation, a SalI site was incorporated at the γ’ end of each fragment to allow 
152 
 
for cloning into pBR322 (SalI has a single recognition site within pB322). Fragment I was 
therefore designed to incorporate a PflFI site flanked by a SalI site at the γ’end; fragment 
II was designed to incorporate a PflF1 site at the 5’ end and a BstBI site flanked by a SalI 
site at the γ’ end; and fragment III was designed to incorporate a BstBI site at the 5’ end 
and a SalI site at the γ’ end. The digestion and fragment synthesis design are illustrated 
in Figure 36B.  
 
(ii) Restriction enzyme digestion and cloning 
The step-wise cloning procedure is illustrated in Figure 36C.  Fragment III was inserted 
into pBR322 first following SapI/PflFI digestion. Likewise, fragment I was inserted into 
pBR322 containing fragment III using ClaI/PflFI digestion and ligation.  Fragment II could 
not be stably inserted into pBR322 containing fragments I and II by restriction enzyme 
digestion and sticky-end ligation, and was therefore inserted into pBR322 containing 
fragments I and III using In-Fusion cloning technology (Clontech, CA, USA).  Briefly, 
fragment II was PCR amplified from pUC57 using a high-fidelity Taq polymerase and 
primers which incorporated 15 base pair overhangs which matched its 5’ and γ’ flanking 
regions within the CAP200 genome. During amplification, the forward primer 
incorporated a 15 base pair overlap with the γ’ end of fragment I and the reverse primer 
incorporated a 15 base pair overlap with the 5’ end of fragment III.  The pBRγββ vector 
containing fragments I and III was then PflFI/BStBI digested and the fragment II PCR 
product was fused with the linearized vector by the In-Fusion HD enzyme.  Sequencing 
of the final pCAP200.T/F IMC revealed the cloned viral sequence to be identical to the 























Figure 36. Construction of pCAP200c transmitted/founder IMC. (A) The location of selected 
single-cutter restriction enzyme sites partitioning the viral genome into three fragments are indicated, 
(B) synthesized fragments with restriction enzyme sites incorporated on 5’ and γ’ ends to facilitate 
step-wise cloning were provided cloned into pUC57 and, (C)  step-wise cloning of each fragment into 
pBR322 is illustrated (steps 1 to 4, which incorporated fragments I and III into pBR322 respectively, 
were carried out by restriction enzyme digestion and ligation, and step 5 was carried out by In-Fusion 
cloning using 15 bp overlaps illustrated by shaded purple bars). 
 
